

**Division of Medicaid  
Office of the Governor  
State of Mississippi  
Drug Utilization Review (DUR) Board Meeting**



MISSISSIPPI DIVISION OF  
**MEDICAID**

**December 9, 2021 at 1:00pm**

**Woolfolk Building, Room 145**

**Jackson, MS**

Prepared by:

**MS|DUR** Evidence-Based DUR Initiative  
*The University of Mississippi School of Pharmacy*

## Drug Utilization Review Board

**Lauren Bloodworth, PharmD**

University of MS School of Pharmacy  
201D Faser Hall  
University, MS 38677  
Term Expires: June 30, 2024

**Ray Montalvo, MD**

KDMC Specialty Clinic  
940 Brookway Boulevard  
Brookhaven, MS 39601  
Term Expires: June 30, 2023

**Terrence Brown, PharmD**

GA Carmichael Family Health Center  
1668 West Peace Street  
Canton, MS 39046  
Term Expires: June 20, 2023

**Holly R. Moore, PharmD**

Anderson Regional Medical Center  
2124 14<sup>th</sup> Street  
Meridian, MS 39301  
Term Expires: June 30, 2023

**Patrick Bynum, MD**

MEA Vicksburg Ambulatory Care Clinic  
4204 Clay Street  
Vicksburg, MS 39183  
Term Expires: June 30, 2022

**Joshua Pierce, PharmD**

McGuffee Drugs  
102 Main St.  
Magee, MS 39111  
Term Expires: June 30, 2024

**Cesar Cardenas, MD**

MS Center for Advanced Medicine  
401 Baptist Drive, Suite 301  
Madison, MS 39110  
Term Expires: June 30, 2024

**Cheryl Sudduth, RPh**

Funderburk's Pharmacy  
134 West Commerce Street  
Hernando, MS 38632  
Term Expires: June 30, 2022

**Rhonda Dunaway, RPh (Co-Chair)**

Coastal Family Health Center  
9113 Hwy 49 Suite 200  
Gulfport, MS 39503  
Term Expires: June 30, 2023

**James Taylor, PharmD (Chair)**

North MS Medical Center  
830 S. Gloster Street  
Tupelo, MS 38801  
Term Expires: June 30, 2022

**Tanya Fitts, MD**

Lafayette Pediatric Clinic  
1300 Access Road, Suite 400  
Oxford, MS 38655  
Term Expires: June 30, 2024

**Alan Torrey, MD**

Merit Health Medical Group  
Pain Management  
2080 South Frontage Road  
Vicksburg, MS 39180  
Term Expires: June 30, 2022

## 2021 DUR Board Meeting Dates

March 4, 2021  
June 10, 2021

September 16, 2021  
December 9, 2021

As with any analysis, great efforts are made to ensure that the information reported in this document is accurate. The most recent administrative claims data available are being used at the time the reports are generated, which includes the most recent adjudication history. As a result, values may vary between reporting periods and between DUR Board meetings, reflecting updated reversals and claims adjustments.

Unless otherwise indicated, all MS-DUR analyses are conducted for the entire Mississippi Medicaid program including beneficiaries receiving services through the Medicaid fee-for-service (FFS) and the two Mississippi Medicaid Coordinated Care Organizations (CCOs). When dollar figures are reported, the reported dollar figures represent reimbursement amounts paid to providers and are not representative of final Medicaid costs after rebates. Any reported enrollment data presented are unofficial and are only for general information purposes for the DUR Board.

Please refer to the Mississippi Division of Medicaid website for the current official Universal Preferred Drug List (PDL).

<http://www.medicaid.ms.gov/providers/pharmacy/preferred-drug-list/>

**MISSISSIPPI DIVISION OF MEDICAID  
OFFICE OF THE GOVERNOR  
DRUG UTILIZATION REVIEW BOARD  
AGENDA  
December 9, 2021**

**Welcome**

**Old Business**

Approval of September 2021 Meeting Minutes page 5

**Resource Utilization Review**

Enrollment Statistics page 11  
Pharmacy Utilization Statistics page 11  
Top 10 Drug Categories by Number of Claims page 12  
Top 10 Drug Categories by Amount Paid page 13  
Top 25 Drug Molecules by Number of Claims page 14  
Top 25 Drug Molecules by Dollars Paid page 15  
Top 25 Drug Molecules by Change in Number of Claims page 16  
Top 25 Drug Molecules by Change in Dollars Paid page 17  
Top 15 Solid Dosage Form High Volume Products By Percent Change In  
Amount Paid Per Unit page 18

**Follow-up and Discussion from the Board**

**New Business**

MS-DUR Educational Interventions page 20

**Special Analysis Projects**

Statin Therapy in Diabetes page 21  
Asthma Update page 26  
90-Day Drug List Utilization page 33

FDA Drug Safety Updates page 82

**Pharmacy Program Update**

Terri Kirby, RPh

**Next Meeting Information**

Proposed 2022 DUR Board Meeting Dates:

March 3, 2022

June 9, 2022

September 15, 2022

December 8, 2022

## **DUR Board Meeting Minutes**

**MISSISSIPPI DIVISION OF MEDICAID  
DRUG UTILIZATION REVIEW (DUR) BOARD  
MINUTES OF THE SEPTEMBER 16, 2021 MEETING**

<b>DUR Board Roster: State Fiscal Year 2022 (July 1, 2021 – June 30, 2022)</b>	<b>Dec 2020</b>	<b>Mar 2021</b>	<b>Jun 2021</b>	<b>Sep 2021</b>
Lauren Bloodworth, PharmD	✓	✓	✓	✓
Terrence Brown, PharmD	NA	✓		✓
Patrick Bynum, MD	NA	✓	✓	✓
Rhonda Dunaway, RPh	✓	✓	✓	✓
Tanya Fitts, MD	✓	✓		✓
Ray Montalvo, MD	✓		✓	✓
Holly Moore, PharmD		✓		✓
Janet Ricks, DO		✓		✓
Cheryl Sudduth, RPh	✓		✓	
James Taylor, PharmD (Chair)	✓	✓		✓
Alan Torrey, MD	✓		✓	
<b>TOTAL PRESENT**</b>	<b>7</b>	<b>9</b>	<b>7</b>	<b>9</b>

*\*\* Total Present may not be reflected by individual members marked as present above due to members who either resigned or whose terms expired being removed from the list.*

**Also Present:**

**Division of Medicaid (DOM) Staff:**

Terri Kirby, RPh, CPM, Pharmacy Director; Dennis Smith, RPh, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Todd Smith, MD, Medical Director;

**University of Mississippi School of Pharmacy - MS-DUR Staff:**

Eric Pittman, PharmD, MS-DUR Project Director; Kaustuv Bhattacharya, Research Assistant Professor;

**Conduent Staff:**

Leslie Leon, PharmD, Clinical Pharmacist, Mississippi Medicaid Project; Lew Anne Snow, RN, BSN, Pharmacy Services Sr. Analyst, Mississippi Medicaid Project;

**Change Healthcare Staff:**

Paige Clayton, PharmD, On-Site Clinical Pharmacist; Shannon Hardwick, RPh, CPC Pharmacist; Sarah Boydston, PharmD, PA Pharmacist; Cheryl Rogers, PharmD, PA Pharmacist;

**Coordinated Care Organization (CCO) Staff:**

Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Mike Todaro, PharmD,

Vice President Pharmacy Operations, Magnolia Health; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare;

**Visitors:**

Kimberly Clark, Viiv Healthcare; Brandon Cope, Otsuka; Natasha Dowd, Alkermes; Tracey Smalley, Amgen; Robert Greely, Biogen; Gene Wingo, Biogen; David Large, Biohaven; Andrew Delgado, BMS; Martin McNulty, Pfizer; Cathy Prine-Eagle, Merck; Wendy Williams, Supernaus; Brent Young, Global Blood Therapeutics; Michelle Shirley, Indivior; Mike Peoples, Lilly; Julie Hardie, Novo Nordisk; Carley Riehle, Takeda; Shawn Healey, Gilead; Chris Lauhoff, Genentech; Angela Daughtridge, Grifols; Monte McCrary, Leo Pharma; Keanna Dandridge, Novartis; Anabelle Keohane, Sanofi Genzyme; Steve Kahn, Sobi; Robert Pedrazza, Vertex; Kim Musick; Philip Merideth, MD; Cesar Cardenas, Jr., MD.

**Call to Order:**

Dr. Pittman called the meeting to order at 1:00 pm and welcomed everyone to the meeting via Zoom.

**OLD BUSINESS:**

Dr. Bloodworth moved to approve the minutes from the June 2021 DUR Board Meeting, seconded by Dr. Montalvo, and unanimously approved by the DUR Board.

**Guest Presentation – CHAMP Program:**

Dr. Philip Merideth provided the Board with an overview of the Child Access to Mental Health and Psychiatry Program. The program provides free, non-urgent, same-day telephone consults to Mississippi primary care providers who have questions about mental health care for patients  $\leq 21$  years. The program is funded through a Health Resources and Services Administration (HRSA) grant that will expire in September 2023. They are currently seeking sources of funding to continue this program once the grant expires.

**Resource Utilization Review:**

Dr. Pittman presented the resource utilization report for June 2021. Enrollment numbers continued to climb. The number of beneficiaries with pharmacy benefits was up 12.2% compared to June 2020. While enrollment numbers increased, the number of prescription fills also increased 22.2% compared to June 2020. One other item of note was the continued increase in the number of paid claims for the administration of COVID-19 vaccines that occurred during the second quarter of 2021. Dr. Pittman also pointed out a change that occurred in the way UHC reported certain encounter claims that has impacted the calculation of amounts paid resulting in values appearing artificially inflated. MS-DUR is currently working with DOM on a process to resolve this issue.

**NEW BUSINESS:**

**Election of Co-chair:**

Ms. Rhonda Dunaway volunteered to serve as Co-chair for SFY 2022 term.

*A motion was made by Dr. Taylor to accept Ms. Dunaway as Co-chair, seconded by Dr. Bloodworth, unanimously approved by the Board.*

#### **Update on MS-DUR Educational Interventions:**

Dr. Pittman provided an overview of all DUR mailings and educational notices that occurred June 2021 – August 2021.

#### **Special Analysis Projects:**

##### **Immune Globulin Utilization**

MS-DUR presented a report describing the utilization of immune globulin (IG) products among Medicaid beneficiaries between January 2017 and December 2020. Although there was a modest increase in the number of beneficiaries treated with IG between 2017 and 2020, the costs associated with the use of IG products increased 123% during the same time period. IG products can be utilized in treating a myriad of health conditions. There are disease state specific factors and appropriate patient dosing weight factors that should be considered when prescribing IG products. Considering the complexities associated with IG product use, close management of this drug class may be warranted.

The following recommendation was discussed:

1. MS-DUR recommended the Division of Medicaid consider moving all IG products on the UPDL to a manual prior authorization process.

*Following a discussion, Dr. Montalvo made a motion, seconded by Dr. Bloodworth, and unanimously approved by the Board to accept the recommendation presented.*

##### **Influenza Vaccination and Treatment Update**

MS-DUR presented a report summarizing influenza vaccination and treatment among Medicaid beneficiaries during the 2020/2021 influenza season. The report detailed flu vaccinations by age group, pharmacy plan, and whether the vaccine was administered in a pharmacy or medical setting. The report also confirmed an atypically low influenza activity season by a dramatic decrease of >95% in the number of beneficiaries treated, number of prescription claims, and the total cost associated with anti-influenza medications compared to prior years. This report for the DUR Board was for informational purposes only.

No action was sought as a result of this report.

##### **Palivizumab Utilization Update**

MS-DUR presented a report detailing the utilization of palivizumab for the prevention of serious lower respiratory tract disease caused by the respiratory syncytial virus (RSV) in children at high risk of severe disease during the 2020/2021 RSV season. In the US, RSV infections typically occur during the fall and winter cold and flu season. The 2020/2021 season was atypical with RSV activity remaining low during fall 2020 through spring 2021. An interseasonal rise in RSV infections began occurring May 2021. This atypical interseasonal activity of RSV prompted



Medicaid to reopen access to palivizumab outside of the typical season parameters. This report for the DUR Board was for informational purposes only.

No action was sought as a result of this report.

**FDA Drug Safety Updates:**

Dr. Pittman presented FDA drug safety communications for June 2021 – August 2021.

**Pharmacy Program Update:**

Ms. Kirby provided a pharmacy program update highlighting 3 updates:

- 1) Medicaid will be changing their fiscal agent from Conduent to Gainwell. This change is scheduled to take place sometime in 2022. Providers should begin seeing communications related to that change soon.
- 2) DOM is continuing to make updates to COVID-19 billing guidance.
- 3) On October 1, 2021, DOM will be implementing a diagnosis requirement for the prescribing of growth hormone agents for all beneficiaries.

Mr. Yount informed guests that beginning with the next in-person DUR Board Meeting, guests will be required to register in advance to attend. The process for registration will be similar to that utilized for P&T meetings

**Next Meeting Information:**

Dr. Pittman announced that the next meeting of the DUR Board will take place on December 9, 2021 at 1pm in-person at the Woolfolk Building.

*Dr. Montalvo motioned to adjourn the meeting at 2:22 pm, seconded by Dr. Taylor, and unanimously approved by the Board.*

Submitted,

Eric Pittman, PharmD  
Evidence-Based DUR Initiative, MS-DUR

**Meeting Location:** Meetings will be held virtually until further notice. Please visit [Medicaid.ms.gov](https://www.Medicaid.ms.gov) and click on the Pharmacy Information link for further information.

**Contact Information:** Office of Pharmacy:

Chris Yount, 601-359-5253; [Christopher.yount@medicaid.ms.gov](mailto:Christopher.yount@medicaid.ms.gov), or

Jessica Tyson, 601-359-5253; [jessica.Tyson@medicaid.ms.gov](mailto:jessica.Tyson@medicaid.ms.gov)

Notice details:

**State Agency:** MS Division of Medicaid

**Public Body:** Drug Utilization Board (DUR) Meeting

**Subject:** Quarterly Meeting

**Date and Time:** March 4, 2021; June 10, 2021; September 16, 2021; and December 9, 2021 at 1PM

**Description:** The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.

## **Resource Utilization Review**

**TABLE 04A: ENROLLMENT STATISTICS FOR LAST 6 MONTHS**

**April 1, 2021 through September 30, 2021**

		Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21
<b>Total enrollment</b>		773,615	778,140	782,886	786,455	789,961	791,724
<b>Dual-eligibles</b>		164,644	164,743	164,896	165,017	165,107	164,871
<b>Pharmacy benefits</b>		659,949	663,929	667,472	670,952	674,343	676,160
<b>PLAN %</b>	<b>LTC</b>	14,869	14,943	14,966	14,981	14,877	14,690
	<b>FFS</b>	26.4%	26.5%	26.5%	29.2%	32.7%	34.8%
	<b>MSCAN-UHC</b>	28.1%	28.1%	28.1%	27.2%	26.0%	25.2%
	<b>MSCAN-Magnolia</b>	30.3%	30.1%	30.0%	28.8%	27.4%	26.6%
	<b>MSCAN-Molina</b>	15.2%	15.3%	15.4%	14.8%	13.9%	13.4%

**TABLE 04B: PHARMACY UTILIZATION STATISTICS FOR LAST 6 MONTHS**

**April 1, 2021 through September 30, 2021**

		Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21
<b># Rx Fills</b>	<b>FFS</b>	120,197	114,497	119,649	124,991	146,486	143,966
	<b>MSCAN-UHC</b>	160,596	159,085	163,647	162,940	177,331	165,147
	<b>MSCAN-Mag</b>	173,819	162,099	165,861	163,614	175,446	165,959
	<b>MSCAN-Mol</b>	59,706	58,564	61,359	57,840	61,947	57,704
<b># Rx Fills / Bene</b>	<b>FFS</b>	0.7	0.7	0.7	0.6	0.7	0.6
	<b>MSCAN-UHC</b>	0.9	0.9	0.9	0.9	1.0	1.0
	<b>MSCAN-Mag</b>	0.9	0.8	0.8	0.8	0.9	0.9
	<b>MSCAN-Mol</b>	0.6	0.6	0.6	0.6	0.7	0.6
<b>\$ Paid Rx</b>	<b>FFS</b>	\$13,871,275	\$13,803,918	\$14,621,674	\$14,914,828	\$16,000,890	\$16,003,264
	<b>MSCAN-UHC</b>	\$19,007,544	\$18,958,402	\$20,097,333	\$19,893,686	\$20,516,103	\$20,378,038
	<b>MSCAN-Mag</b>	\$17,634,915	\$16,435,120	\$17,833,898	\$16,588,816	\$17,086,196	\$16,719,484
	<b>MSCAN-Mol</b>	\$4,962,207	\$4,646,648	\$4,974,067	\$4,536,791	\$4,836,680	\$5,208,513
<b>\$ /Rx Fill</b>	<b>FFS</b>	\$115.40	\$120.56	\$122.20	\$119.33	\$109.23	\$111.16
	<b>MSCAN-UHC</b>	\$118.36	\$119.17	\$122.81	\$122.09	\$115.69	\$123.39
	<b>MSCAN-Mag</b>	\$101.46	\$101.39	\$107.52	\$101.39	\$97.39	\$100.74
	<b>MSCAN-Mol</b>	\$83.11	\$79.34	\$81.06	\$78.44	\$78.08	\$90.26
<b>\$ /Bene</b>	<b>FFS</b>	\$79.62	\$78.46	\$82.66	\$76.13	\$72.56	\$68.01
	<b>MSCAN-UHC</b>	\$102.50	\$101.62	\$107.15	\$109.01	\$117.01	\$119.59
	<b>MSCAN-Mag</b>	\$88.19	\$82.24	\$89.06	\$85.85	\$92.47	\$92.96
	<b>MSCAN-Mol</b>	\$49.47	\$45.74	\$48.39	\$45.69	\$51.60	\$57.49

*NOTE: Paid amounts represent amount reported on claims as paid to the pharmacy. These amounts do not reflect final actual costs after rebates, etc.*

*In April 2021, UHC changed their claims reporting procedure, and the estimates presented in these tables may be slightly higher than the amount actually paid by UHC*

**TABLE C: TOP 10 DRUG CATEGORIES BY NUMBER OF CLAIMS IN SEP 2021 (FFS AND CCOs)**

Category	Month Year	Rank Volume	# RXs	\$ Paid	# Unique Benes
CNS stimulants	Sep 2021	1	26,228	\$4,349,366	21,832
	Aug 2021	2	24,717	\$4,074,682	20,685
	Jul 2021	1	21,949	\$3,681,184	18,314
adrenergic bronchodilators	Sep 2021	2	17,408	\$1,072,902	14,706
	Aug 2021	3	20,881	\$1,381,233	17,617
	Jul 2021	2	16,768	\$1,077,358	14,293
antihistamines	Sep 2021	3	17,057	\$244,750	16,124
	Aug 2021	5	17,163	\$243,901	16,236
	Jul 2021	5	14,586	\$207,502	13,802
nonsteroidal anti-inflammatory agents	Sep 2021	4	15,734	\$231,697	14,740
	Aug 2021	7	15,572	\$231,895	14,610
	Jul 2021	4	14,750	\$218,962	13,863
viral vaccines	Sep 2021	5	14,536	\$493,913	13,352
	Aug 2021	1	25,424	\$846,156	22,161
	Jul 2021	3	14,893	\$496,044	13,680
aminopenicillins	Sep 2021	6	14,469	\$188,751	13,982
	Aug 2021	8	15,188	\$199,468	14,662
	Jul 2021	8	13,395	\$174,010	12,946
atypical antipsychotics	Sep 2021	7	14,396	\$4,204,149	11,997
	Aug 2021	9	14,200	\$4,261,951	11,851
	Jul 2021	6	14,282	\$4,320,576	11,838
macrolides	Sep 2021	8	14,333	\$306,589	13,799
	Aug 2021	4	20,544	\$403,859	19,701
	Jul 2021	12	10,635	\$257,344	10,256
SSRI antidepressants	Sep 2021	9	14,265	\$172,536	13,082
	Aug 2021	10	13,975	\$168,469	12,758
	Jul 2021	7	13,927	\$168,785	12,725
glucocorticoids	Sep 2021	10	13,717	\$332,893	13,015
	Aug 2021	6	16,426	\$296,094	15,532
	Jul 2021	9	13,122	\$323,955	12,420

**TABLE D: TOP 10 DRUG CATEGORIES BY DOLLARS PAID IN SEP 2021 (FFS AND CCOs)**

Category	Month Year	Rank Paid Amt	# RXs	\$ Paid	# Unique Benes
CNS stimulants	Sep 2021	1	26,228	\$4,349,366	21,832
	Aug 2021	2	24,717	\$4,074,682	20,685
	Jul 2021	2	21,949	\$3,681,184	18,314
atypical antipsychotics	Sep 2021	2	14,396	\$4,204,149	11,997
	Aug 2021	1	14,200	\$4,261,951	11,851
	Jul 2021	1	14,282	\$4,320,576	11,838
antiviral combinations	Sep 2021	3	900	\$2,974,482	775
	Aug 2021	3	837	\$2,692,428	749
	Jul 2021	3	857	\$2,696,620	770
interleukin inhibitors	Sep 2021	4	513	\$2,819,314	398
	Aug 2021	6	435	\$2,275,164	341
	Jul 2021	6	432	\$2,199,382	336
insulin	Sep 2021	5	5,597	\$2,597,680	3,989
	Aug 2021	5	5,668	\$2,616,346	4,021
	Jul 2021	5	5,582	\$2,586,395	4,006
TNF alpha inhibitors	Sep 2021	6	354	\$2,552,458	308
	Aug 2021	4	361	\$2,635,227	304
	Jul 2021	4	351	\$2,617,900	294
CFTR combinations	Sep 2021	7	89	\$1,863,320	66
	Aug 2021	8	88	\$1,818,997	68
	Jul 2021	7	78	\$1,730,566	63
miscellaneous uncategorized agents	Sep 2021	8	166	\$1,710,442	147
	Aug 2021	7	161	\$1,950,955	139
	Jul 2021	9	174	\$1,620,509	147
antirheumatics	Sep 2021	9	1,003	\$1,615,033	879
	Aug 2021	9	1,119	\$1,786,229	984
	Jul 2021	8	1,028	\$1,683,591	900
factor for bleeding disorders	Sep 2021	10	130	\$1,351,304	102
	Aug 2021	10	132	\$1,460,313	100
	Jul 2021	10	115	\$1,369,417	94

**TABLE E: TOP 25 DRUG MOLECULES  
BY NUMBER OF CLAIMS IN SEP 2021 (FFS and CCOs)**

Drug Molecule Therapeutic Category	Aug 2021 # Claims	Sep 2021 # Claims	Sep 2021 \$ Paid	Sep 2021 # Unique Benes
albuterol / adrenergic bronchodilators	19,440	16,527	\$810,468	14,137
amoxicillin / aminopenicillins	15,150	14,442	\$188,205	13,958
azithromycin / macrolides	20,153	13,944	\$230,596	13,474
cetirizine / antihistamines	12,367	12,351	\$166,110	11,828
sars-cov-2 mma (tozinameran) vaccine / viral vaccines	21,542	11,314	\$371,321	10,370
montelukast / leukotriene modifiers	10,309	10,345	\$161,840	9,923
fluticasone nasal / nasal steroids	8,459	8,614	\$132,990	8,374
gabapentin / gamma-aminobutyric acid analogs	8,121	8,162	\$123,991	7,485
acetaminophen-hydrocodone / narcotic analgesic combinations	7,567	7,801	\$100,282	7,251
lisdexamfetamine / CNS stimulants	7,302	7,681	\$2,503,467	7,236
ondansetron / 5HT3 receptor antagonists	8,081	7,416	\$109,502	7,062
ibuprofen / nonsteroidal anti-inflammatory agents	7,555	7,351	\$89,102	7,058
clonidine / antiadrenergic agents, centrally acting	6,645	6,698	\$89,567	6,217
amphetamine-dextroamphetamine / CNS stimulants	6,261	6,636	\$196,009	5,572
methylphenidate / CNS stimulants	6,180	6,524	\$1,018,849	5,619
amlodipine / calcium channel blocking agents	6,446	6,481	\$76,987	6,070
cefdinir / third generation cephalosporins	6,253	6,235	\$144,129	6,075
prednisolone / glucocorticoids	7,173	6,050	\$92,562	5,768
omeprazole / proton pump inhibitors	5,808	5,896	\$66,865	5,655
sertraline / SSRI antidepressants	5,163	5,238	\$63,752	4,812
amoxicillin-clavulanate / penicillins/beta-lactamase inhibitors	5,043	5,199	\$113,814	5,007
triamcinolone topical / topical steroids	4,691	4,455	\$73,244	4,195
atorvastatin / HMG-CoA reductase inhibitors (statins)	4,416	4,449	\$49,587	4,152
famotidine / H2 antagonists	4,911	4,274	\$152,133	4,034
guanfacine / antiadrenergic agents, centrally acting	4,132	4,258	\$115,473	3,963

**TABLE F: TOP 25 DRUG MOLECULES  
BY DOLLARS PAID IN SEP 2021 (FFS and CCOs)**

Drug Molecule Therapeutic Category	Aug 2021 \$ Paid	Sep 2021 \$ Paid	Sep 2021 # Claims	Sep 2021 # Unique Benes
adalimumab / antirheumatics	\$3,128,455	\$2,913,734	384	333
lisdexamfetamine / CNS stimulants	\$2,386,750	\$2,503,467	7,681	7,236
paliperidone / atypical antipsychotics	\$1,749,345	\$1,676,746	663	580
elexacaftor/ivacaftor/tezacaftor / CFTR combinations	\$1,546,900	\$1,570,293	75	60
bictegravir/emtricitabine/tenofovir / antiviral combinations	\$1,299,118	\$1,407,051	399	353
dupilumab / interleukin inhibitors	\$961,499	\$1,100,814	348	264
aripiprazole / atypical antipsychotics	\$1,048,813	\$1,095,062	3,959	3,566
carglumic acid / miscellaneous uncategorized agents	\$1,233,572	\$1,027,976	5	2
methylphenidate / CNS stimulants	\$939,767	\$1,018,849	6,524	5,619
insulin glargine / insulin	\$945,819	\$937,673	2,027	1,892
liraglutide / GLP-1 receptor agonists	\$834,759	\$833,085	1,020	951
albuterol / adrenergic bronchodilators	\$957,485	\$810,468	16,527	14,137
ustekinumab / interleukin inhibitors	\$520,099	\$712,542	34	27
emicizumab / factor for bleeding disorders	\$618,340	\$668,133	27	22
somatropin / growth hormones	\$675,735	\$638,209	143	130
lacosamide / miscellaneous anticonvulsants	\$602,034	\$637,465	660	559
etanercept / antirheumatics	\$678,664	\$594,325	110	92
insulin aspart / insulin	\$575,990	\$576,727	1,483	1,354
budesonide-formoterol / bronchodilator combinations	\$575,046	\$559,384	1,767	1,667
empagliflozin / SGLT-2 inhibitors	\$488,439	\$541,372	705	661
corticotropin / corticotropin	\$438,579	\$518,294	6	5
deferasirox / chelating agents	\$473,652	\$487,925	75	63
insulin detemir / insulin	\$485,333	\$485,777	877	804
apixaban / factor Xa inhibitors	\$462,641	\$474,889	1,068	981
fluticasone-salmeterol / bronchodilator combinations	\$426,483	\$428,538	1,175	1,074



**TABLE G: TOP 25 DRUG MOLECULES  
BY CHANGE IN NUMBER OF CLAIMS FROM JUL 2021 TO SEP 2021 (FFS and CCOs)**

Drug Molecule	Jul 2021 # Claims	Aug 2021 # Claims	Sep 2021 # Claims	Sep 2021 \$ Paid	Sep 2021 # Unique Benes
azithromycin / macrolides	10,232	20,153	13,944	\$230,596	13,474
cetirizine / antihistamines	10,122	12,367	12,351	\$166,110	11,828
fluticasone nasal / nasal steroids	7,010	8,459	8,614	\$132,990	8,374
lisdexamfetamine / CNS stimulants	6,295	7,302	7,681	\$2,503,467	7,236
ondansetron / 5HT3 receptor antagonists	6,048	8,081	7,416	\$109,502	7,062
montelukast / leukotriene modifiers	9,128	10,309	10,345	\$161,840	9,923
methylphenidate / CNS stimulants	5,349	6,180	6,524	\$1,018,849	5,619
amoxicillin / aminopenicillins	13,362	15,150	14,442	\$188,205	13,958
albuterol / adrenergic bronchodilators	15,658	19,440	16,527	\$810,468	14,137
amphetamine-dextroamphetamine / CNS stimulants	5,866	6,261	6,636	\$196,009	5,572
cefdinir / third generation cephalosporins	5,531	6,253	6,235	\$144,129	6,075
influenza virus vaccine, inactivated / viral vaccines	0	77	633	\$22,846	624
dexmethylphenidate / CNS stimulants	2,862	3,228	3,470	\$230,124	2,762
ibuprofen / nonsteroidal anti-inflammatory agents	6,764	7,555	7,351	\$89,102	7,058
prednisone / glucocorticoids	3,243	4,315	3,810	\$41,055	3,658
amoxicillin-clavulanate / penicillins/beta-lactamase inhibitors	4,707	5,043	5,199	\$113,814	5,007
famotidine / H2 antagonists	3,798	4,911	4,274	\$152,133	4,034
sars-cov-2 (covid-19) mrna-1273 vaccine / viral vaccines	2,106	3,632	2,497	\$85,975	2,437
methylprednisolone / glucocorticoids	2,451	3,252	2,778	\$38,541	2,714
naproxen / nonsteroidal anti-inflammatory agents	2,401	2,491	2,689	\$58,900	2,593
oseltamivir / neuraminidase inhibitors	277	571	547	\$21,758	525
dexamethasone / glucocorticoids	610	1,503	879	\$13,232	856
guanfacine / antiadrenergic agents, centrally acting	4,001	4,132	4,258	\$115,473	3,963
doxycycline / tetracyclines	2,124	2,514	2,366	\$32,724	2,285
clonidine / antiadrenergic agents, centrally acting	6,456	6,645	6,698	\$89,567	6,217

**TABLE H: TOP 25 DRUG MOLECULES  
BY CHANGE IN AMOUNT PAID FROM JUL 2021 TO SEP 2021 (FFS and CCOs)**

Drug Molecule	Jul 2021 \$ Paid	Aug 2021 \$ Paid	Sep 2021 \$ Paid	Sep 2021 # Claims	Sep 2021 # Unique Benes
lisdexamfetamine / CNS stimulants	\$2,055,275	\$2,386,750	\$2,503,467	7,681	7,236
carglumic acid / miscellaneous uncategorized agents	\$616,786	\$1,233,572	\$1,027,976	5	2
palivizumab / immune globulins	\$15,805	\$150,955	\$267,900	98	77
methylphenidate / CNS stimulants	\$803,326	\$939,767	\$1,018,849	6,524	5,619
ustekinumab / interleukin inhibitors	\$521,454	\$520,099	\$712,542	34	27
ixekizumab / interleukin inhibitors	\$225,140	\$311,003	\$392,253	46	37
glecaprevir-pibrentasvir / antiviral combinations	\$69,422	\$214,820	\$218,781	17	13
bictegravir/emtricitabine/tenofovir / antiviral combinations	\$1,262,734	\$1,299,118	\$1,407,051	399	353
sofosbuvir-velpatasvir / antiviral combinations	\$159,892	\$138,572	\$280,091	28	19
dupilumab / interleukin inhibitors	\$985,046	\$961,499	\$1,100,814	348	264
leuprolide / antineoplastic hormones	\$147,563	\$134,927	\$261,258	50	43
ivacaftor-lumacaftor / CFTR combinations	\$188,375	\$272,097	\$293,027	14	6
elexacaftor/ivacaftor/tezacaftor / CFTR combinations	\$1,474,957	\$1,546,900	\$1,570,293	75	60
risankizumab / interleukin inhibitors	\$51,420	\$34,323	\$138,192	9	7
azacitidine / miscellaneous antineoplastics	\$42,333	\$84,666	\$127,004	6	5
antihemophilic factor / factor for bleeding disorders	\$157,520	\$274,086	\$241,880	16	11
teduglutide / miscellaneous GI agents	\$83,347	\$125,018	\$166,690	4	2
albuterol / adrenergic bronchodilators	\$745,916	\$957,485	\$810,468	16,527	14,137
azithromycin / macrolides	\$167,937	\$331,175	\$230,596	13,944	13,474
guselkumab / interleukin inhibitors	\$35,840	\$59,733	\$96,019	9	9
deferasirox / chelating agents	\$431,638	\$473,652	\$487,925	75	63
dextroamphetamine / CNS stimulants	\$162,885	\$184,860	\$218,142	655	592
glycerol phenylbutyrate / urea cycle disorder agents	\$290,044	\$437,685	\$344,878	5	3
triptorelin / antineoplastic hormones	\$17,672	\$17,672	\$70,689	4	3
emtricitabine/rilpivirine/tenofovir / antiviral combinations	\$170,237	\$163,725	\$223,222	65	57

**TABLE I: TOP 15 DRUG SOLID DOSAGE FORM HIGH VOLUME (100+ RX FILLS LAST MONTH) PRODUCTS  
WITH UNIT COST > \$1  
BY PERCENT CHANGE IN AMOUNT PAID PER UNIT JUL 2021 TO SEP 2021 (FFS and CCOs)**

Drug Product Therapeutic Category	Sep 2021 # Claims	Sep 2021 \$ Paid	Sep 2021 Avr. Paid Per Rx	Sep 2021 Avr. Units Per Rx	Jul 2021 Paid Per Unit	Aug 2021 Paid Per Unit	Sep 2021 Paid Per Unit	Percent Change
atomoxetine 40 mg capsule / CNS stimulants (P)	248	\$11,397	\$45.95	30	\$1.10	\$1.16	\$1.16	5.2%
ivermectin 3 mg tablet / anthelmintics (P)	164	\$8,101	\$49.40	12	\$3.14	\$3.33	\$3.28	4.6%
Eliquis (apixaban) 2.5 mg tablet / factor Xa inhibitors (P)	139	\$58,024	\$417.44	51	\$7.44	\$7.72	\$7.69	3.4%
atomoxetine 60 mg capsule / CNS stimulants (P)	119	\$6,756	\$56.77	30	\$1.47	\$1.55	\$1.52	3.3%
Viibryd (vilazodone) 40 mg tablet / miscellaneous antidepressants (P)	103	\$35,842	\$347.98	34	\$9.34	\$9.39	\$9.46	1.3%
Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir) 150 mg-150 mg-200 mg-10 mg tablet / antiviral combinations (P)	121	\$404,643	\$3,344.16	35	\$105.14	\$107.14	\$106.35	1.1%
atomoxetine 25 mg capsule / CNS stimulants (P)	238	\$12,645	\$53.13	30	\$1.37	\$1.38	\$1.38	1.0%
Vyvanse (lisdexamfetamine) 10 mg capsule / CNS stimulants (P)	229	\$75,089	\$327.90	30	\$10.60	\$10.62	\$10.70	0.9%
dexmethylphenidate 40 mg capsule, extended release / CNS stimulants (P)	146	\$11,030	\$75.55	30	\$2.13	\$2.17	\$2.15	0.8%
Viibryd (vilazodone) 20 mg tablet / miscellaneous antidepressants (P)	103	\$34,691	\$336.80	35	\$9.35	\$9.42	\$9.43	0.8%
dexmethylphenidate 5 mg capsule, extended release / CNS stimulants (P)	225	\$12,232	\$54.36	30	\$1.44	\$1.45	\$1.45	0.7%
dexmethylphenidate 25 mg capsule, extended release / CNS stimulants (P)	241	\$20,154	\$83.62	30	\$2.39	\$2.39	\$2.40	0.5%
QuilliChew ER (methylphenidate) 40 mg/24 hr tablet, chewable, extended release / CNS stimulants (P)	336	\$122,529	\$364.67	30	\$11.69	\$11.76	\$11.75	0.5%
Taytulla (ethinyl estradiol-norethindrone) with iron 20 mcg-1 mg capsule / contraceptives (P)	113	\$27,087	\$239.71	31	\$7.06	\$7.09	\$7.09	0.4%
methylphenidate 18 mg/24 hr tablet, extended release / CNS stimulants (P)	525	\$21,819	\$41.56	30	\$1.01	\$1.01	\$1.01	0.3%

Products are only included if 100 or more fills in last month and average cost per unit in reference month was >= \$1.

**New Business**

**Special Analysis Projects**

**MISSISSIPPI DIVISION OF MEDICAID**  
**MS-DUR INTERVENTION / EDUCATIONAL INITIATIVE UPDATE**  
**SEPTEMBER 2021 – NOVEMBER 2021**

Ongoing Intervention(s):

<b>PROVIDER SHOPPING FOR OPIOIDS (≥4 Prescribers AND ≥4 Pharmacies)</b>				<b>CONCOMITANT USE OF OPIOIDS AND ANTIPSYCHOTICS</b>		
<b>Month</b>	<b>Prescribers Mailed</b>	<b>Pharms Mailed</b>	<b>Benes Addressed</b>	<b>Month</b>	<b>Prescribers Mailed</b>	<b>Benes Addressed</b>
20-Dec	5	4	9	21-May	74	94
21-Jan	3	3	6	21-Jun	60	80
21-Feb	5	4	9	21-Jul	44	48
21-Mar	6	5	11	21-Aug	45	47
21-Apr	6	6	12	21-Sep	46	50
21-May	3	3	6	21-Oct	51	88
21-Jun	4	4	8	21-Nov	43	49
21-Jul	3	2	5			
21-Aug	6	4	10			
21-Sep	5	4	9			
21-Oct	5	1	6			
21-Nov	4	3	7			

## STATIN THERAPY FOR PATIENTS WITH DIABETES

### BACKGROUND

Patients with diabetes are at increased risk of developing atherosclerotic cardiovascular disease (ASCVD). In fact, cardiovascular disease (CVD) is the most prevalent cause of morbidity and mortality among people with diabetes.<sup>1</sup> Minimizing cardiovascular (CV) effects through targeted CV risk factor reductions in patients with diabetes is imperative. For primary prevention of ASCVD, the American Diabetes Association (ADA) Standards of Care for Diabetes recommends patients with diabetes aged 40-75 years without ASCVD use moderate-intensity statin therapy.<sup>2</sup> The Healthcare Effectiveness Data and Information Set (HEDIS) has a quality measure, Statin Therapy for Patients with Diabetes (SPD), that assesses adults 40-75 years of age who have diabetes and who do not have clinical ASCVD, who received and adhered to statin therapy.<sup>3</sup>

MS-DUR ran the HEDIS-SPD quality measure for calendar year (CY) 2020 in the Mississippi Medicaid population.

### METHODS

The HEDIS-SPD measure reports the percentage of members 40-75 years of age during the measurement year with diabetes who do not have clinical ASCVD who met the following criteria. Two rates are reported:

1. Received a Statin Therapy. Members who were dispensed at least one statin medication of any intensity during the measurement year.
2. Statin Adherence 80%. Members who remained on a statin medication of any intensity for at least 80% of the treatment period.<sup>3</sup>

Measurement specifications are outlined in Table 1.<sup>3</sup>

<b>TABLE 1: SPD Measurement Specifications (HEDIS 2021)</b>	
<b>Measurement Year</b>	January 1, 2020 - December 31, 2020
<b>Denominator</b>	Members 40 - 75 years of age during the measurement year with diabetes who did not have clinical atherosclerotic disease
<b>Continuous Enrollment</b>	Beneficiary must be enrolled for entire measurement year with no more than one gap in continuous enrollment of up to 45 days.
<b>Anchor Date</b>	The anchor date for determining age is December 31 of the measurement year.
<b>Exclusions</b>	<p>Beneficiaries are excluded if they:</p> <ul style="list-style-type: none"> <li>- had hospice services during measurement year</li> <li>- had a cardiovascular disease event during the prior year</li> <li>- had a diagnosis for ischemic vascular disease, ESRD or cirrhosis during the measurement year and prior year</li> <li>- were pregnant or had invitro fertilization during the measurement year or prior year</li> <li>- had a diagnosis of myalgia, myositis, myopathy or rhabdomyolysis during the measurement year</li> <li>- had a dialysis procedure during the measurement year</li> <li>- receiving palliative care during the measurement year</li> <li>- were 66 years of age and <ul style="list-style-type: none"> <li>- in skilled nursing facility or other long-term institution any time during measurement year</li> <li>- with frailty and advanced illness during the measurement year or prior year</li> <li>- had a prescription filled for a dementia medication and estrogen agonists medication</li> </ul> </li> </ul>
<b>Treatment Period</b>	The period of time beginning on the date of the earliest dispensing for any statin medication through the last day of the measurement year.
<b>Proportion of Days Covered (PDC)</b>	The number of days the member is covered by at least one statin medication prescription divided by the number of days in the treatment period.
<b>Numerator</b>	<p>Rate 1: Percent of members who had at least one dispensing event for a high-intensity, moderate intensity, or low-intensity statin medication during the measurement year.</p> <p>Rate 2 : The percentage of members receiving statin therapy who achieved a Proportion of Days Covered (PDC) of at least 80% during the treatment period.</p>

Table 2 shows the number of eligible Medicaid beneficiaries included in the denominator and the number of beneficiaries excluded for each of the inclusion/exclusion criteria. A total of 110,042 beneficiaries aged 40 to 75 years were enrolled in Mississippi Medicaid for some period of time during the measurement year (January 1, 2020 – December 31, 2020). Of these, 12,769 beneficiaries met the criteria for inclusion in the denominator for the quality measure.

**TABLE 2: Number of Beneficiaries in Measure Denominator Selection**  
**Mississippi Medicaid January 1, 2020 - Decemeber 31, 2020**

Sequential Steps in Denominator Selection	Total	Medicaid Program			
		FFS	UHC	MAG	MOL
<b>Beneficiaries 40-75 years of age during the measurement year</b>	<b>110,042</b>	<b>66,725</b>	<b>17,054</b>	<b>20,760</b>	<b>5,503</b>
Not continuously enrolled during required period	-8,651	-6,360	-688	-480	-1,123
Excluded for not having diabetes during required period	-83,254	-52,475	-12,427	-14,806	-3,546
Excluded for having MI, CABG, PCI and other vascularization	-1,252	-475	-318	-391	-68
Excluded for having Ischemic vascular disease	-1,118	-386	-273	-416	-43
Excluded beneficiaries with diagnosis of pregnancy	-110	-47	-18	-36	-9
Excluded for in vitro fertilization	0	0	0	0	0
Excluded for estrogen antagonist medication claims	0	0	0	0	0
Excluded for hospice stay	-113	-81	-13	-16	-3
Excluded for having ESRD	-674	-428	-100	-124	-22
Excluded for having cirrhosis	-327	-130	-80	-98	-19
Excluded for having myalgia, myositis, myopathy or rhabdomyolysis	-916	-250	-249	-374	-43
Excluded who are receiving palliative care	-746	-746	0	0	0
Excluded elderly 66+ in SNF or living in long-term institution	-17	-9	-5	-3	0
Excluded elderly 66+ who are frail or have advanced illness	-95	-91	-1	-3	0
<b>Denominator for measure</b>	<b>12,769</b>	<b>5,247</b>	<b>2,882</b>	<b>4,013</b>	<b>627</b>

## RESULTS

Table 3 shows the characteristics of beneficiaries included in the denominators for the HEDIS-SPD quality measure.

**TABLE 3: Characteristics of Beneficiaries in Denominator for HEDIS-SPD Quality Measure**  
**Mississippi Medicaid January 1, 2020 - Decemeber 31, 2020**

Beneficiary Characteristics		TOTAL		Medicaid Program							
				FFS		UHC		MAG		MOL	
<b>Total</b>		<b>12,769</b>		<b>5,247</b>		<b>2,882</b>		<b>4,013</b>		<b>627</b>	
Gender	Female	8,656	67.8%	3,451	65.8%	1,983	68.8%	2,823	70.3%	399	63.6%
	Male	4,113	32.2%	1,796	34.2%	899	31.2%	1,190	29.7%	228	36.4%
Age	40-65	11,758	92.1%	4,262	81.2%	2,871	99.6%	3,998	99.6%	627	100.0%
	66 -75	1,011	7.9%	985	18.8%	11	0.4%	15	0.4%	0	0.0%
Race	Caucasian	3,490	27.3%	1,408	26.8%	827	28.7%	1,048	26.1%	207	33.0%
	Afr. Amer.	7,629	59.7%	3,207	61.1%	1,663	57.7%	2,462	61.4%	297	47.4%
	Amer. Indian	64	0.5%	48	0.9%	5	0.2%	8	0.2%	3	0.5%
	Hispanic	28	0.2%	8	0.2%	10	0.3%	6	0.1%	4	0.6%
	Other	1,558	12.2%	576	11.0%	377	13.1%	489	12.2%	116	18.5%

Table 4 shows the HEDIS-SPD quality measure rates for CY 2020 for all Mississippi Medicaid beneficiaries meeting the inclusion criteria for the denominator. The overall rate within Mississippi Medicaid was 45.8% for ‘Received Statin Therapy’ and 45.8% for ‘Statin Adherence 80%’. Both rates were higher for the male beneficiaries. Likewise, the rate of ‘Received Statin Therapy’ was higher for coordinated care organization (CCO) programs than for the fee-for service (FFS). The



rate of 'Statin Adherence 80%' was higher for CCO programs than for FFS except in the UHC program. African Americans had a higher rate for 'Received Statin Therapy' than Caucasians, however, the opposite was true for 'Statin Adherence 80%' rate. The rates for American Indians and Hispanics should not be considered reliable since the denominators are very small.

TABLE 4: Statin Therapy for Patients With Diabetes (SPD)							
Includes all Medicaid Beneficiaries Meeting Inclusion Criteria							
Mississippi Medicaid January 1, 2020 - December 30, 2020							
Beneficiary Characteristics		Rate 1: Received Statin Therapy			Rate 2: Statin Adherence 80%		
		Denominator	Numerator	Rate	Denominator	Numerator	Rate
TOTAL		12,769	5,853	45.8%	5,853	2,680	45.8%
Gender	Female	8,656	3,949	45.6%	3,949	1,766	44.7%
	Male	4,113	1,904	46.3%	1,904	914	48.0%
AGE	40 - 65	11,758	5,825	49.5%	5,825	2,667	45.8%
	66 - 75	1,011	28	2.8%	28	13	46.4%
Race	Caucasian	3,490	1,587	45.5%	1,587	773	48.7%
	Afr. Amer.	7,629	3,520	46.1%	3,520	1,548	44.0%
	Amer. Indian	64	5	7.8%	5	5	100.0%
	Hispanic	28	17	60.7%	17	7	41.2%
	Other	1,558	724	46.5%	724	347	47.9%
Medicaid Program	FFS	5,247	1,539	29.3%	1,539	617	40.1%
	UHC	2,882	1,625	56.4%	1,625	466	28.7%
	MAG	4,013	2,361	58.8%	2,361	1,165	49.3%
	MOL	627	328	52.3%	328	132	40.2%
NOTE: PDC = proportion of days covered by statin during treatment period.							

As noted, the 'Received Statin Therapy' rates were substantially higher for beneficiaries enrolled in the CCOs compared to FFS. All three CCOs have Gaps In Care programs targeting members with diabetes not on a statin. These programs include communications with physicians, members, and/or pharmacies.

## CONCLUSIONS

It is well established that individuals with diabetes aged 40-75 years without ASCVD should use statin therapy to reduce the risk of developing ASCVD. Using the HEDIS-SPD quality measure we found that overall 45.8% of eligible Medicaid beneficiaries received statin therapy and were 80% adherent to their statin therapy in CY 2020. However, our analysis indicated that beneficiaries enrolled in FFS were less likely to have received statin therapy when compared to those enrolled in the CCOs.

## RECOMMENDATION

1. MS-DUR should work with DOM to develop and implement a Gaps In Care program for the FFS population aimed at improving the rate of beneficiaries with diabetes prescribed statin therapy.
2. DOM should work with CCOs and FFS programs to develop plans for improving adherence rates for beneficiaries with diabetes prescribed statin therapy.

## REFERENCES:

1. Matheus AS de M, Tannus LRM, Cobas RA, Palma CCS, Negrato CA, Gomes M de B. Impact of diabetes on cardiovascular disease: an update. *Int J Hypertens*. 2013;2013:653789. doi:10.1155/2013/653789
2. Association AD. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. *Diabetes Care*. 2021;44(Supplement 1):S125-S150. doi:10.2337/dc21-S010
3. Statin Therapy for Patients With Cardiovascular Disease and Diabetes. NCQA. Accessed October 26, 2021. <https://www.ncqa.org/hedis/measures/statin-therapy-for-patients-with-cardiovascular-disease-and-diabetes/>


# ASTHMA GUIDELINE UPDATE AND UPDL IMPLICATIONS

## BACKGROUND

At the March 2019 DUR Board Meeting, an overview of asthma, along with performance on related quality measures, was presented.<sup>1</sup> The board recommended MS-DUR design and implement an educational intervention program to educate providers about performance on asthma quality measures.<sup>1</sup>

In April 2019, prior to the initiation of any educational interventions, an updated report from the Global Initiative for Asthma (GINA) was released and recommended the most significant changes in asthma management in the last three decades.<sup>2</sup> The landmark changes involved the recommendation that all adults and adolescents with asthma receive symptom-driven or regular low-dose inhaled corticosteroid (ICS) containing controller treatment, specifically low-dose ICS-formoterol. This also represented a move away from recommending short-acting beta agonist (SABA) only treatment for Step 1 treatment. Those changes continue to be reflected in GINA's most recent 2021 report. (Figure 1)

Figure 1: GINA Treatment Guidance for Adults and Adolescents<sup>3</sup>




©2021 Global Initiative for Asthma, reprinted with permission. Available from [www.ginasthma.org](http://www.ginasthma.org)

These recommendations were based on clinical evidence that the use of ICS-containing agents significantly reduces risks of severe exacerbations.<sup>4,5</sup>

Prior to conducting provider education, DOM requested MS-DUR to conduct an updated analysis and review the Universal Preferred Drug List (UPDL) for any issues that may limit providers from prescribing in accordance with the updated guidelines.

Upon examining the UPDL, it was noted that branded Symbicort® (budesonide/formoterol) is a preferred agent. However, orally inhaled agents have individual quantity limits in place. Currently, Symbicort has a quantity limit of 1 inhaler unit per month. (Figure 2) This quantity limit could potentially present a hurdle to those needing maintenance and as-needed therapy with Symbicort®.

Figure 2: Medicaid UPDL for Glucocorticoid/Bronchodilator Combination Inhalers<sup>6</sup>

<div>  <div> <b>MISSISSIPPI DIVISION OF MEDICAID</b>  <b>UNIVERSAL PREFERRED DRUG LIST</b>            (For All Medicaid, MSCAN and CHIP Beneficiaries)         </div> <div> <b>EFFECTIVE 10/01/2021</b>  <b>Version 2021.1b</b>  <b>Updated: 10-04-2021</b> </div> </div>			
Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.			
THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>GLUCOCORTICIDS (Inhaled)<sup>SmartPA</sup></b>			
<b>GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS</b>			
	ADVAIR DISKUS (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol) DULERA (mometasone/formoterol) fluticasone/salmeterol (generic AIRDUO) SYMBICORT (budesonide/formoterol)	<b>AIRDUO Digihaler (fluticasone/salmeterol)</b> AIRDUO Resplick (fluticasone/salmeterol) BREO ELLIPTA (fluticasone/vilanterol) budesonide/formoterol fluticasone/salmeterol (generic ADVAIR) WIXELA INHUB (fluticasone/salmeterol)	<b>Non-Preferred Criteria</b> <ul style="list-style-type: none"> <li>90 consecutive days on the requested agent in the past 105 days <b>OR</b></li> <li>Have tried 2 different preferred agents in the past 6 months</li> </ul> <b>AirDuo Digihaler</b> <ul style="list-style-type: none"> <li>Requires clinical review</li> </ul>

## METHODS

MS-DUR reported performance on the Asthma Medication Ratio (AMR) quality measure. The AMR assesses the appropriate use of controller medications for beneficiaries with persistent asthma and is defined as the percentage of beneficiaries having persistent asthma and a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year. This measure was developed by the National Collaborative for Innovation in Quality Measurement. The measurement specifications are summarized in Table 1.

<b>TABLE 1: AMR Measurement Specifications (Children and Adults)</b>	
<b>Measurement Year</b>	January 1- December 31 of the measure year
<b>Denominator</b>	Medicaid enrollees aged 5-18 years (children) and 19-64 years (adults) identified as having persistent asthma. Beneficiaries were identified as having persistent asthma if they met at least one of the following criteria during the respective measurement years and the year prior to that:
	1) At least one ED visit , with a principal diagnosis of asthma
	2) At least one acute inpatient encounter , with a principal diagnosis of asthma without telehealth
	3) At least one acute inpatient discharge with a principal diagnosis of asthma on the discharge claim.
	4) At least four outpatient visits, observation visits , telephone visits or e-visits or virtual check-ins, on different dates of service, with any diagnosis of asthma and at least two asthma medication dispensing events for any controller or reliever medication.
	5) At least four asthma medication dispensing events for any controller or reliever medication.
<b>Numerator</b>	Beneficiaries with a ratio of controller medication units to total asthma medication units of 0.50 or greater.
<b>Continuous Enrollment</b>	The measurement year and the year prior to the measurement year with a maximum allowable gap of 45 days during each year of continuous enrollment.
<b>Benefits</b>	Medical during the measurement year and the year prior to the measurement year. Pharmacy during the measurement year.
<b>Exclusions</b>	1) Beneficiaries in hospice.
	2) Beneficiaries who had any diagnosis if emphysema, COPD, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions due to fumes and vapors, Cystic Fibrosis, Acute Respiratory failure
	3) Beneficiaries who had no asthma controller medications or reliever medications dispensed during the measurement year.
<b>Anchor Date</b>	December 31 of the measurement year.

Performance is reported for calendar years (CY) 2018 - 2020 for both children and adults and is broken down by the following beneficiary characteristics: age, gender, race, and pharmacy program.

In addition to performance on the CMS/HEDIS AMR quality measure, the relationship between performance on the AMR measure and asthma-related healthcare utilization was assessed. Number of beneficiaries and costs associated with asthma-related healthcare utilization were determined.

## RESULTS

Tables 2a-2c show performance on the AMR quality measure in both children and adults meeting the inclusion criteria for CY 2018-2020. Comparing results from the 2019 DUR Board Report which looked at CY 2017<sup>1</sup>, the overall AMR  $\geq 0.5$  rate within Mississippi Medicaid has risen from 61.8% in 2017 to 63.6% in 2020 for children and from 43.6% in 2017 to 47.9% in 2020 for adults. Comparing CY 2018-2020 rates, the rates for both children and adults were higher across all three years in fee-for-service (FFS) than in the three coordinated care organizations (CCOs). Rates varied across the 2 age categories for children (5-11 yrs and 12-18 yrs) and across different racial groups in both children and adults.

**Table 2a: Mississippi Medicaid Performance on CMS/HEDIS AMR**  
**January 1, 2018 - December 31, 2018**  
*Includes Medicaid ONLY - No CHIP*

Beneficiary characteristics		Children			Adults		
		Denominator	Numerator (AMR ≥ 0.50)	Rate*	Denominator	Numerator (AMR ≥ 0.50)	Rate*
<b>Overall</b>		<b>8343</b>	<b>5341</b>	<b>64.0%</b>	<b>1877</b>	<b>834</b>	<b>44.4%</b>
<b>Age*</b>	<b>Category 1</b>	4693	3277	69.8%	1336	598	44.8%
	<b>Category 2</b>	3650	2064	56.5%	541	236	43.6%
<b>Gender</b>	<b>Female</b>	3399	2214	65.1%	1370	585	42.7%
	<b>Male</b>	4944	3127	63.2%	507	249	49.1%
<b>Race</b>	<b>Caucasian</b>	2542	1965	77.3%	536	261	48.7%
	<b>Hispanic</b>	147	95	64.6%	5	3	60.0%
	<b>African American</b>	5422	3098	57.1%	1168	487	41.7%
	<b>Other</b>	232	183	78.9%	168	83	49.4%
	<b>Plan</b>	751	651	86.7%	156	117	75.0%
<b>Plan</b>	<b>UHC</b>	3320	2095	63.1%	642	258	40.2%
	<b>MAG</b>	4166	2519	60.5%	1059	451	42.6%
	<b>MOL</b>	106	76	71.7%	20	8	40.0%

\*Rate is percentage of beneficiaries with ratio of controller medication units to total asthma medication units of 0.50 or greater; Note: CY - Calendar Year; FFS - Fee-for-Service; UHC - UnitedHealthcare; MAG - Magnolia; MOL - Molina; \*For children age category 1 = 5-11 years, category 2 = 12-18 years; For adults age category 1 = 19-50 years, category 2 = 51-64 years

**Table 2b: Mississippi Medicaid Performance on CMS/HEDIS AMR**  
**January 1, 2019 - December 31, 2019**  
*Includes Medicaid ONLY - No CHIP*

Beneficiary characteristics		Children			Adults		
		Denominator	Numerator (AMR ≥ 0.50)	Rate*	Denominator	Numerator (AMR ≥ 0.50)	Rate*
<b>Overall</b>		<b>8760</b>	<b>5184</b>	<b>59.2%</b>	<b>2151</b>	<b>954</b>	<b>44.4%</b>
<b>Age*</b>	<b>Category 1</b>	4642	3018	65.0%	1475	650	44.1%
	<b>Category 2</b>	4118	2166	52.6%	676	304	45.0%
<b>Gender</b>	<b>Female</b>	3615	2176	60.2%	1609	696	43.3%
	<b>Male</b>	5145	3008	58.5%	542	258	47.6%
<b>Race</b>	<b>Caucasian</b>	2659	1935	72.8%	639	305	47.7%
	<b>Hispanic</b>	142	83	58.5%	11	6	54.5%
	<b>African American</b>	5718	2990	52.3%	1305	551	42.2%
	<b>Other</b>	241	176	73.0%	196	92	46.9%
	<b>Plan</b>	642	560	87.2%	215	174	80.9%
<b>Plan</b>	<b>UHC</b>	3509	2018	57.5%	711	275	38.7%
	<b>MAG</b>	4363	2470	56.6%	1181	488	41.3%
	<b>MOL</b>	246	136	55.3%	44	17	38.6%

\*Rate is percentage of beneficiaries with ratio of controller medication units to total asthma medication units of 0.50 or greater; Note: CY - Calendar Year; FFS - Fee-for-Service; UHC - UnitedHealthcare; MAG - Magnolia; MOL - Molina; \*For children age category 1 = 5-11 years, category 2 = 12-18 years; For adults age category 1 = 19-50 years, category 2 = 51-64 years

**Table 2c: Mississippi Medicaid Performance on CMS/HEDIS AMR**  
**January 1, 2020 - December 31, 2020**  
*Includes Medicaid ONLY - No CHIP*

Beneficiary characteristics		Children			Adults		
		Denominator	Numerator (AMR ≥ 0.50)	Rate*	Denominator	Numerator (AMR ≥ 0.50)	Rate*
<b>Overall</b>		<b>8263</b>	<b>5257</b>	<b>63.6%</b>	<b>2491</b>	<b>1193</b>	<b>47.9%</b>
<b>Age*</b>	<b>Category 1</b>	4274	2983	69.8%	1748	839	48.0%
	<b>Category 2</b>	3989	2274	57.0%	743	354	47.6%
<b>Gender</b>	<b>Female</b>	3467	2231	64.3%	1830	832	45.5%
	<b>Male</b>	4796	3026	63.1%	661	361	54.6%
<b>Race</b>	<b>Caucasian</b>	2585	1938	75.0%	729	360	49.4%
	<b>Hispanic</b>	144	82	56.9%	19	9	47.4%
	<b>African American</b>	5289	3048	57.6%	1508	701	46.5%
	<b>Other</b>	245	189	77.1%	235	123	52.3%
	<b>Plan</b>	534	504	94.4%	448	323	72.1%
<b>Plan</b>	<b>UHC</b>	3240	2030	62.7%	759	323	42.6%
	<b>MAG</b>	3999	2447	61.2%	1156	491	42.5%
	<b>MOL</b>	490	276	56.3%	128	56	43.8%

\*Rate is percentage of beneficiaries with ratio of controller medication units to total asthma medication units of 0.50 or greater; Note: CY - Calendar Year; FFS - Fee-for-Service; UHC - UnitedHealthcare; MAG - Magnolia; MOL - Molina; \*For children age category 1 = 5-11 years, category 2 = 12-18 years; For adults age category 1 = 19-50 years, category 2 = 51-64 years

Table 3 shows the relationship between performance on the CMS/HEDIS AMR measure and asthma-related healthcare utilization as defined by inpatient hospitalizations and emergency department visits. Suboptimal performance on the AMR measure (AMR < 0.5) was shown to be associated with higher proportions of both inpatient hospitalizations and emergency department visits among children and adults across all three years examined (2018-2020). Of note, the difference in proportion of emergency department visits among those with suboptimal AMR performance was significantly higher than for those with AMR  $\geq$  0.5 in both children and adults across all three years.

<b>TABLE 3: Relationship Between Performance on AMR Measure and Asthma Related Healthcare Utilization</b> <b>Mississippi Medicaid January 1 - December 31 of CY</b> <b>Includes Medicaid ONLY - No CHIP</b>												
Beneficiary characteristics	Children						Adults					
	Inpatient Utilization			Emergency Department			Inpatient Utilization			Emergency Department		
	No (N,%)	Yes (N,%)	p value	No (N,%)	Yes (N,%)	p value	No (N,%)	Yes (N,%)	p value	No (N,%)	Yes (N,%)	p value
<b>Overall CY 2018</b>	0.08			<0.001			0.08			<0.001		
<b>CMS/HEDIS AMR &lt;0.5</b>	2953(98.37)	49(1.63)		2516(83.81)	486(16.19)		1034(99.14)	9(0.86)		937(89.84)	106(10.16)	
<b>AMR <math>\geq</math> 0.50</b>	5278(98.82)	63(1.18)		4971(93.07)	370(6.93)		832(99.76)	2(0.24)		802(96.16)	32(3.84)	
<b>Overall CY 2019</b>	0.29			<0.001			0.08			<0.001		
<b>CMS/HEDIS AMR &lt;0.5</b>	3537(98.91)	39(1.09)		3067(85.77)	509(14.23)		1186(99.08)	11(0.92)		1048(87.55)	149(12.45)	
<b>AMR <math>\geq</math> 0.50</b>	5139(99.13)	45(0.87)		4840(93.36)	344(6.63)		951(99.69)	3(0.31)		896(93.92)	58(6.079)	
<b>Overall CY 2020</b>	0.69			<0.001			0.35			<0.001		
<b>CMS/HEDIS AMR &lt;0.5</b>	2988 (99.40)	18 (0.60)		2734 (90.95)	272 (9.05)		1291 (99.46)	7 (0.54)		1187 (91.44)	111 (8.55)	
<b>AMR <math>\geq</math> 0.50</b>	5229 (99.47)	28 (0.53)		5025 (95.59)	232 (4.41)		1190 (99.75)	3 (0.25)		1138 (95.39)	55 (4.61)	
Note: CY - Calendar Year; FFS - Fee-for-Service; UHC - UnitedHealthcare; MAG - Magnolia; MOL - Molina; AMR = Ratio of controller medication units to total asthma medication units; p values reported for Chi-Sq Test; For cells with cell count less than 5, p values for Fisher Exact Test have been reported.												

Demonstrating the relationship between performance on the CMS/HEDIS AMR measure and asthma-related healthcare utilization, MS-DUR calculated the costs of asthma-related healthcare utilization among Medicaid beneficiaries. (Tables 4a/4b)

TABLE 4a: Asthma-Related Healthcare Utilization Costs (Per Member Per Year) by Calendar Year *Children Only*					
Healthcare Utilization	N	Costs			
		Mean (S.D)	Median	25th Percentile	75th Percentile
Hospitalizations					
CY 2018	112	\$5,053.97 (4,559.68)	\$3,280.52	\$2,218.76	\$6,002.97
CY 2019	84	\$4,231.60 (3,846.59)	\$3,275.04	\$2,249.14	\$5,072.60
CY 2020	46	\$2,931.07 (2,354.77)	\$2,247.26	\$2,247.26	\$3,283.01
Emergency Department Visits					
CY 2018	856	\$962.57 (1258.83)	\$564.47	\$343.70	\$1,045.00
CY 2019	853	\$1,132.26 (1,569.06)	\$605.36	\$384.81	\$1,253.68
CY 2020	504	\$1,090.66 (1,772.86)	\$576.48	\$366.89	\$1,074.66
Note: CY - Calendar Year					



TABLE 4b: Asthma-Related Healthcare Utilization Costs (Per Member Per Year) by Calendar Year *Adults Only*					
Healthcare Utilization	N	Costs			
		Mean (S.D)	Median	25th Percentile	75th Percentile
Hospitalizations					
CY 2018	11	\$9,597.01 (20,445.51)	\$3,187.12	\$2,166.49	\$5,997.01
CY 2019	14	\$10,088.69 (15,650.85)	\$3,257.63	\$3,235.04	\$6,481.04
CY 2020	10	\$2,284.96 (917.85)	\$2,227.26	\$2,227.26	\$2,990.50
Emergency Department Visits					
CY 2018	138	\$1,970.86 (2,382.73)	\$1,061.34	\$477.76	\$2,472.21
CY 2019	207	\$2,630.03 (4,829.01)	\$1,140.51	\$565.20	\$2,513.26
CY 2020	166	\$2,232.23 (4,092.06)	\$1,140.22	\$536.25	\$2,146.80
Note: CY - Calendar Year					

Hospitalizations for children ranged from a median of \$2,247.26 - \$3280.52 per member per year and for adults the median ranged from \$2,227.26 – \$3,257.63 per member per year over the three years assessed. Emergency departmental costs ranged from a median of \$564.47 - \$605.36 per member per year in children and from \$1,061.34 - \$1,140.22 per member per year in adults for the three years assessed.

## CONCLUSIONS

Although improvements have been made, work still needs to be done to increase performance rates on the CMS/HEDIS AMR measure and improve asthma care for Medicaid beneficiaries. Through enhanced asthma care for beneficiaries, healthcare utilization costs associated with asthma-related events can be decreased. The UPDL should allow providers to appropriately utilize evidence-based prescribing in the management asthma among Medicaid beneficiaries.

## RECOMMENDATIONS

1. The UPDL quantity limit for Symbicort® should be updated to allow for its prescribing in both as-needed and maintenance therapy concurrently.
2. MS-DUR should design and implement an educational intervention program to educate providers on the updated asthma guidelines, performance on asthma medication management quality measures, and any asthma-related UPDL updates.



## REFERENCES

1. Drug Utilization Review Board Archive | Mississippi Division of Medicaid. Accessed November 1, 2021. <https://medicaid.ms.gov/providers/pharmacy/drug-utilization-review-dur-board/drug-utilization-review-board-archive/>
2. Updated versions of reports available. Global Initiative for Asthma - GINA. Published April 12, 2019. Accessed October 28, 2021. <https://ginasthma.org/1809-2/>
3. 2021 GINA Main Report. Global Initiative for Asthma - GINA. Accessed October 28, 2021. <https://ginasthma.org/gina-reports/>
4. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. *N Engl J Med*. 2018;378(20):1865-1876. doi:10.1056/NEJMoa1715274
5. Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. *N Engl J Med*. 2019;380(21):2020-2030. doi:10.1056/NEJMoa1901963
6. Universal Preferred Drug List | Mississippi Division of Medicaid. Accessed November 1, 2021. <https://medicaid.ms.gov/providers/pharmacy/preferred-drug-list/>

## 90-DAY DRUG LIST UTILIZATION

### BACKGROUND

The Mississippi Division of Medicaid maintains a list of maintenance medications that can be prescribed and dispensed for a 90-day supply (Appendix A).<sup>1</sup> Prescribers may use this list as a tool to manage a beneficiary's prescription drug limit, unless clinically contraindicated. In April 2019, the 90-day list was expanded to create greater access to maintenance medications.

MS-DUR conducted an analysis of the utilization of medications on the 90-day maintenance list since the update occurred in 2019.

### METHODS

A retrospective analysis of Medicaid point of sale (POS) pharmacy claims data from fee-for-service (FFS) and the three coordinated care organizations (CCOs) [United Healthcare (UHC), Magnolia Health (MAG) and Molina Healthcare (MOL)] was conducted for the observational period January 1, 2019 - June 30, 2021. Beneficiaries were included in the analysis if they had at least one fill for 90-day maintenance listing drug with a day-of-supply of 90 days during January 1, 2019 - June 30, 2021. For the utilization of some medications where monthly quantities equal 28 days (ex. oral contraceptives), beneficiaries were included in the analysis if they had at least one fill with a day-of-supply of 84 days.

Utilization trends of the 90-day maintenance listing drugs was captured by quarter and by state fiscal year. The trends were depicted in three aspects: number of fills, proportion of all fills for that specific drug class and spend. All utilization trends were measured at a drug-class level. For some drug classes in which standard utilization tables may not be suitable for demonstrating their unique scenario, a brief description was included.

### RESULTS

Since the beginning of 2019, a total of 428,301 claims were filled with a day-of-supply of 90 days (or equivalent) by 68,205 beneficiaries. (Tables Util-Overall 1-6)

- Quarterly trends in both number of claims and total spend consistently increased throughout the study period.
- Based on an average monthly Medicaid enrollment of just over 700,000 beneficiaries during the study period<sup>2</sup>, approximately 9.7% (68,205/700,000) of beneficiaries utilized the 90-day list over the course of the study period.
- The predominant characteristics of beneficiaries utilizing the 90-list were: age 45-64 years (42.7%); female gender (69%); African American (51.9%); and filling 0-1 prescriptions monthly (66.4%).

TABLE UTIL-OVERALL.1: Claim Level Beneficiaries' Demographic Characteristics for all Claims with 90 days of Supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	5,181	8,480	9,324	1,948	24,933
18-25	7,324	5,462	5,222	1,686	19,694
26-44	15,904	32,390	40,786	10,660	99,740
45-64	53,222	92,245	120,398	15,533	281,398
65+	1,292	525	718	1	2,536
<b>Total</b>	<b>82,923</b>	<b>139,102</b>	<b>176,448</b>	<b>29,828</b>	<b>428,301</b>
<b>Gender</b>					
Female	53,199	88,849	116,288	19,648	277,984
Male	29,720	50,253	60,160	10,180	150,313
<b>Total</b>	<b>82,919</b>	<b>139,102</b>	<b>176,448</b>	<b>29,828</b>	<b>428,297</b>
<b>Race</b>					
Caucasian	30,308	47,864	56,916	11,414	146,502
African American	44,226	70,609	95,414	13,758	224,007
Other	8,389	20,629	24,118	4,656	57,792
<b>Total</b>	<b>82,923</b>	<b>139,102</b>	<b>176,448</b>	<b>29,828</b>	<b>428,301</b>
Note: 378 claims have missing information for pharmacy program; 4 claims' gender variable is valued as "U".					

TABLE UTIL-OVERALL.2: Beneficiary Level Beneficiaries' Demographic Characteristics for all Claims with 90 days of Supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	2,319	3,868	4,183	965	11,335
18-25	3,166	1,688	1,694	730	7,278
26-44	4,602	6,018	7,210	2,405	20,235
45-64	7,927	8,521	11,085	1,604	29,137
65+	123	41	56	0	220
<b>Total</b>	<b>18,137</b>	<b>20,136</b>	<b>24,228</b>	<b>5,704</b>	<b>68,205</b>
<b>Gender</b>					
Female	12,683	13,541	16,694	4,142	47,060
Male	5,453	6,595	7,534	1,562	21,144
<b>Total</b>	<b>18,136</b>	<b>20,136</b>	<b>24,228</b>	<b>5,704</b>	<b>68,204</b>
<b>Race</b>					
Caucasian	7,066	7,552	8,307	2,299	25,224
African American	9,239	10,159	13,198	2,733	35,329
Other	1,832	2,425	2,723	672	7,652
<b>Total</b>	<b>18,137</b>	<b>20,136</b>	<b>24,228</b>	<b>5,704</b>	<b>68,205</b>
<b>Average monthly fills</b>					
0-1	12,120	13,448	15,697	4,035	45,300
2-4	5,605	6,362	8,175	1,565	21,707
5+	412	326	356	104	1,198
<b>Total</b>	<b>18,137</b>	<b>20,136</b>	<b>24,228</b>	<b>5,704</b>	<b>68,205</b>
<b>Mean number of fills per month</b>	<b>1.4</b>	<b>1.4</b>	<b>1.4</b>	<b>1.3</b>	<b>1.4</b>
Note: pharmacy program is determined by beneficiaries' first 90-day claim in the study period; 147 beneficiaries have missing information for pharmacy program; 1 beneficiaries' gender variable is valued as "U"; average monthly fills is defined as average total number of pharmacy claims during the period from each beneficiary's first claim with 90 days of supply to the last one.					

TABLE UTIL-OVERALL.3: Number of Maintenance Listing Drug Claims with 90 days of Supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	4,785	7,831	11,879	570	25,065
Q2 2019	5,906	9,144	14,364	1,016	30,430
Q3 2019	7,296	12,426	16,627	1,521	37,870
Q4 2019	7,408	12,885	17,178	1,668	39,139
Q1 2020	8,204	15,069	18,186	2,618	44,077
Q2 2020	8,356	16,060	18,513	3,239	46,168
Q3 2020	9,097	14,865	19,486	3,902	47,350
Q4 2020	9,856	15,298	19,624	4,492	49,270
Q1 2021	10,390	16,118	19,914	5,096	51,518
Q2 2021	11,625	19,406	20,677	5,706	57,414
<b>Total</b>	<b>82,923</b>	<b>139,102</b>	<b>176,448</b>	<b>29,828</b>	<b>428,301</b>

TABLE UTIL-OVERALL.4: Total Spend of Maintenance Listing Drug Claims with 90 days of Supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 95,310.96	\$ 156,624.02	\$ 259,006.62	\$ 8,921.29	\$ 519,862.89
Q2 2019	\$ 280,971.58	\$ 306,580.57	\$ 578,973.21	\$ 16,571.74	\$ 1,183,097.10
Q3 2019	\$ 405,105.09	\$ 664,558.09	\$ 895,128.69	\$ 24,895.45	\$ 1,989,687.32
Q4 2019	\$ 405,438.56	\$ 783,384.95	\$ 1,065,965.03	\$ 28,537.29	\$ 2,283,325.83
Q1 2020	\$ 528,033.49	\$ 990,927.88	\$ 1,269,655.82	\$ 75,124.04	\$ 2,863,741.23
Q2 2020	\$ 595,595.33	\$ 1,023,988.89	\$ 1,345,114.00	\$ 128,251.47	\$ 3,092,949.69
Q3 2020	\$ 618,187.50	\$ 1,004,541.70	\$ 1,549,482.31	\$ 177,210.68	\$ 3,349,422.19
Q4 2020	\$ 618,478.51	\$ 1,096,239.13	\$ 1,384,524.49	\$ 190,262.79	\$ 3,289,504.92
Q1 2021	\$ 694,311.19	\$ 1,163,134.01	\$ 1,516,251.05	\$ 242,606.97	\$ 3,616,303.22
Q2 2021	\$ 751,486.06	\$ 1,486,342.24	\$ 1,577,515.65	\$ 301,484.14	\$ 4,116,828.09
<b>Total</b>	<b>\$ 4,992,918.27</b>	<b>\$ 8,676,321.48</b>	<b>\$ 11,441,616.87</b>	<b>\$ 1,193,865.86</b>	<b>\$ 26,304,722.48</b>

TABLE UTIL-OVERALL.5: Number of Maintenance Listing Drug Claims with 90 days of Supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	31264	56440	70504	9046	167,254
SFY 2021	40968	65687	79701	19196	205,552
<b>Total</b>	<b>72,232</b>	<b>122,127</b>	<b>150,205</b>	<b>28,242</b>	<b>372,806</b>

TABLE UTIL-OVERALL.6: Total Spend of Maintenance Listing Drug Claims with 90 days of Supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 1,934,172.47	\$ 3,462,859.81	\$ 4,575,863.54	\$ 256,808.25	\$ 10,229,704.07
SFY 2021	\$ 2,682,463.26	\$ 4,750,257.08	\$ 6,027,773.50	\$ 911,564.58	\$ 14,372,058.42
<b>Total</b>	<b>\$ 4,616,635.73</b>	<b>\$ 8,213,116.89</b>	<b>\$ 10,603,637.04</b>	<b>\$ 1,168,372.83</b>	<b>\$ 24,601,762.49</b>

Detailed tables displaying utilization trends measured at the drug-class level can be found in Appendix B. Of note:

- Nearly all drug classes included on the 90-day list saw increases in the proportion of claims for 90 days-of-supply over the period assessed.
- Overall, cardiovascular drug classes saw the highest proportion of 90-day claims with most classes showing > 20% of claims for 90 days-of-supply.
- Drug classes with < 10% of claims for 90 days-of-supply include:
  - HIV antiretrovirals, antivirals, corticosteroids, transplant rejection/rheumatoid arthritis, leukotriene modifiers, anticholinergics, prenatal vitamins, antidepressants, antipsychotics, anticonvulsants, oral contraceptives, cystic fibrosis, incretin mimetics, antifungals, sulfonamide antibiotics, monoamine oxidase inhibitors, and Hep C antivirals.
- Less than 1% of claims for cystic fibrosis agents were filled for 3 months-of-supply. *(Analysis assessed claims with days-of-supply > 80 days.)*

## CONCLUSIONS

The 90-day drug list was expanded in 2019 to allow providers greater flexibility in managing beneficiary prescription drug limits when clinically appropriate. Quarterly trends in both number of claims and total spend consistently increased since the list was expanded. Additionally, the proportion of claims for 90 days-of-supply has increased across nearly all drug classes represented on the list.

## RECOMMENDATIONS

This report is for information and discussion purposes only. No action is being sought at this time.

## REFERENCES:

1. XI T. 90-Day Maintenance Drug List | Mississippi Division of Medicaid. Published online 2019:5. Accessed November 2, 2021. <https://medicaid.ms.gov/wp-content/uploads/2021/08/90-DayMaintenanceList-disease-state.pdf>
2. Resources | Mississippi Division of Medicaid. Accessed November 30, 2021. <https://medicaid.ms.gov/resources/>

## APPENDIX A:

### MS DIVISION OF MEDICAID

#### Voluntary 90 Day Maintenance List

Effective April 1, 2019

Disease State Format



See PDL for preferred agents at <https://medicaid.ms.gov/providers/pharmacy/preferred-drug-list/>.

Drugs on this list may be prescribed and dispensed for a 90 day supply. Clinicians may use this list as a tool to manage beneficiary's monthly prescription drug limit, unless clinically contraindicated.

Drugs and drug strengths appearing in red text denote changes since the last update.

	DRUG CLASS/USE	DRUG NAME	STRENGTH	BRAND NAME
CARDIOVASCULAR	ACE-Inhibitors	LISINOPRIL TAB	2.5, 5, 10, 20, 30, 40 MG	ZESTRIL, PRINIVIL
	ACE-Inhibitor Combination	AMLODIPINE/BENAZEPRIL CAP	2.5/10, 5/10, 5/20, 5/40, 10/20, 10/40 MG	LOTREL
		LISINOPRIL / HCTZ TAB	10/12.5, 20/12.5, 20/25 MG	ZESTORETIC, PRINZIDE
		VERAPAMIL/TRANDOLAPRIL TAB	1/240, 2/180, 2/240, 4/240 MG	TARKA
	Alpha-1 antagonist	DOXAZOSIN MESYLATE TAB	1, 2, 4, 8 MG	CARDURA
	ARBs	LOSARTAN TAB	25, 50, 100 MG	COZAAR
		VALSARTAN TAB	40, 80, 160, 320 MG	DIOVAN
	ARB Combinations	LOSARTAN / HCTZ TAB	50/12.5, 100/12.5, 100/25 MG	HYZAAR
		VALSARTAN/HCTZ TAB	80/12.5, 160/12.5, 320/12.5, 160/25, 320/25 MG	DIOVAN HCT
		VALSARTAN/AMLODIPINE TAB	160/5, 320/5, 160/10, 320/10 MG	EXFORGE
		VALSARTAN/AMLODIPINE/HCTZ TAB	160/5/12.5, 160/5/25, 160/10/12.5, 160/10/25, 320/10/25 MG	EXFORGE HCT
	Beta-Blockers	CARVEDILOL TAB	3.125, 6.25, 12.5, 25 MG	COREG
		METOPROLOL SUCCINATE TAB	25, 50, 100, 200 MG	TOPROL XL
		METOPROLOL TARTRATE TAB	25, 50, 100 MG	LOPRESSOR
		PROPRANOLOL TAB	10, 20, 40, 60, 80 MG	INDERAL
		PROPRANOLOL ER CAP	60, 80, 120, 160 MG	INDERAL LA
	Calcium Channel Blockers	AMLODIPINE TAB	2.5, 5, 10 MG	NORVASC
		DILTIAZEM TAB	30, 60, 90, 120 MG	CARDIZEM
		DILTIAZEM ER 24 HR. CAP, TAB	120, 180, 240, 300, 360, 420 MG	CARDIZEM CD, LA
		NIFEDIPINE ER TAB	30, 60, 90 MG	PROCARDIA XL
		VERAPAMIL TAB	40, 80, 120 MG	CALAN, ISOPTIN
		VERAPAMIL EXTENDED RELEASE TAB	120, 180, 240 MG	CALAN SR
		VERAPAMIL EXTENDED RELEASE 24 HR.	100, 120, 180, 200, 240, 300, 360 MG	COVERA-HS, VERELAN PM
	Cardiac glycosides	DIGOXIN TAB±	125, 250 MCG	LANOXIN
	K+ sparing diuretics	EPLERENONE TAB	25, 50 MG	INSPIRA
		SPIRONOLACTONE TAB	25, 50 MG	ALDACTONE
		TRIAMTERENE/HCTZ CAP & TAB	37.5/25, 50/25, 75/50 MG	DYAZIDE, MAXZIDE

# MS DIVISION OF MEDICAID

## Voluntary 90 Day Maintenance List

Effective April 1, 2019

Disease State Format



	Loop diuretics	FUROSEMIDE TAB	20, 40, 80 MG	LASIX
		TORSEMIDE TAB	5, 10, 20, 100 MG	DEMADEX
	Thiazide diuretics	CHLORTHALIDONE	25, 50 MG	THALITONE
		HYDROCHLOROTHIAZIDE TAB	25 MG	HYDRODIURIL
	Vasodilators	HYDRALAZINE TAB	10, 25, 50, 100 MG	APRESOLINE
	Fibrates	FENOFIBRATE TAB nanocrystallized	48, 145 MG	TRICOR
		GEMFIBROZIL TAB	600 MG	LOPID
	Statins	ATORVASTATIN TAB	20, 40, 80 MG	LIPITOR
		PRAVASTATIN TAB	10, 20, 40, 80 MG	PRAVACHOL
		ROSUVASTATIN TAB	5, 10, 20, 40 MG	CRESTOR
		SIMVASTATIN TAB	10, 20, 40 MG	ZOCOR
CYSTIC FIBROSIS	Platelet inhibitors	CLOPIDOGREL TAB	75 MG	PLAVIX
	Anticoagulants	WARFARIN TABS	ALL STRENGTHS	COUMADIN
		AZTREONAM LYSINE POWDER FOR NEB	75 MG /VIAL SOLN	CAYSTON
		COLISTIN (COLISTIMETHATE NA) VIAL	150 MG /VIAL ,FOR INH USE	COLY-MYCIN M
		DORNASE ALFA AMP	1 MG/ML SOLN FOR INH	PULMOZYME
		IVACAFTOR GRAN & TAB	50, 75 , 150 MG	KALYDECO
		LUMACAFTOR-IVACAFTOR GRAN & TAB	100/125, 150/188, 100/125, 200/125	ORKAMBI
		TEZACAFTOR-IVACAFTOR TAB	150/100 MG	SYMDEKO
		TOBRAMYCIN SOLN FOR INH	300 MG/4 ML SOLN FOR INH	BETHKIS
		TOBRAMYCIN SOLN FOR INH	300 MG/5 ML SOLN FOR INH	KITABIS
		TOBRAMYCIN INH	28 MG POWDER FOR INH	TOBI PODHALER
DIABETES	Alpha-Glucosidase Inhibitors	ACARBOSE	25, 50, 100 MG	PRECOSE
		MIGLITOL	25, 50, 100 MG	GLYSET
	Biguanides	METFORMIN HCL TAB	500, 850, 1000 MG	GLUCOPHAGE
		METFORMIN HCL ER 24 HR TAB	500, 750 MG	GLUCOPHAGE XR
	DPP4 & Combinations	LINAGLIPTIN TAB	5 MG	TRADJENTA
		LINAGLIPTIN/METFORMIN TAB	2.5/500, 2.5/850, 2.5/1000 MG	JENTADUETO
		SITAGLIPTIN TAB	25, 50, 100 MG	JANUVIA
		SITAGLIPTIN/METFORMIN TAB	50/500, 50/1000 MG	JANUMET
	Incretin Mimetics	SITAGLIPTIN/METFORMIN XR TAB	50/500, 50/1000, 100/1000 MG	JANUMET XR
		EXENATIDE SQ INJECTION	2 MG VIAL, 2 MG PEN INJ	BYDUREON
		EXENATIDE SQ INJECTION	5, 10 MCG DOSE PEN	BYETTA
		LIRAGLUTIDE INJECTION	18 MG/3 ML (2-PAK , 3-PAK)	VICTOZA
	Meglitinides	NATEGLINIDE TAB	60, 120 MG	STARLIX
		REPAGLINIDE TAB	0.5, 1, 2 MG	PRANDIN

# MS DIVISION OF MEDICAID

## Voluntary 90 Day Maintenance List

Effective April 1, 2019

Disease State Format



	Sodium Glucose Cotransporter 2 Inhibitors & Combinations	DAPAGLIFLOZIN TAB	5, 10 MG	FARXIGA
		EMPAGLIFLOZIN TAB	10, 25 MG	JARDIANCE
		EMPAGLIFLOZIN/METFORMIN TAB	5/500, 5/1000, 12.5/500, 12.5/1000 MG	SYNJARDY
	Sulfonylurea	GLIMIPIRIDE TAB	1, 2, 4 MG	AMARYL
		GLIPIZIDE TAB	5, 10 MG	GLUCOTROL
		GLIPIZIDE ER 24 HR TAB	2.5, 5, 10 MG	GLUCOTROL XL
		GLYBURIDE TAB	1.25, 2.5, 5 MG	
		GLYBURIDE MICRONIZED TAB	1.5, 3, 6 MG	GLYNASE PRESTAB
	Sulfonylurea/Biguanide	GLIPIZIDE/METFORMIN TAB	2.5/250, 2.5/500, 5/500 MG	METAGLIP
		GLYBURIDE/METFORMIN TAB	2.5/500, 5/500 MG	GLUCOVANCE
GI	H2-antagonists	FAMOTIDINE TAB	20, 40 MG	PEPCID
		RANITIDINE TAB	150, 300 MG	ZANTAC
GOUT	Xanthine Oxidase Inhibitors	ALLOPURINOL TAB	100, 300 MG	ZYLOPRIM
ID/Antiretrovirals	Antiretrovirals (HIV)	ALL DRUGS	ALL STRENGTHS	ALL
	Antiviral	ACYCLOVIR CAP & TAB	200 MG, 400 MG	ZOVIRAX
	Antiviral/HepC	RIBAVIRIN CAP & TAB	200 MG	REBETOL/COPEGUS
	Azole antifungals	FLUCONAZOLE TAB	50, 100, 150, 200 MG	DIFLUCAN
	Sulfonamide antibiotics	SULFAMETHOXAZOLE/TMP TAB	400/80, 800/160 MG	BACTRIM SS, BACTRIM DS
IMMUNE SUPPRESSION	Corticosteroid	PREDNISONE TAB	2.5, 5, 10, 20, 50 MG	DELTAONE
	Transplant Rejection	CYCLOSPORINE (MODIFIED) SOFT GEL	25, 50, 100 MG	GENGRAF, NEORAL
		CYCLOSPORINE CAP	25, 100 MG	SANDIMMUNE
		MYCOPHENOLATE CAP	250, 500 MG	CELLCEPT
		SIROLIMUS TAB	0.5, 1, 2 MG	RAPAMUNE
		MYCOPHENOLATE SODIUM TAB	180, 360 MG	MYFORTIC
		TACROLIMUS CAP	0.5, 1, 5 MG	PROGRAF
	Transplant rejection, Rheumatoid arthritis (RA)	AZATHIOPRINE TAB	50 MG	IMURAN
		METHOTREXATE TAB	2.5 MG	TREXALL
MISC	Fibromyalgia	DULOXETINE CAP	20, 30, 40, 60 MG	CYMBALTA
	Hypothyroidism	LEVOTHYROXINE TABS±	ALL STRENGTHS	SYNTHROID, LEVOXYL, LEVOTHROID
	Leukotriene Modifiers	MONTELUKAST TAB	4, 5, 10 MG	SINGULAIR
	Malignancies	HYDROXYUREA CAP	500 MG	HYDREA, DROXIA
PAR KINS ONS	Anticholinergics	AMANTADINE CAP	100 MG	SYMMETREL

# MS DIVISION OF MEDICAID

## Voluntary 90 Day Maintenance List

Effective April 1, 2019

Disease State Format



		BENZTROPINE TAB	0.5, 1, 2 MG	COGENTIN
	Dopamine replacement	LEVODOPA/CARBIDOPA TAB	100/10, 100/25, 250/25, 100/25 CR, 200/50 MG CR	SINEMET/SINEMET CR
	MAO Inhibitors	SELEGILINE CAP & TAB	5 MG	ELDEPRYL
Prenatal Vitamins	Prenatal Vitamins	ALL PRODUCTS* (See PDL for preferred products)	ALL	ALL
PSYCH	Antidepressants - SSRIs	BUPROPION TAB	75, 100 MG	WELLBUTRIN
		BUPROPION SR TAB	100, 150, 200 MG	WELLBUTRIN SR
		BUPROPION XL TAB	150, 300 MG	WELLBUTRIN XL
		CITALOPRAM TAB	10, 20, 40 MG	CELEXA
		ESCITALOPRAM TAB	5, 10, 20 MG	LEXAPRO
		FLUOXETINE CAP	10, 20, 40 MG	PROZAC
		MIRTAZAPINE TAB	7.5, 15, 30, 45 MG	REMERON
		PAROXETINE TAB	10, 20, 30, 40 MG	PAXIL
		PAROXETINE CR TAB	12.5, 25, 37.5 MG	PAXIL CR
		SERTRALINE TAB	25, 50, 100 MG	ZOLOFT
		TRAZODONE TAB	50, 100, 150, 300 MG	DESYREL
		VENLAFAXINE TAB	25, 37.5, 50, 75, 100 MG	EFFEXOR
		VENLAFAXINE ER CAP/TAB	37.5, 75, 150, 225 MG	EFFEXOR XR
	Antipsychotics – Atypical	ARIPIRAZOLE TAB	2, 5, 10, 15, 20, 30 MG	ABILIFY
		OLANZAPINE TAB	2.5, 5, 7.5, 10, 15, 20 MG	ZYPREXA
		OLANZAPINE ODT	5, 10, 15, 20 MG	ZYPREXA ZYDIS
		RISPERIDONE TAB	0.25, 0.5, 1, 2, 3, 4 MG	RISPERDAL
		RISPERIDONE ODT	0.25, 0.5, 1, 2, 3, 4 MG	RISPERIDAL M-TAB/ODT
		QUETIAPINE TAB	25, 50, 100, 200, 300, 400 MG	SEROQUEL
		QUETIAPINE ER TAB	50, 150, 200, 300, 400 MG	SEROQUEL XR
		ZIPRASIDONE CAP	20, 40, 60, 80 MG	GEODON
SEIZURES	Anticonvulsants	CARBAMAZEPINE TAB	200 MG	EPITOL
		CARBAMAZEPINE ER TAB±	100, 200, 400 MG	TEGRETOL XR
		CARBAMAZEPINE ER CAP±	100, 200, 300 MG	CARBATROL/EQUETRO
		DIVALPROEX SODIUM DR TAB	125, 250, 500 MG	DEPAKOTE
		DIVALPROEX SODIUM ER TAB	250, 500 MG	DEPAKOTE ER
		ETHOSUXIMIDE CAP	250 MG	ZARONTIN
		LAMOTRIGINE TAB	25, 100, 150, 200 MG	LAMICTAL
		LAMOTRIGINE ODT TAB	25, 50, 100, 200 MG	LAMICTAL ODT
		LAMOTRIGINE ER TAB	25, 50, 100, 200, 250, 300 MG	LAMICTAL XR



## MS DIVISION OF MEDICAID

### Voluntary 90 Day Maintenance List

Effective April 1, 2019

Disease State Format



		LEVETIRACETAM TAB	250, 500, 750, 1000 MG	KEPPRA
		LEVETIRACETAM ER TAB	500, 750 MG	KEPPRA XR
		OXCARBAZEPINE TAB	150, 300, 600 MG	TRILEPTAL
		PHENYTOIN SODIUM ER CAP±	30, 100 MG	DILANTIN KAPSEAL
		PHENYTOIN SODIUM ER CAP±	200, 300 MG	PHENYTEK
		TOPIRAMATE TAB	25, 50, 100, 200 MG	TOPAMAX
		TOPIRAMATE SPRINKLE CAPSULE	15, 25 MG	TOPAMAX SPRINKLE CAP
		VALPROIC ACID CAP	250 MG	DEPAKENE
		ZONISAMIDE CAP	25, 50, 100 MG	ZONEGRAN
Select Contraceptives	Oral Contraceptives* (See PDL for preferred products)	ALL PRODUCTS	ALL	ALL

± Narrow therapeutic index drugs (NTI). Branded agents must be billed with DAW7

Last updated 8/31/2021

APPENDIX B:  
CARDIOVASCULAR – ACE INHIBITORS:

TABLE UTIL-CARD-ACE.1: Beneficiaries' Demographic Characteristics for ACE Inhibitor Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	127	234	214	37	612
18-25	110	253	168	68	599
26-44	727	2,179	2,442	666	6,014
45-64	3,484	6,264	8,511	1,220	19,479
65+	85	25	40	0	150
<b>Total</b>	<b>4,533</b>	<b>8,955</b>	<b>11,375</b>	<b>1,991</b>	<b>26,854</b>
<b>Gender</b>					
Female	2,407	4,725	6,240	1,044	14,416
Male	2,125	4,230	5,135	947	12,437
<b>Total</b>	<b>4,532</b>	<b>8,955</b>	<b>11,375</b>	<b>1,991</b>	<b>26,853</b>
<b>Race</b>					
Caucasian	1,872	3,617	4,484	844	10,817
African American	2,071	3,841	5,158	718	11,788
Other	590	1,497	1,733	429	4,249
<b>Total</b>	<b>4,533</b>	<b>8,955</b>	<b>11,375</b>	<b>1,991</b>	<b>26,854</b>

Note: 5 claims have missing information for pharmacy program; 1 claims' gender variable is valued as "U".

TABLE UTIL-CARD-ACE.2: Number of ACE Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	288	648	882	55	1,873
Q2 2019	332	727	996	99	2,154
Q3 2019	402	823	1,122	140	2,487
Q4 2019	406	820	1,121	161	2,508
Q1 2020	449	944	1,188	196	2,777
Q2 2020	467	1,019	1,198	215	2,899
Q3 2020	484	925	1,259	259	2,927
Q4 2020	537	937	1,229	272	2,975
Q1 2021	551	986	1,182	283	3,002
Q2 2021	617	1,126	1,198	311	3,252
<b>Total</b>	<b>4,533</b>	<b>8,955</b>	<b>11,375</b>	<b>1,991</b>	<b>26,854</b>

TABLE UTIL-CARD-ACE.5: Number of ACE Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	1,724	3,606	4,629	712	10,671
SFY 2021	2,189	3,974	4,868	1,125	12,156
<b>Total</b>	<b>3,913</b>	<b>7,580</b>	<b>9,497</b>	<b>1,837</b>	<b>22,827</b>

TABLE UTIL-CARD-ACE.3: Proportion of ACE Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	10.64%	20.64%	18.08%	15.28%
Q2 2019	11.86%	23.92%	20.71%	18.72%
Q3 2019	14.72%	27.51%	24.45%	21.51%
Q4 2019	15.25%	27.49%	27.00%	23.13%
Q1 2020	16.30%	29.63%	28.33%	28.53%
Q2 2020	17.80%	30.97%	30.29%	29.57%
Q3 2020	18.86%	30.78%	31.74%	33.04%
Q4 2020	19.73%	33.23%	32.64%	34.96%
Q1 2021	20.97%	35.15%	33.75%	32.05%
Q2 2021	22.86%	36.97%	34.59%	33.77%

TABLE UTIL-CARD-ACE.6: Proportion of ACE Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	16.00%	28.96%	27.41%	25.79%
SFY 2021	20.62%	34.04%	33.12%	33.42%

TABLE UTIL-CARD-ACE.4: Total Spend of ACE Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 2,885.30	\$ 6,554.63	\$ 8,974.97	\$ 530.65	\$ 18,945.55
Q2 2019	\$ 3,431.53	\$ 7,479.51	\$ 10,491.18	\$ 1,036.27	\$ 22,438.49
Q3 2019	\$ 4,087.32	\$ 8,492.57	\$ 11,686.60	\$ 1,433.81	\$ 25,700.30
Q4 2019	\$ 4,110.66	\$ 8,423.08	\$ 11,625.79	\$ 1,649.91	\$ 25,809.44
Q1 2020	\$ 4,975.96	\$ 10,174.98	\$ 12,647.80	\$ 2,163.18	\$ 29,961.92
Q2 2020	\$ 5,869.03	\$ 10,730.45	\$ 12,546.68	\$ 2,178.59	\$ 31,324.75
Q3 2020	\$ 6,254.78	\$ 10,176.23	\$ 13,579.32	\$ 2,809.60	\$ 32,819.93
Q4 2020	\$ 5,725.93	\$ 9,988.11	\$ 13,270.51	\$ 2,779.44	\$ 31,763.99
Q1 2021	\$ 5,711.12	\$ 10,288.27	\$ 12,414.77	\$ 2,821.67	\$ 31,235.83
Q2 2021	\$ 6,416.12	\$ 11,642.44	\$ 12,574.66	\$ 3,147.68	\$ 33,780.90
<b>Total</b>	<b>\$ 49,467.75</b>	<b>\$ 93,950.27</b>	<b>\$ 119,812.28</b>	<b>\$ 20,550.80</b>	<b>\$ 283,781.10</b>

TABLE UTIL-CARD-ACE.7: Total Spend of ACE Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 19,042.97	\$ 37,821.08	\$ 48,506.87	\$ 7,425.49	\$ 112,796.41
SFY 2021	\$ 24,107.95	\$ 42,095.05	\$ 51,839.26	\$ 11,558.39	\$ 129,600.65
<b>Total</b>	<b>\$ 43,150.92</b>	<b>\$ 79,916.13</b>	<b>\$ 100,346.13</b>	<b>\$ 18,983.88</b>	<b>\$ 242,397.06</b>

# CARDIOVASCULAR - ACE INHIBITOR COMBINATION:

TABLE UTIL-CARD-ACEC.1: Beneficiaries' Demographic Characteristics for ACE Inhibitor Combination Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	24	28	44	6	102
18-25	37	73	41	12	163
26-44	355	1,274	1,717	390	3,736
45-64	2,014	4,045	5,163	628	11,850
65+	34	20	51	-	105
<b>Total</b>	<b>2,464</b>	<b>5,440</b>	<b>7,016</b>	<b>1,036</b>	<b>15,956</b>
<b>Gender</b>					
Female	1649	3585	4813	661	10,708
Male	815	1,855	2,203	375	5,248
<b>Total</b>	<b>2,464</b>	<b>5,440</b>	<b>7,016</b>	<b>1,036</b>	<b>15,956</b>
<b>Race</b>					
Caucasian	767	1,656	1,909	341	4,673
African American	1,476	3,026	4,194	550	9,246
Other	221	758	913	145	2,037
<b>Total</b>	<b>2,464</b>	<b>5,440</b>	<b>7,016</b>	<b>1,036</b>	<b>15,956</b>

TABLE UTIL-CARD-ACEC.2: Number of ACE Inhibitor Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	225	406	634	34	1,299
Q2 2019	216	469	661	63	1,409
Q3 2019	226	511	709	69	1,515
Q4 2019	213	549	705	81	1,548
Q1 2020	231	604	751	108	1,694
Q2 2020	246	610	723	127	1,706
Q3 2020	258	540	709	103	1,610
Q4 2020	262	559	715	137	1,673
Q1 2021	284	551	708	148	1,691
Q2 2021	303	641	701	166	1,811
<b>Total</b>	<b>2,464</b>	<b>5,440</b>	<b>7,016</b>	<b>1,036</b>	<b>15,956</b>

TABLE UTIL-CARD-ACEC.5: Number of ACE Inhibitor Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	916	2,274	2,888	385	6,463
SFY 2021	1,107	2,291	2,833	554	6,785
<b>Total</b>	<b>2,023</b>	<b>4,565</b>	<b>5,721</b>	<b>939</b>	<b>13,248</b>

TABLE UTIL-CARD-ACEC.3: Proportion of ACE Inhibitor Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	20.68%	18.19%	17.55%	16.35%
Q2 2019	22.52%	21.20%	19.41%	19.69%
Q3 2019	23.13%	23.67%	21.80%	16.95%
Q4 2019	22.33%	27.14%	23.24%	20.93%
Q1 2020	24.55%	28.28%	25.82%	26.54%
Q2 2020	25.71%	28.49%	27.69%	29.13%
Q3 2020	26.43%	29.75%	28.43%	25.82%
Q4 2020	27.52%	33.21%	29.28%	28.60%
Q1 2021	27.07%	32.72%	31.22%	29.78%
Q2 2021	27.85%	33.90%	32.30%	34.58%

TABLE UTIL-CARD-ACEC.6: Proportion of ACE Inhibitor Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	23.92%	26.88%	24.46%	23.52%
SFY 2021	27.23%	32.39%	30.22%	29.87%

TABLE UTIL-CARD-ACEC.4: Total Spend of ACE Inhibitor Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 3,053.88	\$ 5,119.83	\$ 7,934.96	\$ 410.21	\$ 16,518.88
Q2 2019	\$ 3,001.00	\$ 6,240.60	\$ 8,533.95	\$ 813.70	\$ 18,589.25
Q3 2019	\$ 3,104.25	\$ 6,768.45	\$ 9,300.54	\$ 866.45	\$ 20,039.69
Q4 2019	\$ 2,813.69	\$ 7,293.25	\$ 9,203.36	\$ 1,081.98	\$ 20,392.28
Q1 2020	\$ 3,364.66	\$ 8,163.50	\$ 10,108.76	\$ 1,526.41	\$ 23,163.33
Q2 2020	\$ 4,003.94	\$ 7,993.83	\$ 9,500.07	\$ 1,689.39	\$ 23,187.23
Q3 2020	\$ 4,142.34	\$ 7,548.56	\$ 9,653.12	\$ 1,395.31	\$ 22,739.33
Q4 2020	\$ 3,553.71	\$ 7,556.32	\$ 9,696.76	\$ 1,777.43	\$ 22,584.22
Q1 2021	\$ 3,954.80	\$ 7,384.61	\$ 9,787.05	\$ 1,978.58	\$ 23,105.04
Q2 2021	\$ 4,221.65	\$ 8,739.09	\$ 9,669.47	\$ 2,272.89	\$ 24,903.10
<b>Total</b>	<b>\$ 35,213.92</b>	<b>\$ 72,808.04</b>	<b>\$ 93,388.04</b>	<b>\$ 13,812.35</b>	<b>\$ 215,222.35</b>

TABLE UTIL-CARD-ACEC.7: Total Spend of ACE Inhibitor Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 13,286.54	\$ 30,219.03	\$ 38,112.73	\$ 5,164.21	\$ 86,782.51
SFY 2021	\$ 15,872.50	\$ 31,228.58	\$ 38,806.40	\$ 7,424.21	\$ 93,331.69
<b>Total</b>	<b>\$ 29,159.04</b>	<b>\$ 61,447.61</b>	<b>\$ 76,919.13</b>	<b>\$ 12,588.42</b>	<b>\$ 180,114.20</b>

## CARDIOVASCULAR – ALPHA-1 ANTAGONISTS

TABLE UTIL-CARD-A1A.1: Beneficiaries' Demographic Characteristics for Alpha-1 Antagonist Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	-	-	-	-	-
18-25	1	1	3	-	5
26-44	13	12	20	7	52
45-64	143	128	172	13	456
65+	-	-	1	-	1
<b>Total</b>	<b>157</b>	<b>141</b>	<b>196</b>	<b>20</b>	<b>514</b>
<b>Gender</b>					
Female	41	13	62	0	116
Male	116	128	134	20	398
<b>Total</b>	<b>157</b>	<b>141</b>	<b>196</b>	<b>20</b>	<b>514</b>
<b>Race</b>					
Caucasian	64	47	46	2	159
African American	84	59	130	14	287
Other	9	35	20	4	68
<b>Total</b>	<b>157</b>	<b>141</b>	<b>196</b>	<b>20</b>	<b>514</b>

TABLE UTIL-CARD-A1A.2: Number of Alpha-1 Antagonist Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	11	12	15	1	39
Q2 2019	14	13	15	-	42
Q3 2019	17	14	21	2	54
Q4 2019	14	11	21	4	50
Q1 2020	18	20	20	2	60
Q2 2020	14	14	23	2	53
Q3 2020	16	19	24	1	60
Q4 2020	15	13	20	3	51
Q1 2021	16	13	16	2	47
Q2 2021	22	12	21	3	58
<b>Total</b>	<b>157</b>	<b>141</b>	<b>196</b>	<b>20</b>	<b>514</b>

TABLE UTIL-CARD-A1A.5: Number of Alpha-1 Antagonist Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	63	59	85	10	217
SFY 2021	69	57	81	9	216
<b>Total</b>	<b>132</b>	<b>116</b>	<b>166</b>	<b>19</b>	<b>433</b>

TABLE UTIL-CARD-A1A.3: Proportion of Alpha-1 Antagonist Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	10.00%	17.14%	16.85%	20.00%	
Q2 2019	10.77%	22.81%	16.67%	0.00%	
Q3 2019	13.93%	24.56%	20.59%	15.39%	
Q4 2019	13.08%	19.30%	25.61%	26.67%	
Q1 2020	16.51%	35.09%	29.41%	11.77%	
Q2 2020	17.07%	35.90%	32.39%	12.50%	
Q3 2020	16.84%	38.00%	28.24%	8.33%	
Q4 2020	17.86%	30.23%	27.40%	21.43%	
Q1 2021	20.00%	34.21%	27.12%	25.00%	
Q2 2021	23.91%	35.29%	32.81%	30.00%	

TABLE UTIL-CARD-A1A.6: Proportion of Alpha-1 Antagonist Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	15.00%	28.10%	26.32%	16.39%	
SFY 2021	19.66%	34.55%	28.83%	20.46%	

TABLE UTIL-CARD-A1A.4: Total Spend of Alpha-1 Antagonist Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 390.70	\$ 305.30	\$ 441.13	\$ 21.00	\$ 1,158.13
Q2 2019	\$ 400.67	\$ 316.12	\$ 367.87	\$ -	\$ 1,084.66
Q3 2019	\$ 498.48	\$ 369.69	\$ 615.79	\$ 66.98	\$ 1,550.94
Q4 2019	\$ 419.78	\$ 271.37	\$ 613.67	\$ 118.37	\$ 1,423.19
Q1 2020	\$ 509.14	\$ 561.74	\$ 563.34	\$ 42.31	\$ 1,676.53
Q2 2020	\$ 411.96	\$ 398.57	\$ 668.35	\$ 40.73	\$ 1,519.61
Q3 2020	\$ 475.72	\$ 487.86	\$ 609.27	\$ 23.08	\$ 1,595.93
Q4 2020	\$ 342.68	\$ 317.38	\$ 487.69	\$ 59.38	\$ 1,207.13
Q1 2021	\$ 311.77	\$ 278.19	\$ 347.41	\$ 41.33	\$ 978.70
Q2 2021	\$ 405.58	\$ 255.47	\$ 432.78	\$ 57.68	\$ 1,151.51
<b>Total</b>	<b>\$ 4,166.48</b>	<b>\$ 3,561.69</b>	<b>\$ 5,147.30</b>	<b>\$ 470.86</b>	<b>\$ 13,346.33</b>

TABLE UTIL-CARD-A1A.7: Total Spend of Alpha-1 Antagonist Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 1,839.36	\$ 1,601.37	\$ 2,461.15	\$ 268.39	\$ 6,170.27
SFY 2021	\$ 1,535.75	\$ 1,338.90	\$ 1,877.15	\$ 181.47	\$ 4,933.27
<b>Total</b>	<b>\$ 3,375.11</b>	<b>\$ 2,940.27</b>	<b>\$ 4,338.30</b>	<b>\$ 449.86</b>	<b>\$ 11,103.54</b>

## CARDIOVASCULAR - ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)

TABLE UTIL-CARD-ARB.1: Beneficiaries' Demographic Characteristics for ARB Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	19	53	35	11	118
18-25	67	87	89	27	270
26-44	464	1,339	1,672	470	3,945
45-64	2,612	4,427	5,631	699	13,369
65+	43	25	33	-	101
<b>Total</b>	<b>3,205</b>	<b>5,931</b>	<b>7,460</b>	<b>1,207</b>	<b>17,803</b>
<b>Gender</b>					
Female	2,000	3,791	4,951	773	11,515
Male	1,205	2,140	2,509	434	6,288
<b>Total</b>	<b>3,205</b>	<b>5,931</b>	<b>7,460</b>	<b>1,207</b>	<b>17,803</b>
<b>Race</b>					
Caucasian	852	1,559	1,944	350	4,705
African American	2,013	3,586	4,501	686	10,786
Other	340	786	1,015	171	2,312
<b>Total</b>	<b>3,205</b>	<b>5,931</b>	<b>7,460</b>	<b>1,207</b>	<b>17,803</b>

TABLE UTIL-CARD-ARB.2: Number of ARB Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	174	325	486	37	1,022
Q2 2019	198	370	543	52	1,163
Q3 2019	257	467	643	74	1,441
Q4 2019	283	569	780	76	1,708
Q1 2020	314	682	812	114	1,922
Q2 2020	342	738	762	137	1,979
Q3 2020	348	623	831	140	1,942
Q4 2020	415	651	862	164	2,092
Q1 2021	417	678	846	196	2,137
Q2 2021	457	828	895	217	2,397
<b>Total</b>	<b>3,205</b>	<b>5,931</b>	<b>7,460</b>	<b>1,207</b>	<b>17,803</b>

TABLE UTIL-CARD-ARB.4: Number of ARB Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	1,196	2,456	2,997	401	7,050
SFY 2021	1,637	2,780	3,434	717	8,568
<b>Total</b>	<b>2,833</b>	<b>5,236</b>	<b>6,431</b>	<b>1,118</b>	<b>15,618</b>

TABLE UTIL-CARD-ARB.2: Proportion of ARB Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	13.62%	17.09%	16.83%	19.17%	
Q2 2019	16.02%	20.87%	19.68%	21.67%	
Q3 2019	18.79%	25.39%	22.13%	23.49%	
Q4 2019	19.42%	26.80%	24.36%	21.11%	
Q1 2020	19.11%	28.66%	24.13%	24.95%	
Q2 2020	20.52%	31.00%	24.37%	29.21%	
Q3 2020	20.42%	28.86%	27.48%	28.57%	
Q4 2020	23.45%	30.07%	30.07%	29.82%	
Q1 2021	22.95%	31.49%	31.94%	29.97%	
Q2 2021	22.98%	34.36%	32.32%	28.52%	

TABLE UTIL-CARD-ARB.5: Proportion of ARB Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	19.50%	28.16%	23.79%	25.05%	
SFY 2021	22.49%	31.28%	30.37%	29.21%	

TABLE UTIL-CARD-ARB.3: Total Spend of ARB Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 1,811.62	\$ 3,603.65	\$ 5,555.64	\$ 399.74	\$ 11,370.65
Q2 2019	\$ 2,422.05	\$ 4,622.56	\$ 7,029.97	\$ 591.44	\$ 14,666.02
Q3 2019	\$ 3,516.46	\$ 6,855.93	\$ 9,300.35	\$ 951.50	\$ 20,624.24
Q4 2019	\$ 4,469.14	\$ 9,420.99	\$ 12,932.65	\$ 1,142.29	\$ 27,965.07
Q1 2020	\$ 6,007.82	\$ 13,250.94	\$ 15,454.27	\$ 2,125.77	\$ 36,838.80
Q2 2020	\$ 7,786.07	\$ 15,366.40	\$ 15,809.97	\$ 2,797.18	\$ 41,759.62
Q3 2020	\$ 8,164.25	\$ 13,368.24	\$ 17,593.80	\$ 2,829.18	\$ 41,955.47
Q4 2020	\$ 8,397.62	\$ 13,587.68	\$ 18,022.54	\$ 3,167.58	\$ 43,175.42
Q1 2021	\$ 7,756.00	\$ 12,847.62	\$ 16,209.15	\$ 3,460.71	\$ 40,273.48
Q2 2021	\$ 8,481.01	\$ 15,448.84	\$ 16,807.18	\$ 3,785.82	\$ 44,522.85
<b>Total</b>	<b>\$ 58,812.04</b>	<b>\$ 108,372.85</b>	<b>\$ 134,715.52</b>	<b>\$ 21,251.21</b>	<b>\$ 323,151.62</b>

TABLE UTIL-CARD-ARB.6: Total Spend of ARB Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 21,779.49	\$ 44,894.26	\$ 53,497.24	\$ 7,016.74	\$ 127,187.73
SFY 2021	\$ 32,798.88	\$ 55,252.38	\$ 68,632.67	\$ 13,243.29	\$ 169,927.22
<b>Total</b>	<b>\$ 54,578.37</b>	<b>\$ 100,146.64</b>	<b>\$ 122,129.91</b>	<b>\$ 20,260.03</b>	<b>\$ 297,114.95</b>

# CARDIOVASCULAR – ANGIOTENSIN RECEPTOR BLOCKER (ARB) COMBINATIONS

TABLE UTIL-CARD-ARBC.1: Beneficiaries' Demographic Characteristics for ARB Combination Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	3	7	2	2	14
18-25	14	24	21	6	65
26-44	221	645	944	203	2,013
45-64	998	1,920	2,669	256	5,843
65+	36	4	24	-	64
<b>Total</b>	<b>1,272</b>	<b>2,600</b>	<b>3,660</b>	<b>467</b>	<b>7,999</b>
<b>Gender</b>					
Female	894	1,904	2,711	349	5,858
Male	378	696	949	118	2,141
<b>Total</b>	<b>1,272</b>	<b>2,600</b>	<b>3,660</b>	<b>467</b>	<b>7,999</b>
<b>Race</b>					
Caucasian	268	443	561	105	1,377
African American	884	1,836	2,682	326	5,728
Other	120	321	417	36	894
<b>Total</b>	<b>1,272</b>	<b>2,600</b>	<b>3,660</b>	<b>467</b>	<b>7,999</b>

TABLE UTIL-CARD-ARBC.2: Number of ARB Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	97	211	335	11	654
Q2 2019	119	224	376	18	737
Q3 2019	130	277	397	40	844
Q4 2019	90	190	304	19	603
Q1 2020	96	212	278	29	615
Q2 2020	106	243	311	40	700
Q3 2020	119	250	362	55	786
Q4 2020	147	274	416	64	901
Q1 2021	175	316	444	84	1,019
Q2 2021	193	403	437	107	1,140
<b>Total</b>	<b>1,272</b>	<b>2,600</b>	<b>3,660</b>	<b>467</b>	<b>7,999</b>

TABLE UTIL-CARD-ARBC.5: Number of ARB Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	422	922	1290	128	2,762
SFY 2021	634	1243	1659	310	3,846
<b>Total</b>	<b>1,056</b>	<b>2,165</b>	<b>2,949</b>	<b>438</b>	<b>6,608</b>

TABLE UTIL-CARD-ARBC.3: Proportion of ARB Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	12.93%	13.34%	13.13%	7.80%	
Q2 2019	16.48%	15.11%	16.05%	9.33%	
Q3 2019	17.74%	19.89%	18.09%	17.32%	
Q4 2019	17.93%	20.13%	18.96%	10.22%	
Q1 2020	22.17%	24.48%	20.98%	16.48%	
Q2 2020	23.98%	26.91%	23.21%	22.22%	
Q3 2020	22.16%	27.41%	25.17%	21.74%	
Q4 2020	23.94%	28.34%	27.75%	22.70%	
Q1 2021	27.26%	28.99%	30.92%	26.25%	
Q2 2021	26.33%	32.76%	29.15%	28.61%	

TABLE UTIL-CARD-ARBC.6: Proportion of ARB Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	20.00%	22.46%	19.96%	16.56%	
SFY 2021	25.10%	29.60%	28.25%	25.22%	

TABLE UTIL-CARD-ARBC.4: Total Spend of ARB Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 1,473.83	\$ 3,168.46	\$ 5,212.96	\$ 165.38	\$ 10,020.63
Q2 2019	\$ 2,169.60	\$ 3,973.05	\$ 6,744.68	\$ 295.73	\$ 13,183.06
Q3 2019	\$ 2,907.28	\$ 5,293.36	\$ 7,961.66	\$ 650.71	\$ 16,813.01
Q4 2019	\$ 2,228.19	\$ 4,302.14	\$ 7,153.14	\$ 330.04	\$ 14,013.51
Q1 2020	\$ 3,507.70	\$ 6,607.73	\$ 9,257.85	\$ 916.47	\$ 20,289.75
Q2 2020	\$ 4,358.56	\$ 7,387.19	\$ 10,375.74	\$ 1,146.08	\$ 23,267.57
Q3 2020	\$ 4,284.35	\$ 7,928.37	\$ 11,294.90	\$ 1,660.36	\$ 25,167.98
Q4 2020	\$ 4,805.49	\$ 8,988.72	\$ 13,447.48	\$ 1,943.27	\$ 29,184.96
Q1 2021	\$ 5,507.33	\$ 9,569.96	\$ 13,223.07	\$ 2,613.70	\$ 30,914.06
Q2 2021	\$ 5,800.40	\$ 12,566.86	\$ 13,047.85	\$ 3,098.96	\$ 34,514.07
<b>Total</b>	<b>\$ 37,042.73</b>	<b>\$ 69,785.84</b>	<b>\$ 97,719.33</b>	<b>\$ 12,820.70</b>	<b>\$ 217,368.60</b>

TABLE UTIL-CARD-ARBC.7: Total Spend of ARB Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 13,001.73	\$ 23,590.42	\$ 34,748.39	\$ 3,043.30	\$ 74,383.84
SFY 2021	\$ 20,397.57	\$ 39,053.91	\$ 51,013.30	\$ 9,316.29	\$ 119,781.07
<b>Total</b>	<b>\$ 33,399.30</b>	<b>\$ 62,644.33</b>	<b>\$ 85,761.69</b>	<b>\$ 12,359.59</b>	<b>\$ 194,164.91</b>

## CARDIOVASCULAR – BETA-BLOCKERS

TABLE UTIL-CARD-BB.1: Beneficiaries' Demographic Characteristics for Beta Blocker Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	75	143	112	12	342
18-25	118	220	250	70	658
26-44	1,241	2,726	3,449	989	8,405
45-64	5,874	9,359	11,773	1,677	28,683
65+	168	48	63	-	279
<b>Total</b>	<b>7,476</b>	<b>12,496</b>	<b>15,647</b>	<b>2,748</b>	<b>38,367</b>
<b>Gender</b>					
Female	4,213	7,597	9,766	1,646	23,222
Male	3,262	4,899	5,881	1,102	15,144
<b>Total</b>	<b>7,475</b>	<b>12,496</b>	<b>15,647</b>	<b>2,748</b>	<b>38,366</b>
<b>Race</b>					
Caucasian	2,404	4,078	4,678	941	12,101
African American	4,225	6,404	8,631	1,330	20,590
Other	847	2,014	2,338	477	5,676
<b>Total</b>	<b>7,476</b>	<b>12,496</b>	<b>15,647</b>	<b>2,748</b>	<b>38,367</b>
Note: 3 claims have missing information for pharmacy program; 1 claims' gender variable is valued as "U".					

TABLE UTIL-CARD-BB.2: Number of Beta Blocker Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	447	793	1,066	57	2,363
Q2 2019	511	918	1,256	109	2,794
Q3 2019	664	1,150	1,452	157	3,423
Q4 2019	639	1,145	1,498	169	3,451
Q1 2020	780	1,335	1,626	259	4,000
Q2 2020	765	1,439	1,653	284	4,141
Q3 2020	819	1,294	1,755	361	4,229
Q4 2020	910	1,375	1,740	421	4,446
Q1 2021	939	1,424	1,783	456	4,602
Q2 2021	1,002	1,623	1,818	475	4,918
<b>Total</b>	<b>7,476</b>	<b>12,496</b>	<b>15,647</b>	<b>2,748</b>	<b>38,367</b>

TABLE UTIL-CARD-BB.5: Number of Beta Blocker Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	2,848	5,069	6,229	869	15,015
SFY 2021	3,670	5,716	7,096	1,713	18,195
<b>Total</b>	<b>6,518</b>	<b>10,785</b>	<b>13,325</b>	<b>2,582</b>	<b>33,210</b>

TABLE UTIL-CARD-BB.3: Proportion of Beta Blocker Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	9.44%	14.77%	13.16%	9.11%	
Q2 2019	10.50%	17.34%	15.89%	12.67%	
Q3 2019	13.17%	22.02%	18.94%	14.03%	
Q4 2019	12.71%	22.32%	20.69%	13.89%	
Q1 2020	15.00%	23.66%	22.46%	19.92%	
Q2 2020	15.22%	24.41%	24.17%	21.42%	
Q3 2020	15.63%	24.65%	25.22%	24.98%	
Q4 2020	16.16%	26.64%	26.05%	25.24%	
Q1 2021	17.00%	27.65%	27.12%	26.64%	
Q2 2021	17.50%	28.27%	28.08%	24.56%	

TABLE UTIL-CARD-BB.6: Proportion of Beta Blocker Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	14.03%	23.16%	21.49%	17.51%	
SFY 2021	16.59%	26.83%	26.59%	25.34%	

TABLEUTIL-CARD-BB.4: Total Spend of Beta Blocker Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 7,311.19	\$ 13,743.81	\$ 18,591.04	\$ 993.58	\$ 40,639.62
Q2 2019	\$ 8,271.13	\$ 15,584.00	\$ 22,286.65	\$ 1,809.77	\$ 47,951.55
Q3 2019	\$ 10,272.28	\$ 20,235.06	\$ 27,241.91	\$ 2,652.55	\$ 60,401.80
Q4 2019	\$ 10,308.05	\$ 20,402.18	\$ 27,156.46	\$ 2,728.50	\$ 60,595.19
Q1 2020	\$ 13,075.13	\$ 23,634.50	\$ 29,983.11	\$ 4,434.15	\$ 71,126.89
Q2 2020	\$ 14,388.86	\$ 25,196.19	\$ 29,640.59	\$ 4,933.86	\$ 74,159.50
Q3 2020	\$ 14,941.06	\$ 23,169.03	\$ 30,823.72	\$ 6,436.16	\$ 75,369.97
Q4 2020	\$ 14,012.19	\$ 23,215.18	\$ 30,241.41	\$ 6,966.74	\$ 74,435.52
Q1 2021	\$ 14,130.62	\$ 23,962.74	\$ 30,122.61	\$ 7,272.36	\$ 75,488.33
Q2 2021	\$ 14,845.28	\$ 26,305.27	\$ 30,823.24	\$ 7,567.53	\$ 79,541.32
<b>Total</b>	<b>\$ 121,555.79</b>	<b>\$ 215,447.96</b>	<b>\$ 276,910.74</b>	<b>\$ 45,795.20</b>	<b>\$ 659,709.69</b>

TABLE UTIL-CARD-BB.7: Total Spend of Beta Blocker Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 48,044.32	\$ 89,467.93	\$ 114,022.07	\$ 14,749.06	\$ 266,283.38
SFY 2021	\$ 57,929.15	\$ 96,652.22	\$ 122,010.98	\$ 28,242.79	\$ 304,835.14
<b>Total</b>	<b>\$ 105,973.47</b>	<b>\$ 186,120.15</b>	<b>\$ 236,033.05</b>	<b>\$ 42,991.85</b>	<b>\$ 571,118.52</b>

## CARDIOVASCULAR – CALCIUM CHANNEL BLOCKERS

**TABLE UTIL-CARD-CCB.1: Beneficiaries' Demographic Characteristics for Calcium Channel Blocker Claims with 90 days of supply (Jan 2019- Jun 2021)**

Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	164	203	214	55	636
18-25	172	223	216	104	715
26-44	1,447	3,860	4,548	1,257	11,112
45-64	6,746	12,561	15,300	2,137	36,744
65+	166	78	107	-	351
<b>Total</b>	<b>8,695</b>	<b>16,925</b>	<b>20,385</b>	<b>3,553</b>	<b>49,558</b>
<b>Gender</b>					
Female	5,057	10,556	12,669	2,259	30,541
Male	3,638	6,369	7,716	1,294	19,017
<b>Total</b>	<b>8,695</b>	<b>16,925</b>	<b>20,385</b>	<b>3,553</b>	<b>49,558</b>
<b>Race</b>					
Caucasian	1,691	3,187	3,398	690	8,966
African American	6,092	11,197	14,068	2,238	33,595
Other	912	2,541	2,919	625	6,997
<b>Total</b>	<b>8,695</b>	<b>16,925</b>	<b>20,385</b>	<b>3,553</b>	<b>49,558</b>

Note: 4 claims have missing information for pharmacy program.

**TABLE UTIL-CARD-CCB.2: Number of Calcium Channel Blocker Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)**

Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	524	1,051	1,423	77	3,075
Q2 2019	619	1,214	1,649	131	3,613
Q3 2019	751	1,499	1,798	201	4,249
Q4 2019	723	1,552	1,893	229	4,397
Q1 2020	847	1,801	2,057	335	5,040
Q2 2020	866	1,958	2,135	379	5,338
Q3 2020	973	1,768	2,291	449	5,481
Q4 2020	1,058	1,883	2,313	514	5,768
Q1 2021	1,110	1,918	2,345	587	5,960
Q2 2021	1,224	2,281	2,481	651	6,637
<b>Total</b>	<b>8,695</b>	<b>16,925</b>	<b>20,385</b>	<b>3,553</b>	<b>49,558</b>

**TABLE UTIL-CARD-CCB.5: Number of Calcium Channel Blocker Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)**

Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	3,187	6,810	7,883	1,144	19,024
SFY 2021	4,365	7,850	9,430	2,201	23,846
<b>Total</b>	<b>7,552</b>	<b>14,660</b>	<b>17,313</b>	<b>3,345</b>	<b>42,870</b>

**TABLE UTIL-CARD-CCB.3: Proportion of Calcium Channel Blocker Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)**

Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	10.74%	14.96%	13.48%	8.34%
Q2 2019	12.43%	18.00%	16.25%	9.23%
Q3 2019	14.53%	21.74%	18.41%	11.72%
Q4 2019	14.12%	23.24%	20.24%	13.66%
Q1 2020	15.86%	24.73%	22.00%	19.20%
Q2 2020	16.60%	26.90%	24.07%	21.98%
Q3 2020	17.87%	26.09%	25.90%	23.23%
Q4 2020	18.47%	28.82%	27.65%	23.85%
Q1 2021	19.23%	30.24%	28.98%	25.28%
Q2 2021	19.98%	31.59%	30.14%	25.57%

**TABLE UTIL-CARD-CCB.6: Proportion of Calcium Channel Blocker Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)**

Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	15.29%	24.21%	21.11%	16.68%
SFY 2021	18.92%	29.21%	28.12%	24.58%

**TABLE UTIL-CARD-CCB.4: Total Spend of Calcium Channel Blocker Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)**

Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 6,773.20	\$ 14,206.20	\$ 19,409.04	\$ 1,003.53	\$ 41,391.97
Q2 2019	\$ 9,279.30	\$ 16,211.25	\$ 21,413.54	\$ 1,815.43	\$ 48,719.52
Q3 2019	\$ 10,534.97	\$ 21,832.28	\$ 23,358.29	\$ 2,513.30	\$ 58,238.84
Q4 2019	\$ 11,064.67	\$ 23,944.90	\$ 25,640.51	\$ 2,670.87	\$ 63,320.95
Q1 2020	\$ 13,301.35	\$ 28,903.44	\$ 29,558.88	\$ 4,887.19	\$ 76,650.86
Q2 2020	\$ 16,411.12	\$ 29,964.32	\$ 30,022.16	\$ 5,352.74	\$ 81,750.34
Q3 2020	\$ 18,153.09	\$ 29,006.00	\$ 35,231.57	\$ 7,020.64	\$ 89,411.30
Q4 2020	\$ 17,311.46	\$ 27,733.64	\$ 35,758.21	\$ 7,242.22	\$ 88,045.53
Q1 2021	\$ 17,911.75	\$ 29,187.63	\$ 35,772.73	\$ 9,104.71	\$ 91,976.82
Q2 2021	\$ 17,864.88	\$ 37,754.84	\$ 38,670.92	\$ 9,113.37	\$ 103,404.01
<b>Total</b>	<b>\$ 138,605.79</b>	<b>\$ 258,744.50</b>	<b>\$ 294,835.85</b>	<b>\$ 50,724.00</b>	<b>\$ 742,910.14</b>

**TABLE UTIL-CARD-CCB.7: Total Spend of Calcium Channel Blocker Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)**

Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 51,312.11	\$ 104,644.94	\$ 108,579.84	\$ 15,424.10	\$ 279,960.99
SFY 2021	\$ 71,241.18	\$ 123,682.11	\$ 145,433.43	\$ 32,480.94	\$ 372,837.66
<b>Total</b>	<b>\$ 122,553.29</b>	<b>\$ 228,327.05</b>	<b>\$ 254,013.27</b>	<b>\$ 47,905.04</b>	<b>\$ 652,798.65</b>



## CARDIOVASCULAR – CARDIAC GLYCOSIDES

TABLE UTIL-CARD-CARG.1: Beneficiaries' Demographic Characteristics for Cardiac Glycoside Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	6	2	4	-	12
18-25	3	1	20	-	24
26-44	64	62	99	23	248
45-64	190	132	430	47	799
65+	4	11	1	-	16
<b>Total</b>	<b>267</b>	<b>208</b>	<b>554</b>	<b>70</b>	<b>1,099</b>
<b>Gender</b>					
Female	135	97	278	11	521
Male	132	111	276	59	578
<b>Total</b>	<b>267</b>	<b>208</b>	<b>554</b>	<b>70</b>	<b>1,099</b>
<b>Race</b>					
Caucasian	94	62	168	20	344
African American	144	109	307	30	590
Other	29	37	79	20	165
<b>Total</b>	<b>267</b>	<b>208</b>	<b>554</b>	<b>70</b>	<b>1,099</b>

TABLE UTIL-CARD-CARG.2: Number of Cardiac Glycoside Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	24	24	52	1	101
Q2 2019	26	27	56	2	111
Q3 2019	31	27	59	3	120
Q4 2019	25	26	58	5	114
Q1 2020	29	18	46	5	98
Q2 2020	27	17	58	10	112
Q3 2020	28	10	57	8	103
Q4 2020	26	17	57	15	115
Q1 2021	26	19	56	11	112
Q2 2021	25	23	55	10	113
<b>Total</b>	<b>267</b>	<b>208</b>	<b>554</b>	<b>70</b>	<b>1,099</b>

TABLE UTIL-CARD-CARG.5: Number of Cardiac Glycoside Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	112	88	221	23	444
SFY 2021	105	69	225	44	443
<b>Total</b>	<b>217</b>	<b>157</b>	<b>446</b>	<b>67</b>	<b>887</b>

TABLE UTIL-CARD-CARG.3: Proportion of Cardiac Glycoside Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	9.76%	11.59%	16.25%	3.57%
Q2 2019	10.57%	12.86%	18.92%	5.41%
Q3 2019	13.08%	13.37%	21.93%	7.32%
Q4 2019	12.82%	12.81%	22.48%	10.64%
Q1 2020	13.18%	8.91%	18.47%	11.36%
Q2 2020	14.06%	7.17%	22.22%	21.28%
Q3 2020	14.66%	4.39%	25.22%	19.05%
Q4 2020	13.68%	8.17%	26.64%	36.59%
Q1 2021	15.85%	9.50%	26.67%	31.43%
Q2 2021	15.24%	12.99%	26.57%	21.28%

TABLE UTIL-CARD-CARG.6: Proportion of Cardiac Glycoside Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	13.27%	10.43%	21.31%	12.85%
SFY 2021	14.81%	8.49%	26.25%	26.67%

TABLE UTIL-CARD-CARG.4: Total Spend of Cardiac Glycoside Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 750.97	\$ 824.51	\$ 1,783.40	\$ 21.00	\$ 3,379.88
Q2 2019	\$ 769.93	\$ 792.96	\$ 1,715.91	\$ 72.26	\$ 3,351.06
Q3 2019	\$ 1,058.28	\$ 823.53	\$ 1,867.75	\$ 81.36	\$ 3,830.92
Q4 2019	\$ 855.27	\$ 831.36	\$ 1,811.00	\$ 141.14	\$ 3,638.77
Q1 2020	\$ 984.17	\$ 633.74	\$ 1,392.49	\$ 139.84	\$ 3,150.24
Q2 2020	\$ 974.22	\$ 611.67	\$ 1,805.55	\$ 308.27	\$ 3,699.71
Q3 2020	\$ 962.89	\$ 359.42	\$ 3,062.58	\$ 230.07	\$ 4,614.96
Q4 2020	\$ 798.51	\$ 600.94	\$ 2,981.37	\$ 427.44	\$ 4,808.26
Q1 2021	\$ 783.04	\$ 666.02	\$ 4,435.05	\$ 313.25	\$ 6,197.36
Q2 2021	\$ 827.49	\$ 732.76	\$ 1,762.01	\$ 279.45	\$ 3,601.71
<b>Total</b>	<b>\$ 8,764.77</b>	<b>\$ 6,876.91</b>	<b>\$ 22,617.11</b>	<b>\$ 2,014.08</b>	<b>\$ 40,272.87</b>

TABLE UTIL-CARD-CARG.7: Total Spend of Cardiac Glycoside Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 3,871.94	\$ 2,900.30	\$ 6,876.79	\$ 670.61	\$ 14,319.64
SFY 2021	\$ 3,371.93	\$ 2,359.14	\$ 12,241.01	\$ 1,250.21	\$ 19,222.29
<b>Total</b>	<b>\$ 7,243.87</b>	<b>\$ 5,259.44</b>	<b>\$ 19,117.80</b>	<b>\$ 1,920.82</b>	<b>\$ 33,541.93</b>

## CARDIOVASCULAR – POTASSIUM SPARING DIURETICS

TABLE UTIL-CARD-KSPAR.1: Beneficiaries' Demographic Characteristics for Potassium-sparing Diuretics Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	12	23	24	4	63
18-25	27	32	67	15	141
26-44	236	421	638	144	1,439
45-64	911	1,277	1,930	336	4,454
65+	7	16	8	-	31
<b>Total</b>	<b>1,193</b>	<b>1,769</b>	<b>2,667</b>	<b>499</b>	<b>6,128</b>
<b>Gender</b>					
Female	689	1,053	1,608	262	3,612
Male	504	716	1,059	237	2,516
<b>Total</b>	<b>1,193</b>	<b>1,769</b>	<b>2,667</b>	<b>499</b>	<b>6,128</b>
<b>Race</b>					
Caucasian	291	406	588	119	1,404
African American	783	1,065	1,682	277	3,807
Other	119	298	397	103	917
<b>Total</b>	<b>1,193</b>	<b>1,769</b>	<b>2,667</b>	<b>499</b>	<b>6,128</b>

Note: 3 claims have missing information for pharmacy program.

TABLE UTIL-CARD-KSPAR.2: Number of Potassium-sparing Diuretics Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	74	89	183	9	355
Q2 2019	97	110	218	21	446
Q3 2019	103	161	225	25	514
Q4 2019	107	142	248	37	534
Q1 2020	119	171	277	47	614
Q2 2020	111	200	275	60	646
Q3 2020	135	208	289	57	689
Q4 2020	140	191	302	78	711
Q1 2021	135	217	313	84	749
Q2 2021	172	280	337	81	870
<b>Total</b>	<b>1,193</b>	<b>1,769</b>	<b>2,667</b>	<b>499</b>	<b>6,128</b>

TABLE UTIL-CARD-KSPAR.5: Number of Potassium-sparing Diuretics Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	440	674	1025	169	2,308
SFY 2021	582	896	1241	300	3,019
<b>Total</b>	<b>1,022</b>	<b>1,570</b>	<b>2,266</b>	<b>469</b>	<b>5,327</b>

TABLE UTIL-CARD-KSPAR.3: Proportion of Potassium-sparing Diuretics Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	12.76%	14.11%	15.70%	11.25%	
Q2 2019	14.95%	16.44%	18.99%	20.59%	
Q3 2019	14.23%	22.68%	20.07%	15.34%	
Q4 2019	14.17%	20.29%	22.61%	20.33%	
Q1 2020	15.70%	21.65%	25.48%	24.74%	
Q2 2020	14.74%	24.91%	25.99%	28.30%	
Q3 2020	18.78%	27.77%	26.81%	28.22%	
Q4 2020	18.42%	26.06%	28.79%	33.33%	
Q1 2021	18.37%	28.86%	30.51%	33.60%	
Q2 2021	20.53%	32.75%	31.61%	28.62%	

TABLE UTIL-CARD-KSPAR.6: Proportion of Potassium-sparing Diuretics Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	14.72%	22.44%	23.49%	22.62%	
SFY 2021	19.07%	29.01%	29.42%	30.96%	

TABLE UTIL-CARD-KSPAR.4: Total Spend of Potassium-sparing Diuretics Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 1,135.47	\$ 1,473.15	\$ 3,125.86	\$ 146.23	\$ 5,880.71
Q2 2019	\$ 1,736.55	\$ 1,848.12	\$ 3,954.58	\$ 352.95	\$ 7,892.20
Q3 2019	\$ 1,781.76	\$ 3,077.70	\$ 4,201.67	\$ 383.61	\$ 9,444.74
Q4 2019	\$ 1,838.21	\$ 2,500.48	\$ 4,888.11	\$ 625.29	\$ 9,852.09
Q1 2020	\$ 2,360.18	\$ 2,986.02	\$ 5,130.01	\$ 791.75	\$ 11,267.96
Q2 2020	\$ 2,340.30	\$ 3,424.15	\$ 4,787.55	\$ 918.41	\$ 11,470.41
Q3 2020	\$ 2,771.47	\$ 3,585.94	\$ 4,839.42	\$ 894.57	\$ 12,091.40
Q4 2020	\$ 2,430.53	\$ 3,210.15	\$ 5,295.47	\$ 1,304.98	\$ 12,241.13
Q1 2021	\$ 2,394.43	\$ 3,823.24	\$ 5,421.17	\$ 1,281.68	\$ 12,920.52
Q2 2021	\$ 2,675.72	\$ 4,749.79	\$ 5,699.58	\$ 1,268.40	\$ 14,393.49
<b>Total</b>	<b>\$ 21,464.62</b>	<b>\$ 30,678.74</b>	<b>\$ 47,343.42</b>	<b>\$ 7,967.87</b>	<b>\$ 107,454.65</b>

TABLE UTIL-CARD-KSPAR.7: Total Spend of Potassium-sparing Diuretics Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 8,320.45	\$ 11,988.35	\$ 19,007.34	\$ 2,719.06	\$ 42,035.20
SFY 2021	\$ 10,272.15	\$ 15,369.12	\$ 21,255.64	\$ 4,749.63	\$ 51,646.54
<b>Total</b>	<b>\$ 18,592.60</b>	<b>\$ 27,357.47</b>	<b>\$ 40,262.98</b>	<b>\$ 7,468.69</b>	<b>\$ 93,681.74</b>

## CARDIOVASCULAR – LOOP DIURETICS

TABLE UTIL-CARD-LOOP.1: Beneficiaries' Demographic Characteristics for Loop Diuretic Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	32	13	15	4	64
18-25	37	49	64	21	171
26-44	487	1,074	1,376	346	3,283
45-64	2,460	4,074	5,194	733	12,461
65+	44	21	25	-	90
<b>Total</b>	<b>3,060</b>	<b>5,231</b>	<b>6,674</b>	<b>1,104</b>	<b>16,069</b>
<b>Gender</b>					
Female	1,914	3,489	4,593	679	10,675
Male	1,146	1,742	2,081	425	5,394
<b>Total</b>	<b>3,060</b>	<b>5,231</b>	<b>6,674</b>	<b>1,104</b>	<b>16,069</b>
<b>Race</b>					
Caucasian	790	1,265	1,676	311	4,042
African American	1,967	3,226	4,109	599	9,901
Other	303	740	889	194	2,126
<b>Total</b>	<b>3,060</b>	<b>5,231</b>	<b>6,674</b>	<b>1,104</b>	<b>16,069</b>

TABLE UTIL-CARD-LOOP.2: Number of Loop Diuretic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	173	247	407	16	843
Q2 2019	224	328	537	39	1,128
Q3 2019	259	470	666	57	1,452
Q4 2019	283	472	632	65	1,452
Q1 2020	295	584	701	104	1,684
Q2 2020	320	620	734	130	1,804
Q3 2020	363	599	744	139	1,845
Q4 2020	362	595	740	166	1,863
Q1 2021	367	598	741	173	1,879
Q2 2021	414	718	772	215	2,119
<b>Total</b>	<b>3,060</b>	<b>5,231</b>	<b>6,674</b>	<b>1,104</b>	<b>16,069</b>

TABLE UTIL-CARD-LOOP.5: Number of Loop Diuretic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	1,157	2,146	2,733	356	6,392
SFY 2021	1,506	2,510	2,997	693	7,706
<b>Total</b>	<b>2,663</b>	<b>4,656</b>	<b>5,730</b>	<b>1,049</b>	<b>14,098</b>

TABLE UTIL-CARD-LOOP.3: Proportion of Loop Diuretic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	7.26%	11.15%	11.17%	6.67%	
Q2 2019	8.82%	14.13%	14.80%	9.68%	
Q3 2019	9.70%	19.00%	18.64%	10.98%	
Q4 2019	10.47%	21.44%	20.37%	13.13%	
Q1 2020	10.84%	24.17%	22.43%	18.47%	
Q2 2020	12.18%	22.82%	23.54%	23.38%	
Q3 2020	14.16%	24.03%	23.91%	23.01%	
Q4 2020	14.75%	26.53%	25.58%	24.48%	
Q1 2021	14.73%	27.27%	26.39%	23.73%	
Q2 2021	14.91%	27.33%	26.49%	23.73%	

TABLE UTIL-CARD-LOOP.6: Proportion of Loop Diuretic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	10.79%	21.88%	21.15%	16.69%	
SFY 2021	14.64%	26.27%	25.56%	23.76%	

TABLE UTIL-CARD-LOOP.4: Total Spend of Loop Diuretic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 2,062.63	\$ 3,020.70	\$ 4,672.36	\$ 181.75	\$ 9,937.44
Q2 2019	\$ 2,621.85	\$ 4,269.25	\$ 6,510.05	\$ 434.32	\$ 13,835.47
Q3 2019	\$ 3,203.58	\$ 6,360.56	\$ 8,507.94	\$ 646.51	\$ 18,718.59
Q4 2019	\$ 3,389.92	\$ 6,214.70	\$ 7,959.98	\$ 730.42	\$ 18,295.02
Q1 2020	\$ 3,797.70	\$ 7,766.68	\$ 9,121.13	\$ 1,289.31	\$ 21,974.82
Q2 2020	\$ 4,693.32	\$ 8,162.45	\$ 9,366.71	\$ 1,665.09	\$ 23,887.57
Q3 2020	\$ 5,361.34	\$ 7,890.96	\$ 9,817.99	\$ 1,838.57	\$ 24,908.86
Q4 2020	\$ 4,382.16	\$ 7,751.59	\$ 9,496.77	\$ 2,010.58	\$ 23,641.10
Q1 2021	\$ 4,526.56	\$ 7,746.50	\$ 9,695.67	\$ 2,219.21	\$ 24,187.94
Q2 2021	\$ 5,103.04	\$ 9,579.37	\$ 10,209.57	\$ 2,756.93	\$ 27,648.91
<b>Total</b>	<b>\$ 39,142.10</b>	<b>\$ 68,762.76</b>	<b>\$ 85,358.17</b>	<b>\$ 13,772.69</b>	<b>\$ 207,035.72</b>

TABLE UTIL-CARD-LOOP.7: Total Spend of Loop Diuretic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	15084.52	28504.39	34955.76	4331.33	\$ 82,876.00
SFY 2021	19373.1	32968.42	39220	8825.29	\$ 100,386.81
<b>Total</b>	<b>\$ 34,457.62</b>	<b>\$ 61,472.81</b>	<b>\$ 74,175.76</b>	<b>\$ 13,156.62</b>	<b>\$ 183,262.81</b>

## CARDIOVASCULAR – THIAZIDE DIURETICS

Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	34	30	43	10	117
18-25	34	57	49	23	163
26-44	436	1,158	1,589	454	3,637
45-64	1,755	2,982	3,863	483	9,083
65+	36	6	30	-	72
<b>Total</b>	<b>2,295</b>	<b>4,233</b>	<b>5,574</b>	<b>970</b>	<b>13,072</b>
<b>Gender</b>					
Female	1,524	2,998	4,027	742	9,291
Male	771	1,235	1,547	228	3,781
<b>Total</b>	<b>2,295</b>	<b>4,233</b>	<b>5,574</b>	<b>970</b>	<b>13,072</b>
<b>Race</b>					
Caucasian	500	897	1,081	204	2,682
African American	1,613	2,807	3,894	646	8,960
Other	182	529	599	120	1,430
<b>Total</b>	<b>2,295</b>	<b>4,233</b>	<b>5,574</b>	<b>970</b>	<b>13,072</b>

Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	111	219	300	17	647
Q2 2019	145	287	414	43	889
Q3 2019	182	354	490	50	1,076
Q4 2019	218	374	547	75	1,214
Q1 2020	239	472	615	93	1,419
Q2 2020	225	532	608	111	1,476
Q3 2020	253	468	660	123	1,504
Q4 2020	292	462	638	136	1,528
Q1 2021	287	490	638	135	1,550
Q2 2021	343	575	664	187	1,769
<b>Total</b>	<b>2,295</b>	<b>4,233</b>	<b>5,574</b>	<b>970</b>	<b>13,072</b>

Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	864	1,732	2,260	329	5,185
SFY 2021	1,175	1,995	2,600	581	6,351
<b>Total</b>	<b>2,039</b>	<b>3,727</b>	<b>4,860</b>	<b>910</b>	<b>11,536</b>

Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	11.72%	15.37%	12.40%	9.61%
Q2 2019	13.97%	20.37%	16.65%	13.87%
Q3 2019	16.37%	24.74%	21.06%	13.12%
Q4 2019	18.57%	24.62%	23.03%	19.28%
Q1 2020	19.79%	28.23%	25.31%	21.78%
Q2 2020	19.51%	30.13%	27.59%	27.01%
Q3 2020	21.44%	29.70%	29.33%	27.52%
Q4 2020	23.68%	32.40%	29.74%	30.77%
Q1 2021	23.64%	33.54%	31.55%	26.52%
Q2 2021	25.30%	33.18%	31.89%	29.97%

Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	18.59%	27.11%	24.21%	20.46%
SFY 2021	23.58%	32.20%	30.59%	28.73%

Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 907.85	\$ 1,871.43	\$ 2,585.87	\$ 149.02	\$ 5,514.17
Q2 2019	\$ 1,984.34	\$ 3,217.02	\$ 4,863.76	\$ 379.55	\$ 10,444.67
Q3 2019	\$ 3,024.73	\$ 4,945.63	\$ 7,855.86	\$ 447.41	\$ 16,273.63
Q4 2019	\$ 3,200.56	\$ 5,566.01	\$ 7,386.83	\$ 661.62	\$ 16,815.02
Q1 2020	\$ 3,871.42	\$ 7,020.60	\$ 8,421.70	\$ 1,095.66	\$ 20,409.38
Q2 2020	\$ 3,761.18	\$ 7,140.30	\$ 8,304.36	\$ 1,448.34	\$ 20,654.18
Q3 2020	\$ 4,162.49	\$ 6,565.38	\$ 8,814.11	\$ 1,719.12	\$ 21,261.10
Q4 2020	\$ 3,858.99	\$ 6,318.51	\$ 8,579.66	\$ 1,766.15	\$ 20,523.31
Q1 2021	\$ 3,615.94	\$ 6,144.32	\$ 7,922.52	\$ 1,764.90	\$ 19,447.68
Q2 2021	\$ 3,893.71	\$ 7,192.53	\$ 7,915.33	\$ 2,314.56	\$ 21,316.13
<b>Total</b>	<b>\$ 32,281.21</b>	<b>\$ 55,981.73</b>	<b>\$ 72,650.00</b>	<b>\$ 11,746.33</b>	<b>\$ 172,659.27</b>

Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 13,857.89	\$ 24,672.54	\$ 31,968.75	\$ 3,653.03	\$ 74,152.21
SFY 2021	\$ 15,531.13	\$ 26,220.74	\$ 33,231.62	\$ 7,564.73	\$ 82,548.22
<b>Total</b>	<b>\$ 29,389.02</b>	<b>\$ 50,893.28</b>	<b>\$ 65,200.37</b>	<b>\$ 11,217.76</b>	<b>\$ 156,700.43</b>

## CARDIOVASCULAR – VASODILATORS

TABLE UTIL-CARD-VAS.1: Beneficiaries' Demographic Characteristics for Vasodilator Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	-	-	-	-	-
18-25	4	6	16	6	32
26-44	131	175	306	70	682
45-64	787	967	1,356	142	3,252
65+	22	9	3	-	34
<b>Total</b>	<b>944</b>	<b>1,157</b>	<b>1,681</b>	<b>218</b>	<b>4,000</b>
<b>Gender</b>					
Female	473	593	893	126	2,085
Male	471	564	788	92	1,915
<b>Total</b>	<b>944</b>	<b>1,157</b>	<b>1,681</b>	<b>218</b>	<b>4,000</b>
<b>Race</b>					
Caucasian	89	131	167	20	407
African American	762	852	1,265	151	3,030
Other	93	174	249	47	563
<b>Total</b>	<b>944</b>	<b>1,157</b>	<b>1,681</b>	<b>218</b>	<b>4,000</b>

TABLE UTIL-CARD-VAS.2: Number of Vasodilator Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	67	80	123	1	271
Q2 2019	65	87	140	9	301
Q3 2019	95	105	157	15	372
Q4 2019	91	107	151	20	369
Q1 2020	114	121	182	24	441
Q2 2020	101	126	183	22	432
Q3 2020	99	120	185	27	431
Q4 2020	101	124	184	32	441
Q1 2021	103	126	175	32	436
Q2 2021	108	161	201	36	506
<b>Total</b>	<b>944</b>	<b>1,157</b>	<b>1,681</b>	<b>218</b>	<b>4,000</b>

TABLE UTIL-CARD-VAS.5: Number of Vasodilator Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	401	459	673	81	1,614
SFY 2021	411	531	745	127	1,814
<b>Total</b>	<b>812</b>	<b>990</b>	<b>1,418</b>	<b>208</b>	<b>3,428</b>

TABLE UTIL-CARD-VAS.3: Proportion of Vasodilator Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	8.32%	13.45%	15.02%	1.52%	
Q2 2019	7.28%	15.10%	16.57%	9.89%	
Q3 2019	10.51%	17.47%	18.38%	12.82%	
Q4 2019	10.09%	18.94%	18.44%	15.50%	
Q1 2020	12.22%	20.54%	22.30%	17.14%	
Q2 2020	11.62%	21.88%	23.52%	18.03%	
Q3 2020	11.05%	21.78%	23.90%	19.85%	
Q4 2020	11.19%	24.22%	24.80%	18.18%	
Q1 2021	11.50%	25.35%	23.91%	18.18%	
Q2 2021	10.85%	28.60%	26.00%	18.09%	

TABLE UTIL-CARD-VAS.6: Proportion of Vasodilator Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	11.11%	19.69%	20.60%	15.95%	
SFY 2021	11.14%	25.01%	24.66%	18.49%	

TABLE UTIL-CARD-VAS.4: Total Spend of Vasodilator Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 1,262.21	\$ 1,817.80	\$ 2,688.34	\$ 12.38	\$ 5,780.73
Q2 2019	\$ 1,285.94	\$ 1,913.74	\$ 3,042.68	\$ 167.10	\$ 6,409.46
Q3 2019	\$ 1,795.32	\$ 2,098.42	\$ 3,060.03	\$ 195.73	\$ 7,149.50
Q4 2019	\$ 1,833.82	\$ 2,203.71	\$ 3,049.36	\$ 334.79	\$ 7,421.68
Q1 2020	\$ 2,304.55	\$ 2,555.40	\$ 3,802.69	\$ 467.51	\$ 9,130.15
Q2 2020	\$ 2,123.13	\$ 2,626.99	\$ 3,823.78	\$ 313.14	\$ 8,887.04
Q3 2020	\$ 2,270.93	\$ 2,504.81	\$ 3,690.91	\$ 539.42	\$ 9,006.07
Q4 2020	\$ 1,856.19	\$ 2,509.50	\$ 3,852.85	\$ 685.76	\$ 8,904.30
Q1 2021	\$ 1,894.37	\$ 2,727.15	\$ 3,458.30	\$ 623.00	\$ 8,702.82
Q2 2021	\$ 1,938.35	\$ 3,518.73	\$ 4,000.57	\$ 757.44	\$ 10,215.09
<b>Total</b>	<b>\$ 18,564.81</b>	<b>\$ 24,476.25</b>	<b>\$ 34,469.51</b>	<b>\$ 4,096.27</b>	<b>\$ 81,606.84</b>

TABLE UTIL-CARD-VAS.7: Total Spend of Vasodilator Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 8,056.82	\$ 9,484.52	\$ 13,735.86	\$ 1,311.17	\$ 69,416.65
SFY 2021	\$ 7,959.84	\$ 11,260.19	\$ 15,002.63	\$ 2,605.62	\$ 36,828.28
<b>Total</b>	<b>\$ 16,016.66</b>	<b>\$ 20,744.71</b>	<b>\$ 28,738.49</b>	<b>\$ 3,916.79</b>	<b>\$ 106,244.93</b>

## CARDIOVASCULAR – FIBRATES

TABLE UTIL-CARD-FIB.1: Beneficiaries' Demographic Characteristics for Fibrates Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	-	9	4	1	14
18-25	5	1	2	-	8
26-44	38	50	102	7	197
45-64	197	280	462	26	965
65+	5	2	2	-	9
<b>Total</b>	<b>245</b>	<b>342</b>	<b>572</b>	<b>34</b>	<b>1,193</b>
<b>Gender</b>					
Female	116	168	324	20	628
Male	129	174	248	14	565
<b>Total</b>	<b>245</b>	<b>342</b>	<b>572</b>	<b>34</b>	<b>1,193</b>
<b>Race</b>					
Caucasian	167	185	299	20	671
African American	66	101	152	9	328
Other	12	56	121	5	194
<b>Total</b>	<b>245</b>	<b>342</b>	<b>572</b>	<b>34</b>	<b>1,193</b>

TABLE UTIL-CARD-FIB.2: Number of Fibrates Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	12	9	19	-	40
Q2 2019	13	14	30	-	57
Q3 2019	17	33	49	2	101
Q4 2019	22	33	69	3	127
Q1 2020	19	45	68	1	133
Q2 2020	26	46	69	4	145
Q3 2020	32	38	64	6	140
Q4 2020	30	35	73	4	142
Q1 2021	39	42	69	4	154
Q2 2021	35	47	62	10	154
<b>Total</b>	<b>245</b>	<b>342</b>	<b>572</b>	<b>34</b>	<b>1,193</b>

TABLE UTIL-CARD-FIB.5: Number of Fibrates Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	84	157	255	10	506
SFY 2021	136	162	268	24	590
<b>Total</b>	<b>220</b>	<b>319</b>	<b>523</b>	<b>34</b>	<b>1,096</b>

TABLE UTIL-CARD-FIB.3: Proportion of Fibrates Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	6.32%	4.97%	5.81%	0.00%	
Q2 2019	5.58%	8.38%	8.93%	0.00%	
Q3 2019	6.77%	22.15%	15.96%	20.00%	
Q4 2019	9.78%	23.57%	24.82%	25.00%	
Q1 2020	8.48%	33.33%	25.66%	7.69%	
Q2 2020	11.87%	34.59%	28.40%	20.00%	
Q3 2020	17.20%	29.46%	28.07%	22.22%	
Q4 2020	17.14%	32.71%	31.47%	19.05%	
Q1 2021	21.20%	35.29%	31.51%	17.39%	
Q2 2021	19.23%	36.43%	28.44%	30.30%	

TABLE UTIL-CARD-FIB.6: Proportion of Fibrates Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	9.14%	28.19%	23.33%	18.18%	
SFY 2021	18.71%	33.47%	29.88%	23.08%	

TABLE UTIL-CARD-FIB.4: Total Spend of Fibrates Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 286.20	\$ 201.22	\$ 448.28	\$ -	\$ 935.70
Q2 2019	\$ 316.64	\$ 345.43	\$ 718.42	\$ -	\$ 1,380.49
Q3 2019	\$ 394.17	\$ 903.62	\$ 1,296.82	\$ 46.41	\$ 2,641.02
Q4 2019	\$ 571.63	\$ 837.70	\$ 1,784.36	\$ 64.25	\$ 3,257.94
Q1 2020	\$ 486.64	\$ 1,103.56	\$ 1,669.08	\$ 28.00	\$ 3,287.28
Q2 2020	\$ 720.03	\$ 1,096.66	\$ 1,713.62	\$ 88.43	\$ 3,618.74
Q3 2020	\$ 883.24	\$ 965.61	\$ 1,673.32	\$ 137.05	\$ 3,659.22
Q4 2020	\$ 767.37	\$ 917.41	\$ 2,003.40	\$ 89.96	\$ 3,778.14
Q1 2021	\$ 974.91	\$ 1,095.70	\$ 1,800.05	\$ 107.68	\$ 3,978.34
Q2 2021	\$ 842.00	\$ 1,112.98	\$ 1,556.57	\$ 267.01	\$ 3,778.56
<b>Total</b>	<b>\$ 6,242.83</b>	<b>\$ 8,579.89</b>	<b>\$ 14,663.92</b>	<b>\$ 828.79</b>	<b>\$ 30,315.43</b>

TABLE UTIL-CARD-FIB.7: Total Spend of Fibrates Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 2,172.47	\$ 3,941.54	\$ 6,463.88	\$ 227.09	\$ 12,804.98
SFY 2021	\$ 3,467.52	\$ 4,091.70	\$ 7,033.34	\$ 601.70	\$ 15,194.26
<b>Total</b>	<b>\$ 5,639.99</b>	<b>\$ 8,033.24</b>	<b>\$ 13,497.22</b>	<b>\$ 828.79</b>	<b>\$ 27,999.24</b>

## CARDIOVASCULAR – STATINS

TABLE UTIL-CARD-STAT.1: Beneficiaries' Demographic Characteristics for Statins Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	24	17	40	3	84
18-25	75	114	125	16	330
26-44	1,046	2,587	3,586	741	7,960
45-64	8,490	13,987	18,864	2,207	43,548
65+	228	100	125	-	453
<b>Total</b>	<b>9,863</b>	<b>16,805</b>	<b>22,740</b>	<b>2,967</b>	<b>52,375</b>
<b>Gender</b>					
Female	5,720	9,953	13,921	1,618	31,212
Male	4,142	6,852	8,819	1,349	21,162
<b>Total</b>	<b>9,862</b>	<b>16,805</b>	<b>22,740</b>	<b>2,967</b>	<b>52,374</b>
<b>Race</b>					
Caucasian	3,481	5,948	7,648	1,154	18,231
African American	5,227	8,173	11,642	1,246	26,288
Other	1,155	2,684	3,450	567	7,856
<b>Total</b>	<b>9,863</b>	<b>16,805</b>	<b>22,740</b>	<b>2,967</b>	<b>52,375</b>

Note: 1 claims' gender variable is valued as "U".

TABLE UTIL-CARD-STAT.2: Number of Statins Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	549	1,036	1,610	67	3,262
Q2 2019	723	1,092	1,877	86	3,778
Q3 2019	869	1,467	2,133	148	4,617
Q4 2019	910	1,543	2,199	155	4,807
Q1 2020	987	1,802	2,339	266	5,394
Q2 2020	988	1,892	2,395	334	5,609
Q3 2020	1,103	1,813	2,468	381	5,765
Q4 2020	1,153	1,825	2,496	435	5,909
Q1 2021	1,246	1,987	2,582	498	6,313
Q2 2021	1,335	2,348	2,641	597	6,921
<b>Total</b>	<b>9,863</b>	<b>16,805</b>	<b>22,740</b>	<b>2,967</b>	<b>52,375</b>

TABLE UTIL-CARD-STAT.5: Number of Statins Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	3,754	6,704	9,066	903	20,427
SFY 2021	4,837	7,973	10,187	1,911	24,908
<b>Total</b>	<b>8,591</b>	<b>14,677</b>	<b>19,253</b>	<b>2,814</b>	<b>45,335</b>

TABLE UTIL-CARD-STAT.3: Proportion of Statins Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	10.74%	19.38%	18.91%	16.79%	
Q2 2019	13.67%	20.91%	22.75%	15.93%	
Q3 2019	16.24%	27.82%	26.39%	18.66%	
Q4 2019	16.70%	30.08%	28.30%	19.87%	
Q1 2020	17.84%	32.90%	30.50%	26.08%	
Q2 2020	18.42%	33.03%	32.22%	31.75%	
Q3 2020	20.02%	34.65%	33.43%	33.02%	
Q4 2020	20.32%	36.44%	34.68%	34.42%	
Q1 2021	21.33%	39.39%	36.66%	34.73%	
Q2 2021	21.63%	41.15%	37.47%	37.83%	

TABLE UTIL-CARD-STAT.6: Proportion of Statins Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	17.30%	31.02%	29.29%	24.77%	
SFY 2021	20.85%	37.99%	35.53%	35.19%	

TABLE UTIL-CARD-STAT.4: Total Spend of Statins Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 8,787.46	\$ 16,749.47	\$ 26,684.78	\$ 1,110.05	\$ 53,331.76
Q2 2019	\$ 12,069.35	\$ 18,171.89	\$ 31,701.63	\$ 1,434.04	\$ 63,376.91
Q3 2019	\$ 14,417.36	\$ 24,687.09	\$ 35,912.47	\$ 2,533.91	\$ 77,550.83
Q4 2019	\$ 14,924.84	\$ 25,740.14	\$ 36,901.24	\$ 2,561.81	\$ 80,128.03
Q1 2020	\$ 17,194.51	\$ 30,534.59	\$ 39,216.08	\$ 4,647.71	\$ 91,592.89
Q2 2020	\$ 18,936.20	\$ 31,059.45	\$ 39,453.32	\$ 5,583.29	\$ 95,032.26
Q3 2020	\$ 20,726.29	\$ 30,208.10	\$ 40,256.04	\$ 6,334.00	\$ 97,524.43
Q4 2020	\$ 17,929.98	\$ 28,565.39	\$ 39,363.29	\$ 6,781.16	\$ 92,639.82
Q1 2021	\$ 19,183.07	\$ 30,516.15	\$ 39,873.42	\$ 7,704.05	\$ 97,276.69
Q2 2021	\$ 19,797.10	\$ 34,929.81	\$ 39,480.77	\$ 8,929.45	\$ 103,137.13
<b>Total</b>	<b>\$ 163,966.16</b>	<b>\$ 271,162.08</b>	<b>\$ 368,843.04</b>	<b>\$ 47,619.47</b>	<b>\$ 851,590.75</b>

TABLE UTIL-CARD-STAT.7: Total Spend of Statins Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 65,472.91	\$ 112,021.27	\$ 151,483.11	\$ 15,326.72	\$ 344,304.01
SFY 2021	\$ 77,636.44	\$ 124,219.45	\$ 158,973.52	\$ 29,748.66	\$ 390,578.07
<b>Total</b>	<b>\$ 143,109.35</b>	<b>\$ 236,240.72</b>	<b>\$ 310,456.63</b>	<b>\$ 45,075.38</b>	<b>\$ 734,882.08</b>

## CARDIOVASCULAR – PLATELET INHIBITORS

TABLE UTIL-CARD-PLATI.1: Beneficiaries' Demographic Characteristics for Platelet Inhibitor Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	1	2	-	-	3
18-25	4	3	7	1	15
26-44	80	155	226	62	523
45-64	1,603	2,385	2,780	428	7,196
65+	45	28	28	-	101
<b>Total</b>	<b>1,733</b>	<b>2,573</b>	<b>3,041</b>	<b>491</b>	<b>7,838</b>
<b>Gender</b>					
Female	863	1,217	1,680	224	3,984
Male	869	1,356	1,361	267	3,853
<b>Total</b>	<b>1,732</b>	<b>2,573</b>	<b>3,041</b>	<b>491</b>	<b>7,837</b>
<b>Race</b>					
Caucasian	678	1,041	1,118	188	3,025
African American	864	1,104	1,352	177	3,497
Other	191	428	571	126	1,316
<b>Total</b>	<b>1,733</b>	<b>2,573</b>	<b>3,041</b>	<b>491</b>	<b>7,838</b>

Note: 1 claims' gender variable is valued as "U".

TABLE UTIL-CARD-PLATI.2: Number of Platelet Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	149	213	299	19	680
Q2 2019	179	238	332	23	772
Q3 2019	198	298	348	40	884
Q4 2019	201	305	350	41	897
Q1 2020	183	283	333	47	846
Q2 2020	143	262	251	50	706
Q3 2020	134	231	294	61	720
Q4 2020	161	223	283	60	727
Q1 2021	176	254	282	78	790
Q2 2021	209	266	269	72	816
<b>Total</b>	<b>1,733</b>	<b>2,573</b>	<b>3,041</b>	<b>491</b>	<b>7,838</b>

TABLE UTIL-CARD-PLATI.5: Number of Platelet Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	725	1,148	1,282	178	3,333
SFY 2021	680	974	1,128	271	3,053
<b>Total</b>	<b>1,405</b>	<b>2,122</b>	<b>2,410</b>	<b>449</b>	<b>6,386</b>

TABLE UTIL-CARD-PLATI.3: Proportion of Platelet Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	11.37%	20.32%	19.15%	19.00%	
Q2 2019	12.94%	23.45%	22.80%	16.79%	
Q3 2019	14.40%	29.83%	24.84%	21.98%	
Q4 2019	15.01%	30.11%	25.81%	21.58%	
Q1 2020	14.68%	30.17%	26.64%	23.27%	
Q2 2020	13.13%	29.98%	24.85%	29.76%	
Q3 2020	12.75%	30.00%	28.19%	32.11%	
Q4 2020	15.13%	31.63%	29.63%	30.00%	
Q1 2021	15.66%	35.52%	31.51%	35.95%	
Q2 2021	16.04%	36.04%	31.17%	34.12%	

TABLE UTIL-CARD-PLATI.6: Proportion of Platelet Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	14.36%	30.02%	25.55%	23.99%	
SFY 2021	14.97%	33.27%	30.03%	33.13%	

TABLE UTIL-CARD-PLATI.4: Total Spend of Platelet Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 2,032.90	\$ 2,949.10	\$ 4,159.98	\$ 273.33	\$ 9,415.31
Q2 2019	\$ 2,422.96	\$ 3,306.74	\$ 4,621.24	\$ 321.16	\$ 10,672.10
Q3 2019	\$ 2,736.40	\$ 4,221.09	\$ 4,947.72	\$ 574.33	\$ 12,479.54
Q4 2019	\$ 2,763.62	\$ 4,336.44	\$ 4,994.31	\$ 585.12	\$ 12,679.49
Q1 2020	\$ 2,673.41	\$ 4,182.24	\$ 4,900.12	\$ 696.51	\$ 12,452.28
Q2 2020	\$ 2,348.32	\$ 3,757.57	\$ 3,606.11	\$ 735.75	\$ 10,447.75
Q3 2020	\$ 2,200.02	\$ 3,435.48	\$ 4,245.72	\$ 908.70	\$ 10,789.92
Q4 2020	\$ 2,140.49	\$ 3,158.77	\$ 4,066.80	\$ 844.68	\$ 10,210.74
Q1 2021	\$ 2,257.00	\$ 3,546.46	\$ 3,943.09	\$ 1,094.39	\$ 10,840.94
Q2 2021	\$ 2,734.24	\$ 3,764.81	\$ 3,805.26	\$ 1,015.82	\$ 11,320.13
<b>Total</b>	<b>\$ 24,309.36</b>	<b>\$ 36,658.70</b>	<b>\$ 43,290.35</b>	<b>\$ 7,049.79</b>	<b>\$ 111,308.20</b>

TABLE UTIL-CARD-PLATI.7: Total Spend of Platelet Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 10,521.75	\$ 16,497.34	\$ 18,448.26	\$ 2,591.71	\$ 48,059.06
SFY 2021	\$ 9,331.75	\$ 13,905.52	\$ 16,060.87	\$ 3,863.59	\$ 43,161.73
<b>Total</b>	<b>\$ 19,853.50</b>	<b>\$ 30,402.86</b>	<b>\$ 34,509.13</b>	<b>\$ 6,455.30</b>	<b>\$ 91,220.79</b>



## CARDIOVASCULAR – ANTICOAGULANTS

TABLE UTIL-CARD-AC.1: Beneficiaries' Demographic Characteristics for Anticoagulant Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	19	3	39	2	63
18-25	-	4	8	3	15
26-44	-	67	89	17	173
45-64	2	305	407	48	762
65+	-	-	6	-	6
<b>Total</b>	21	379	549	70	1,019
<b>Gender</b>					
Female	1	208	267	26	502
Male	20	171	282	44	517
<b>Total</b>	21	379	549	70	1,019
<b>Race</b>					
Caucasian	5	137	174	23	339
African American	15	176	286	32	509
Other	1	66	89	15	171
<b>Total</b>	21	379	549	70	1,019

TABLE UTIL-CARD-AC.2: Number of Anticoagulant Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	-	-	-	-	-
Q2 2019	-	11	31	-	42
Q3 2019	4	28	64	-	96
Q4 2019	3	41	58	-	102
Q1 2020	2	43	61	4	110
Q2 2020	2	51	72	11	136
Q3 2020	3	44	64	13	124
Q4 2020	2	53	73	18	146
Q1 2021	2	54	65	14	135
Q2 2021	3	54	61	10	128
<b>Total</b>	21	379	549	70	1,019

TABLE UTIL-CARD-AC.5: Number of Anticoagulant Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	11	163	255	15	444
SFY 2021	10	205	263	55	533
<b>Total</b>	21	368	518	70	977

TABLE UTIL-CARD-AC.3: Proportion of Anticoagulant Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	0.00%	0.00%	0.00%	0.00%
Q2 2019	0.00%	2.49%	4.80%	0.00%
Q3 2019	0.63%	6.07%	10.87%	0.00%
Q4 2019	0.47%	8.93%	11.22%	0.00%
Q1 2020	0.34%	9.13%	12.42%	4.17%
Q2 2020	0.35%	11.67%	15.35%	11.96%
Q3 2020	0.63%	10.50%	13.85%	16.67%
Q4 2020	0.44%	13.56%	16.86%	18.95%
Q1 2021	0.46%	14.96%	16.01%	19.18%
Q2 2021	0.66%	13.24%	15.10%	15.15%

TABLE UTIL-CARD-AC.6: Proportion of Anticoagulant Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	0.45%	8.92%	12.34%	3.90%
SFY 2021	0.55%	12.98%	15.43%	17.63%

TABLE UTIL-CARD-AC.4: Total Spend of Anticoagulant Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ -	\$ -	\$ -	\$ -	\$ -
Q2 2019	\$ 181.16	\$ 1,167.78	\$ -	\$ -	\$ 1,348.94
Q3 2019	\$ 95.51	\$ 446.44	\$ 1,761.15	\$ -	\$ 2,303.10
Q4 2019	\$ 74.82	\$ 715.27	\$ 1,635.57	\$ -	\$ 2,425.66
Q1 2020	\$ 52.28	\$ 757.84	\$ 1,912.93	\$ 71.44	\$ 2,794.49
Q2 2020	\$ 52.97	\$ 829.51	\$ 2,266.84	\$ 368.08	\$ 3,517.40
Q3 2020	\$ 68.53	\$ 762.36	\$ 1,109.70	\$ 417.82	\$ 2,358.41
Q4 2020	\$ 53.47	\$ 851.99	\$ 1,394.90	\$ 370.26	\$ 2,670.62
Q1 2021	\$ 44.36	\$ 908.49	\$ 1,213.04	\$ 262.09	\$ 2,427.98
Q2 2021	\$ 72.83	\$ 851.03	\$ 1,141.97	\$ 169.99	\$ 2,235.82
<b>Total</b>	\$ 695.93	\$ 7,290.71	\$ 12,436.10	\$ 1,659.68	\$ 22,082.42

TABLE UTIL-CARD-AC.7: Total Spend of Anticoagulant Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 275.58	\$ 2,749.06	\$ 7,576.49	\$ 439.52	\$ 11,040.65
SFY 2021	\$ 239.19	\$ 3,373.87	\$ 4,859.61	\$ 1,220.16	\$ 9,692.83
<b>Total</b>	\$ 514.77	\$ 6,122.93	\$ 12,436.10	\$ 1,659.68	\$ 20,733.48

## DIABETES – BIGUANIDES

TABLE UTIL-DIAB-BIG.1: Beneficiaries' Demographic Characteristics for Biguanide Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	78	149	132	49	408
18-25	94	150	161	35	440
26-44	400	1,328	1,707	413	3,848
45-64	2,185	4,175	5,864	564	12,788
65+	53	12	41	-	106
<b>Total</b>	<b>2,810</b>	<b>5,814</b>	<b>7,905</b>	<b>1,061</b>	<b>17,590</b>
<b>Gender</b>					
Female	1,796	3,838	5,410	750	11,794
Male	1,014	1,976	2,495	311	5,796
<b>Total</b>	<b>2,810</b>	<b>5,814</b>	<b>7,905</b>	<b>1,061</b>	<b>17,590</b>
<b>Race</b>					
Caucasian	932	1,668	2,292	388	5,280
African American	1,584	3,288	4,489	533	9,894
Other	294	858	1,124	140	2,416
<b>Total</b>	<b>2,810</b>	<b>5,814</b>	<b>7,905</b>	<b>1,061</b>	<b>17,590</b>

Note: 2 claims have missing information for pharmacy program.

TABLE UTIL-DIAB-BIG.2: Number of Biguanide Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	216	377	629	23	1,245
Q2 2019	230	425	729	64	1,448
Q3 2019	266	574	814	76	1,730
Q4 2019	257	526	751	70	1,604
Q1 2020	266	589	762	94	1,711
Q2 2020	276	678	818	104	1,876
Q3 2020	274	602	819	126	1,821
Q4 2020	302	597	849	145	1,893
Q1 2021	339	664	843	174	2,020
Q2 2021	384	782	891	185	2,242
<b>Total</b>	<b>2,810</b>	<b>5,814</b>	<b>7,905</b>	<b>1,061</b>	<b>17,590</b>

TABLE UTIL-DIAB-BIG.3: Proportion of Biguanide Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	9.81%	15.28%	15.66%	8.24%
Q2 2019	10.68%	17.14%	18.79%	16.00%
Q3 2019	12.27%	22.31%	21.31%	16.93%
Q4 2019	12.16%	23.38%	22.46%	16.17%
Q1 2020	12.84%	25.21%	23.80%	19.50%
Q2 2020	13.46%	26.22%	25.89%	18.81%
Q3 2020	12.73%	25.41%	26.79%	20.76%
Q4 2020	13.72%	26.49%	28.99%	22.31%
Q1 2021	15.36%	28.70%	29.53%	25.11%
Q2 2021	16.42%	30.09%	30.74%	24.28%

TABLE UTIL-DIAB-BIG.4: Total Spend of Biguanide Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 2,174.83	\$ 4,013.30	\$ 6,763.03	\$ 239.34	\$ 13,190.50
Q2 2019	\$ 2,371.37	\$ 4,565.37	\$ 7,805.82	\$ 678.86	\$ 15,421.42
Q3 2019	\$ 2,696.78	\$ 6,169.85	\$ 8,744.56	\$ 839.13	\$ 18,450.32
Q4 2019	\$ 2,713.41	\$ 5,736.06	\$ 8,274.20	\$ 752.57	\$ 17,476.24
Q1 2020	\$ 2,998.29	\$ 6,792.21	\$ 8,601.69	\$ 1,087.88	\$ 19,480.07
Q2 2020	\$ 3,621.29	\$ 7,690.01	\$ 9,178.20	\$ 1,218.25	\$ 21,707.75
Q3 2020	\$ 3,623.85	\$ 7,190.69	\$ 9,362.06	\$ 1,449.98	\$ 21,626.58
Q4 2020	\$ 3,311.79	\$ 6,893.76	\$ 9,665.57	\$ 1,691.88	\$ 21,563.00
Q1 2021	\$ 3,741.23	\$ 7,610.00	\$ 9,541.83	\$ 1,930.04	\$ 22,823.10
Q2 2021	\$ 4,364.66	\$ 9,085.67	\$ 10,256.48	\$ 2,133.14	\$ 25,839.95
<b>Total</b>	<b>\$ 31,617.50</b>	<b>\$ 65,746.92</b>	<b>\$ 88,193.44</b>	<b>\$ 12,021.07</b>	<b>\$ 197,578.93</b>

TABLE UTIL-DIAB-BIG.5: Number of Biguanide Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	1,065	2,367	3,145	344	6,921
SFY 2021	1,299	2,645	3,402	630	7,976
<b>Total</b>	<b>2,364</b>	<b>5,012</b>	<b>6,547</b>	<b>974</b>	<b>14,897</b>

TABLE UTIL-DIAB-BIG.6: Proportion of Biguanide Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	12.67%	24.29%	23.26%	17.95%
SFY 2021	14.60%	27.74%	28.98%	23.23%

TABLE UTIL-DIAB-BIG.7: Total Spend of Biguanide Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 12,029.77	\$ 26,388.13	\$ 34,798.65	\$ 3,897.83	\$ 77,114.38
SFY 2021	\$ 15,041.53	\$ 30,780.12	\$ 38,825.94	\$ 7,205.04	\$ 91,852.63
<b>Total</b>	<b>\$ 27,071.30</b>	<b>\$ 57,168.25</b>	<b>\$ 73,624.59</b>	<b>\$ 11,102.87</b>	<b>\$ 168,967.01</b>

## DIABETES – DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND COMBINATIONS

TABLE UTIL-DIAB-DPP4.1: Beneficiaries' Demographic Characteristics for DPP-4 Inhibitor Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	-	-	-	-	-
18-25	2	10	10	5	27
26-44	71	199	349	59	678
45-64	552	1,232	1,599	114	3,497
65+	29	3	4	1	37
<b>Total</b>	<b>654</b>	<b>1,444</b>	<b>1,962</b>	<b>179</b>	<b>4,239</b>
<b>Gender</b>					
Female	441	927	1,355	116	2,839
Male	213	517	607	63	1,400
<b>Total</b>	<b>654</b>	<b>1,444</b>	<b>1,962</b>	<b>179</b>	<b>4,239</b>
<b>Race</b>					
Caucasian	215	387	509	79	1,190
African Am	383	790	1,217	74	2,464
Other	56	267	236	26	585
<b>Total</b>	<b>654</b>	<b>1,444</b>	<b>1,962</b>	<b>179</b>	<b>4,239</b>

TABLE UTIL-DIAB-DPP4.2: Number of DPP-4 Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	-	1	2	-	3
Q2 2019	42	38	104	-	184
Q3 2019	56	119	172	-	347
Q4 2019	61	148	214	-	423
Q1 2020	71	178	220	8	477
Q2 2020	75	180	243	19	517
Q3 2020	80	164	236	25	505
Q4 2020	87	179	250	28	544
Q1 2021	90	185	265	47	587
Q2 2021	92	252	256	52	652
<b>Total</b>	<b>654</b>	<b>1,444</b>	<b>1,962</b>	<b>179</b>	<b>4,239</b>

TABLE UTIL-DIAB-DPP4.5: Number of DPP-4 Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	263	625	849	27	1,764
SFY 2021	349	780	1,007	152	2,288
<b>Total</b>	<b>612</b>	<b>1,405</b>	<b>1,856</b>	<b>179</b>	<b>4,052</b>

TABLE UTIL-DIAB-DPP4.3: Proportion of DPP-4 Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	0.00%	0.09%	0.12%	0.00%
Q2 2019	5.94%	3.45%	6.35%	0.00%
Q3 2019	7.91%	11.89%	11.63%	0.00%
Q4 2019	9.44%	16.02%	15.91%	0.00%
Q1 2020	10.91%	18.54%	17.95%	5.80%
Q2 2020	11.77%	19.65%	19.76%	12.34%
Q3 2020	12.74%	19.69%	18.88%	16.13%
Q4 2020	13.74%	20.94%	20.33%	17.83%
Q1 2021	13.89%	22.84%	21.81%	25.00%
Q2 2021	13.61%	26.01%	22.22%	25.00%

TABLE UTIL-DIAB-DPP4.6: Proportion of DPP-4 Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	9.96%	16.44%	16.08%	5.36%
SFY 2021	13.50%	22.50%	20.78%	21.47%

TABLE UTIL-DIAB-DPP4.4: Total Spend of DPP-4 Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 1,307.74	\$ 1,367.90	\$ -	\$ -	\$ 2,675.64
Q2 2019	\$ 52,761.55	\$ 49,392.84	\$ 130,825.35	\$ -	\$ 232,979.74
Q3 2019	\$ 70,619.83	\$ 150,678.31	\$ 215,463.46	\$ -	\$ 436,761.60
Q4 2019	\$ 71,817.64	\$ 189,019.29	\$ 271,912.61	\$ -	\$ 532,749.54
Q1 2020	\$ 94,904.20	\$ 237,403.85	\$ 293,031.22	\$ 10,919.50	\$ 636,258.77
Q2 2020	\$ 100,342.27	\$ 229,722.28	\$ 322,713.26	\$ 25,260.20	\$ 678,038.01
Q3 2020	\$ 105,863.48	\$ 214,698.14	\$ 313,418.55	\$ 32,793.53	\$ 666,773.70
Q4 2020	\$ 115,128.17	\$ 235,646.59	\$ 331,075.05	\$ 32,927.08	\$ 714,776.89
Q1 2021	\$ 117,583.73	\$ 254,028.23	\$ 370,661.42	\$ 59,777.36	\$ 802,050.74
Q2 2021	\$ 127,088.16	\$ 346,525.17	\$ 358,630.99	\$ 70,917.40	\$ 903,161.72
<b>Total</b>	<b>\$ 857,416.77</b>	<b>\$ 1,908,482.60</b>	<b>\$ 2,607,731.91</b>	<b>\$ 232,595.07</b>	<b>\$ 5,606,226.35</b>

TABLE UTIL-DIAB-DPP4.7: Total Spend of DPP-4 Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	337683.94	806823.73	1103120.55	36179.7	\$ 2,283,807.92
SFY 2021	465663.54	1050898.13	1373786.01	196415.37	\$ 3,086,763.05
<b>Total</b>	<b>\$ 803,347.48</b>	<b>\$ 1,857,721.86</b>	<b>\$ 2,476,906.56</b>	<b>\$ 232,595.07</b>	<b>\$ 5,370,570.97</b>

## DIABETES – SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS AND COMBINATIONS

TABLE UTIL-DIAB-SGLT.1: Beneficiaries' Demographic Characteristics for SGLT-2 Inhibitor or Combination Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	1	9	1	-	11
18-25	9	13	12	6	40
26-44	88	221	383	72	764
45-64	520	772	1,276	143	2,711
65+	3	11	5	-	19
<b>Total</b>	<b>621</b>	<b>1,026</b>	<b>1,677</b>	<b>221</b>	<b>3,545</b>
<b>Gender</b>					
Female	377	669	1,111	157	2,314
Male	244	357	566	64	1,231
<b>Total</b>	<b>621</b>	<b>1,026</b>	<b>1,677</b>	<b>221</b>	<b>3,545</b>
<b>Race</b>					
Caucasian	269	367	604	107	1,347
African American	276	472	823	82	1,653
Other	76	187	250	32	545
<b>Total</b>	<b>621</b>	<b>1,026</b>	<b>1,677</b>	<b>221</b>	<b>3,545</b>

TABLE UTIL-DIAB-SGLT.2: Number of SGLT-2 Inhibitor or Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	-	-	2	-	2
Q2 2019	21	22	52	-	95
Q3 2019	51	70	113	-	234
Q4 2019	59	89	128	-	276
Q1 2020	43	113	163	11	330
Q2 2020	58	113	183	25	379
Q3 2020	76	111	218	35	440
Q4 2020	92	144	246	39	521
Q1 2021	99	146	268	45	558
Q2 2021	122	218	304	66	710
<b>Total</b>	<b>621</b>	<b>1,026</b>	<b>1,677</b>	<b>221</b>	<b>3,545</b>

TABLE UTIL-DIAB-SGLT.5: Number of SGLT-2 Inhibitor or Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	211	385	587	36	1,219
SFY 2021	389	619	1,036	185	2,229
<b>Total</b>	<b>600</b>	<b>1,004</b>	<b>1,623</b>	<b>221</b>	<b>3,448</b>

TABLE UTIL-DIAB-SGLT.3: Proportion of SGLT-2 Inhibitor or Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	0.00%	0.00%	0.23%	0.00%	
Q2 2019	5.48%	3.23%	5.32%	0.00%	
Q3 2019	13.42%	9.67%	11.80%	0.00%	
Q4 2019	14.50%	12.96%	12.69%	0.00%	
Q1 2020	10.21%	15.09%	16.47%	7.91%	
Q2 2020	11.77%	13.81%	17.45%	16.67%	
Q3 2020	14.15%	12.89%	18.96%	22.58%	
Q4 2020	14.63%	15.64%	18.43%	20.00%	
Q1 2021	13.98%	13.74%	20.15%	17.38%	
Q2 2021	14.58%	15.89%	20.75%	21.09%	

TABLE UTIL-DIAB-SGLT.6: Proportion of SGLT-2 Inhibitor or Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	12.40%	12.93%	14.65%	7.68%	
SFY 2021	14.35%	14.68%	19.62%	20.07%	

TABLE UTIL-DIAB-SGLT.4: Total Spend of SGLT-2 Inhibitor or Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 1,486.14	\$ -	\$ -	\$ -	\$ 1,486.14
Q2 2019	\$ 30,007.87	\$ 29,309.68	\$ 70,921.17	\$ -	\$ 130,238.72
Q3 2019	\$ 70,120.30	\$ 93,633.20	\$ 157,149.30	\$ -	\$ 320,902.80
Q4 2019	\$ 82,763.36	\$ 125,575.43	\$ 179,808.10	\$ -	\$ 388,146.89
Q1 2020	\$ 62,918.82	\$ 167,815.86	\$ 239,425.02	\$ 14,877.10	\$ 485,036.80
Q2 2020	\$ 84,983.89	\$ 166,308.70	\$ 268,970.05	\$ 37,453.34	\$ 557,715.98
Q3 2020	\$ 110,304.72	\$ 165,574.30	\$ 318,751.74	\$ 52,772.40	\$ 647,403.16
Q4 2020	\$ 133,418.58	\$ 212,379.66	\$ 363,881.43	\$ 58,776.80	\$ 768,456.47
Q1 2021	\$ 150,466.02	\$ 229,055.87	\$ 411,643.43	\$ 68,790.11	\$ 859,955.43
Q2 2021	\$ 179,237.68	\$ 340,189.26	\$ 469,268.25	\$ 101,860.00	\$ 1,090,555.19
<b>Total</b>	<b>\$ 905,707.38</b>	<b>\$ 1,529,841.96</b>	<b>\$ 2,479,818.49</b>	<b>\$ 334,529.75</b>	<b>\$ 5,249,897.58</b>

TABLE UTIL-DIAB-SGLT.7: Total Spend of SGLT-2 Inhibitor or Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 300,786.37	\$ 553,333.19	\$ 845,352.47	\$ 52,330.44	\$ 1,751,802.47
SFY 2021	\$ 573,427.00	\$ 947,199.09	\$ 1,563,544.85	\$ 282,199.31	\$ 3,366,370.25
<b>Total</b>	<b>\$ 874,213.37</b>	<b>\$ 1,500,532.28</b>	<b>\$ 2,408,897.32</b>	<b>\$ 334,529.75</b>	<b>\$ 5,118,172.72</b>

## DIABETES – SULFONYLUREAS

TABLE UTIL-DIAB-SU.1: Beneficiaries' Demographic Characteristics for Sulfonyleurea Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	2	-	1	-	3
18-25	12	17	13	4	46
26-44	186	344	548	121	1,199
45-64	1,038	1,768	2,404	256	5,466
65+	32	10	7	-	49
<b>Total</b>	<b>1,270</b>	<b>2,139</b>	<b>2,973</b>	<b>381</b>	<b>6,763</b>
<b>Gender</b>					
Female	821	1,306	2,006	272	4,405
Male	449	833	967	109	2,358
<b>Total</b>	<b>1,270</b>	<b>2,139</b>	<b>2,973</b>	<b>381</b>	<b>6,763</b>
<b>Race</b>					
Caucasian	332	566	810	106	1,814
African American	773	1,209	1,865	207	4,054
Other	165	364	298	68	895
<b>Total</b>	<b>1,270</b>	<b>2,139</b>	<b>2,973</b>	<b>381</b>	<b>6,763</b>

TABLE UTIL-DIAB-SU.2: Number of Sulfonyleurea Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	26	48	172	3	249
Q2 2019	83	87	244	5	419
Q3 2019	114	167	283	10	574
Q4 2019	115	218	323	5	661
Q1 2020	139	257	288	34	718
Q2 2020	131	263	297	52	743
Q3 2020	147	262	337	44	790
Q4 2020	159	267	330	61	817
Q1 2021	158	248	354	79	839
Q2 2021	198	322	345	88	953
<b>Total</b>	<b>1,270</b>	<b>2,139</b>	<b>2,973</b>	<b>381</b>	<b>6,763</b>

TABLE UTIL-DIAB-SU.5: Number of Sulfonyleurea Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	499	905	1,191	101	2,696
SFY 2021	662	1,099	1,366	272	3,399
<b>Total</b>	<b>1,161</b>	<b>2,004</b>	<b>2,557</b>	<b>373</b>	<b>6,095</b>

TABLE UTIL-DIAB-SU.3: Proportion of Sulfonyleurea Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	3.03%	4.57%	10.53%	2.89%	
Q2 2019	9.62%	8.58%	16.37%	3.31%	
Q3 2019	13.23%	17.60%	20.30%	5.16%	
Q4 2019	13.96%	23.02%	24.51%	2.81%	
Q1 2020	16.37%	25.22%	21.92%	15.74%	
Q2 2020	14.84%	24.02%	24.57%	22.71%	
Q3 2020	16.96%	27.75%	27.18%	20.09%	
Q4 2020	18.49%	28.59%	28.28%	25.31%	
Q1 2021	19.68%	27.02%	30.62%	28.83%	
Q2 2021	23.63%	30.64%	30.13%	27.59%	

TABLE UTIL-DIAB-SU.6: Proportion of Sulfonyleurea Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	14.60%	22.57%	22.75%	12.36%	
SFY 2021	19.66%	28.57%	29.01%	25.83%	

TABLE UTIL-DIAB-SU.4: Total Spend of Sulfonyleurea Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$265.62	\$572.84	\$2,634.25	\$25.41	\$ 3,498.12
Q2 2019	\$1,108.10	\$1,318.13	\$4,155.94	\$56.04	\$ 6,638.21
Q3 2019	\$1,817.13	\$2,837.60	\$5,230.45	\$85.18	\$ 9,970.36
Q4 2019	\$1,761.07	\$3,816.57	\$5,851.42	\$35.23	\$ 11,464.29
Q1 2020	\$2,330.12	\$4,772.19	\$5,435.92	\$511.41	\$ 13,049.64
Q2 2020	\$2,475.17	\$4,557.15	\$5,552.02	\$876.55	\$ 13,460.89
Q3 2020	\$2,875.43	\$4,554.30	\$6,203.82	\$740.84	\$ 14,374.39
Q4 2020	\$2,520.49	\$4,498.52	\$6,041.73	\$913.42	\$ 13,974.16
Q1 2021	\$2,434.31	\$4,255.14	\$6,384.66	\$1,225.01	\$ 14,299.12
Q2 2021	\$3,191.97	\$5,842.09	\$6,253.04	\$1,459.89	\$ 16,746.99
<b>Total</b>	<b>\$ 20,779.41</b>	<b>\$ 37,024.53</b>	<b>\$ 53,743.25</b>	<b>\$ 5,928.98</b>	<b>\$ 100,729.18</b>

TABLE UTIL-DIAB-SU.7: Total Spend of Sulfonyleurea Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$8,383.49	\$15,983.51	\$22,069.81	\$1,508.37	\$ 47,945.18
SFY 2021	\$11,022.20	\$19,150.05	\$24,883.25	\$4,339.16	\$ 59,394.66
<b>Total</b>	<b>\$ 19,405.69</b>	<b>\$ 35,133.56</b>	<b>\$ 46,953.06</b>	<b>\$ 5,847.53</b>	<b>\$ 107,339.84</b>

## DIABETES – SULFONYLUREA/BIGUANIDES

TABLE UTIL-DIAB-SUBG.1: Beneficiaries' Demographic Characteristics for Sulfonyleurea-Biguanide Combination Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
Age Category (yrs)					
0-17	-	-	-	-	-
18-25	-	1	1	-	2
26-44	7	4	13	5	29
45-64	90	123	235	15	463
65+	4	-	3	-	7
Total	101	128	252	20	501
Gender					
Female	61	97	201	12	371
Male	40	31	51	8	130
Total	101	128	252	20	501
Race					
Caucasian	9	16	46	5	76
African American	83	94	173	7	357
Other	9	18	33	8	68
Total	101	128	252	20	501

TABLE UTIL-DIAB-SUBG.2: Number of Sulfonyleurea-Biguanide Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	11	16	20	-	47
Q2 2019	8	16	27	1	52
Q3 2019	5	13	22	3	43
Q4 2019	9	12	23	2	46
Q1 2020	11	11	28	1	51
Q2 2020	14	12	29	3	58
Q3 2020	11	8	21	-	40
Q4 2020	11	14	32	3	60
Q1 2021	11	10	24	4	49
Q2 2021	10	16	26	3	55
Total	101	128	252	20	501

TABLE UTIL-DIAB-SUBG.5: Number of Sulfonyleurea-Biguanide Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	39	48	102	9	198
SFY 2021	43	48	103	10	204
Total	82	96	205	19	402

TABLE UTIL-DIAB-SUBG.3: Proportion of Sulfonyleurea-Biguanide Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	14.10%	16.00%	11.30%	0.00%	
Q2 2019	11.59%	15.69%	14.60%	11.11%	
Q3 2019	6.67%	13.83%	14.19%	27.27%	
Q4 2019	13.04%	14.82%	15.13%	15.39%	
Q1 2020	18.97%	12.09%	19.31%	12.50%	
Q2 2020	33.33%	13.19%	19.73%	23.08%	
Q3 2020	28.21%	9.30%	15.91%	0.00%	
Q4 2020	28.21%	16.87%	21.05%	25.00%	
Q1 2021	22.92%	12.35%	18.32%	23.53%	
Q2 2021	22.73%	22.22%	19.55%	11.54%	

TABLE UTIL-DIAB-SUBG.6: Proportion of Sulfonyleurea-Biguanide Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	15.98%	13.45%	17.03%	20.00%	
SFY 2021	25.29%	14.91%	18.80%	15.39%	

TABLE UTIL-DIAB-SUBG.4: Total Spend of Sulfonyleurea-Biguanide Combination Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 333.91	\$ 416.81	\$ 453.44	\$ -	\$ 1,204.16
Q2 2019	\$ 270.43	\$ 403.23	\$ 719.96	\$ 94.10	\$ 1,487.72
Q3 2019	\$ 266.26	\$ 312.43	\$ 602.14	\$ 145.31	\$ 1,326.14
Q4 2019	\$ 184.67	\$ 300.20	\$ 785.58	\$ 168.52	\$ 1,438.97
Q1 2020	\$ 338.78	\$ 278.07	\$ 1,112.55	\$ 29.98	\$ 1,759.38
Q2 2020	\$ 461.01	\$ 327.50	\$ 909.05	\$ 151.02	\$ 1,848.58
Q3 2020	\$ 273.60	\$ 156.15	\$ 521.76	\$ -	\$ 951.51
Q4 2020	\$ 239.53	\$ 506.96	\$ 1,132.18	\$ 114.56	\$ 1,993.23
Q1 2021	\$ 270.18	\$ 481.02	\$ 992.11	\$ 179.63	\$ 1,922.94
Q2 2021	\$ 227.51	\$ 492.34	\$ 866.55	\$ 110.81	\$ 1,697.21
Total	\$ 2,865.88	\$ 3,674.71	\$ 8,095.32	\$ 993.93	\$ 15,629.84

TABLE UTIL-DIAB-SUBG.7: Total Spend of Sulfonyleurea-Biguanide Combination Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 1,250.72	\$ 1,218.20	\$ 3,409.32	\$ 494.83	\$ 6,373.07
SFY 2021	\$ 1,010.82	\$ 1,636.47	\$ 3,512.60	\$ 405.00	\$ 6,564.89
Total	\$ 2,261.54	\$ 2,854.67	\$ 6,921.92	\$ 899.83	\$ 12,937.96

## GI – H2-ANTAGONISTS

TABLE UTIL-GI.1: Beneficiaries' Demographic Characteristics for H2-Antagonists Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
Age Category (yrs)					
0-17	147	198	223	38	606
18-25	61	108	112	32	313
26-44	209	395	734	183	1,521
45-64	593	1,172	1,929	168	3,862
65+	10	7	6	0	23
Total	1,020	1,880	3,004	421	6,325
Gender					
Female	650	1,330	2,126	327	4,433
Male	370	550	878	94	1,892
Total	1,020	1,880	3,004	421	6,325
Race					
Caucasian	427	740	1,176	165	2,508
African American	507	862	1,517	220	3,106
Other	86	278	311	36	711
Total	1,020	1,880	3,004	421	6,325
Note: 5 claims have missing plan information. As such, there are no demographics data for these claims					

TABLE UTIL-GI.2: Number of H2-Antagonists Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	97	171	307	10	585
Q2 2019	95	170	381	20	666
Q3 2019	131	221	432	46	830
Q4 2019	93	187	378	35	693
Q1 2020	95	181	293	37	606
Q2 2020	85	155	219	33	492
Q3 2020	71	119	173	33	396
Q4 2020	97	172	255	55	579
Q1 2021	129	217	269	70	685
Q2 2021	127	287	297	82	793
Total	1,020	1,880	3,004	421	6,325

TABLE UTIL-GI.5: Number of H2-Antagonists Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	404	744	1,322	151	2,621
SFY 2021	424	795	994	240	2,453
Total	828	1,539	2,316	391	5,074

TABLE UTIL-GI.3: Proportion of H2-Antagonists Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	4.32%	7.23%	7.86%	2.32%	
Q2 2019	4.15%	7.94%	10.49%	3.63%	
Q3 2019	5.32%	9.17%	11.63%	6.11%	
Q4 2019	4.24%	9.68%	12.46%	6.52%	
Q1 2020	4.86%	10.64%	12.10%	8.59%	
Q2 2020	5.44%	12.26%	12.41%	8.27%	
Q3 2020	4.69%	8.82%	10.13%	7.40%	
Q4 2020	5.20%	9.99%	11.48%	8.63%	
Q1 2021	6.49%	10.50%	12.24%	9.78%	
Q2 2021	6.23%	13.53%	13.95%	10.83%	

TABLE UTIL-GI.6: Proportion of H2-Antagonists Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	4.94%	10.18%	12.09%	7.12%	
SFY 2021	5.72%	10.95%	12.04%	9.39%	

TABLE UTIL-GI.4: Total Spend of H2-Antagonists Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 1,514.78	\$ 2,809.28	\$ 5,015.94	\$ 184.79	\$ 9,524.79
Q2 2019	\$ 1,421.77	\$ 2,732.83	\$ 6,186.57	\$ 345.89	\$ 10,687.06
Q3 2019	\$ 2,058.86	\$ 3,551.39	\$ 7,100.44	\$ 754.87	\$ 13,465.56
Q4 2019	\$ 1,427.53	\$ 2,927.02	\$ 5,902.15	\$ 535.05	\$ 10,791.75
Q1 2020	\$ 1,683.79	\$ 3,138.32	\$ 5,066.54	\$ 667.45	\$ 10,556.10
Q2 2020	\$ 1,442.27	\$ 2,240.78	\$ 3,272.76	\$ 482.48	\$ 7,438.29
Q3 2020	\$ 1,249.67	\$ 1,879.19	\$ 2,644.48	\$ 533.35	\$ 6,306.69
Q4 2020	\$ 1,483.46	\$ 2,726.60	\$ 4,053.82	\$ 892.94	\$ 9,156.82
Q1 2021	\$ 2,195.35	\$ 3,801.23	\$ 4,634.11	\$ 1,214.70	\$ 11,845.39
Q2 2021	\$ 2,127.18	\$ 4,798.04	\$ 4,937.41	\$ 1,354.88	\$ 13,217.51
Total	\$ 16,604.66	\$ 30,604.68	\$ 48,814.22	\$ 6,966.40	\$ 102,989.96

TABLE UTIL-GI.7: Total Spend of H2-Antagonists Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 6,612.45	\$ 11,857.51	\$ 21,341.89	\$ 2,439.85	\$ 42,251.70
SFY 2021	\$ 7,055.66	\$ 13,205.06	\$ 16,269.82	\$ 3,995.87	\$ 40,526.41
Total	\$ 13,668.11	\$ 25,062.57	\$ 37,611.71	\$ 6,435.72	\$ 82,778.11

## GOUT – XANTHINE OXIDASE INHIBITORS

TABLE UTIL-GOU.1: Beneficiaries' Demographic Characteristics for Xanthine Oxidase Inhibitor Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
Age Category (yrs)					
0-17	1	5	1	0	7
18-25	2	2	3	0	7
26-44	80	200	307	13	600
45-64	680	1,162	1,633	131	3,606
65+	13	0	5	0	18
<b>Total</b>	<b>776</b>	<b>1,369</b>	<b>1,949</b>	<b>144</b>	<b>4,238</b>
Gender					
Female	318	549	844	53	1,764
Male	458	820	1,105	91	2,474
<b>Total</b>	<b>776</b>	<b>1,369</b>	<b>1,949</b>	<b>144</b>	<b>4,238</b>
Race					
Caucasian	208	343	529	43	1,123
African American	479	751	1,042	66	2,338
Other	89	275	378	35	777
<b>Total</b>	<b>776</b>	<b>1,369</b>	<b>1,949</b>	<b>144</b>	<b>4,238</b>

TABLE UTIL-GOU.2: Number of Xanthine Oxidase Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	52	79	146	5	282
Q2 2019	61	89	155	7	312
Q3 2019	67	146	183	10	406
Q4 2019	69	120	179	14	382
Q1 2020	70	147	184	16	417
Q2 2020	78	151	218	15	462
Q3 2020	78	148	215	20	461
Q4 2020	90	155	238	15	498
Q1 2021	113	152	215	20	500
Q2 2021	98	182	216	22	518
<b>Total</b>	<b>776</b>	<b>1,369</b>	<b>1,949</b>	<b>144</b>	<b>4,238</b>

TABLE UTIL-GOU.3: Proportion of Xanthine Oxidase Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	11.02%	15.64%	16.30%	20.83%
Q2 2019	12.92%	18.86%	18.02%	18.92%
Q3 2019	13.11%	27.97%	21.16%	25.00%
Q4 2019	13.80%	25.70%	22.40%	25.46%
Q1 2020	14.77%	29.82%	23.65%	27.59%
Q2 2020	15.18%	27.91%	28.87%	25.42%
Q3 2020	15.26%	30.39%	29.78%	24.69%
Q4 2020	16.89%	32.77%	34.10%	16.48%
Q1 2021	22.16%	33.33%	34.35%	21.51%
Q2 2021	19.41%	34.54%	34.67%	21.36%

TABLE UTIL-GOU.4: Total Spend of Xanthine Oxidase Inhibitor Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 942.73	\$ 1,525.74	\$ 2,665.82	\$ 87.39	\$ 5,221.68
Q2 2019	\$ 1,048.09	\$ 1,692.55	\$ 2,809.37	\$ 111.47	\$ 5,661.48
Q3 2019	\$ 1,157.56	\$ 2,653.06	\$ 3,296.05	\$ 168.34	\$ 7,275.01
Q4 2019	\$ 1,173.55	\$ 2,129.23	\$ 3,179.53	\$ 251.59	\$ 6,733.90
Q1 2020	\$ 1,230.07	\$ 2,616.77	\$ 3,297.66	\$ 303.21	\$ 7,447.71
Q2 2020	\$ 1,517.65	\$ 2,611.94	\$ 3,777.45	\$ 261.80	\$ 8,168.84
Q3 2020	\$ 1,450.80	\$ 2,593.04	\$ 3,650.83	\$ 331.06	\$ 8,025.73
Q4 2020	\$ 1,440.16	\$ 2,558.77	\$ 3,866.48	\$ 238.38	\$ 8,103.79
Q1 2021	\$ 1,779.20	\$ 2,466.58	\$ 3,440.96	\$ 325.93	\$ 8,012.67
Q2 2021	\$ 1,555.70	\$ 2,936.22	\$ 3,492.17	\$ 348.55	\$ 8,332.64
<b>Total</b>	<b>\$ 13,295.51</b>	<b>\$ 23,783.90</b>	<b>\$ 33,476.32</b>	<b>\$ 2,427.72</b>	<b>\$ 72,983.45</b>

TABLE UTIL-GOU.5: Number of Xanthine Oxidase Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	284	564	764	55	1,667
SFY 2021	379	637	884	77	1,977
<b>Total</b>	<b>663</b>	<b>1,201</b>	<b>1,648</b>	<b>132</b>	<b>3,644</b>

TABLE UTIL-GOU.6: Proportion of Xanthine Oxidase Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	14.21%	27.88%	23.90%	25.94%
SFY 2021	18.41%	32.78%	33.12%	20.92%

TABLE UTIL-GOU.7: Total Spend of Xanthine Oxidase Inhibitor Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 5,078.83	\$ 10,011.00	\$ 13,550.69	\$ 984.94	\$ 29,625.46
SFY 2021	\$ 6,225.86	\$ 10,554.61	\$ 14,450.44	\$ 1,243.92	\$ 32,474.83
<b>Total</b>	<b>\$ 11,304.69</b>	<b>\$ 20,565.61</b>	<b>\$ 28,001.13</b>	<b>\$ 2,228.86</b>	<b>\$ 62,100.29</b>



## ID/ANTIRETROVIRALS – ANTIRETROVIRALS (HIV)

TABLE UTIL-ID-ARV.1: Beneficiaries' Demographic Characteristics for Antiretroviral Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17					
18-25	19	11	5	0	35
26-44	51	71	130	0	252
45-64	85	176	164	0	425
65+					
<b>Total</b>	155	258	299	0	712
<b>Gender</b>					
Female	71	66	159	0	296
Male	84	192	140	0	416
<b>Total</b>	155	258	299	0	712
<b>Race</b>					
Caucasian	14	30	30	0	74
African American	127	177	224	0	528
Other	14	51	45	0	110
<b>Total</b>	155	258	299	0	712

TABLE UTIL-ID-ARV.2: Number of Antiretroviral Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				Total
	FFS	UHC	MAG	MOL	
Q1 2019	0	0	4	0	4
Q2 2019	9	6	12	0	27
Q3 2019	12	18	22	0	52
Q4 2019	11	22	31	0	64
Q1 2020	20	29	38	0	87
Q2 2020	22	34	38	0	94
Q3 2020	19	33	53	0	105
Q4 2020	17	37	31	0	85
Q1 2021	23	37	34	0	94
Q2 2021	22	42	36	0	100
<b>Total</b>	155	258	299	0	712

TABLE UTIL-ID-ARV.5: Number of Antiretroviral Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				Total
	FFS	UHC	MAG	MOL	
SFY 2020	65	103	129	0	297
SFY 2021	81	149	154	0	384
<b>Total</b>	146	252	283	0	681

TABLE UTIL-ID-ARV.3: Proportion of Antiretroviral Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	0.00%	0.00%	0.67%	0.00%
Q2 2019	4.35%	1.36%	2.02%	0.00%
Q3 2019	5.24%	3.93%	3.57%	0.00%
Q4 2019	4.74%	4.52%	5.08%	0.00%
Q1 2020	9.05%	5.54%	6.10%	0.00%
Q2 2020	10.95%	6.54%	6.07%	0.00%
Q3 2020	8.52%	6.60%	8.48%	0.00%
Q4 2020	7.05%	7.61%	5.25%	0.00%
Q1 2021	7.88%	7.54%	5.77%	0.00%
Q2 2021	6.88%	7.11%	5.90%	0.00%

TABLE UTIL-ID-ARV.6: Proportion of Antiretroviral Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	7.36%	5.18%	5.21%	0.00%
SFY 2021	7.53%	7.21%	6.38%	0.00%

TABLE UTIL-ID-ARV.4: Total Spend of Antiretroviral Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				Total
	FFS	UHC	MAG	MOL	
Q1 2019	\$ 34,300.41	\$ -	\$ -	\$ -	\$ 34,300.41
Q2 2019	\$ 71,304.48	\$ 49,121.19	\$ 103,081.86	\$ -	\$ 223,507.53
Q3 2019	\$ 97,343.61	\$ 146,767.43	\$ 193,242.76	\$ -	\$ 437,353.80
Q4 2019	\$ 83,319.39	\$ 183,347.94	\$ 267,719.86	\$ -	\$ 534,387.19
Q1 2020	\$ 165,996.03	\$ 249,518.48	\$ 351,418.01	\$ -	\$ 766,932.52
Q2 2020	\$ 185,112.08	\$ 281,435.38	\$ 358,877.58	\$ -	\$ 825,425.04
Q3 2020	\$ 153,718.70	\$ 284,129.41	\$ 496,440.07	\$ -	\$ 934,288.18
Q4 2020	\$ 137,173.80	\$ 314,274.56	\$ 289,250.59	\$ -	\$ 740,698.95
Q1 2021	\$ 190,076.32	\$ 332,307.43	\$ 334,208.82	\$ -	\$ 856,592.57
Q2 2021	\$ 178,480.91	\$ 378,146.88	\$ 342,099.51	\$ -	\$ 898,727.30
<b>Total</b>	\$ 1,296,825.73	\$ 2,219,048.70	\$ 2,736,339.06	\$ -	\$ 6,252,213.49

TABLE UTIL-ID-ARV.7: Total Spend of Antiretroviral Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				Total
	FFS	UHC	MAG	MOL	
SFY 2020	\$ 531,771.11	\$ 861,069.23	\$ 1,171,258.21	\$ -	\$ 2,564,098.55
SFY 2021	\$ 659,449.73	\$ 1,308,858.28	\$ 1,461,998.99	\$ -	\$ 3,430,307.00
<b>Total</b>	\$ 1,191,220.84	\$ 2,169,927.51	\$ 2,633,257.20	\$ -	\$ 5,994,405.55

## ID/ANTIRETROVIRALS – ANTIVIRALS

TABLE UTIL-ID-AV.1: Beneficiaries' Demographic Characteristics for Antiviral Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	6	1	3	0	10
18-25	10	15	5	6	36
26-44	13	38	31	10	92
45-64	23	76	84	6	189
65+					
<b>Total</b>	52	130	123	22	327
<b>Gender</b>					
Female	33	114	104	17	268
Male	19	16	19	5	59
<b>Total</b>	52	130	123	22	327
<b>Race</b>					
Caucasian	16	42	50	8	116
African American	31	72	62	10	175
Other	5	16	11	4	36
<b>Total</b>	52	130	123	22	327

TABLE UTIL-ID-AV.2: Number of Antiviral Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)						
Quarter	Pharmacy Program					Total
	FFS	UHC	MAG	MOL		
Q1 2019	1	7	10	2		20
Q2 2019	5	6	10	2		23
Q3 2019	4	15	9	3		31
Q4 2019	4	13	10	0		27
Q1 2020	5	16	11	3		35
Q2 2020	5	14	17	3		39
Q3 2020	5	9	15	1		30
Q4 2020	7	13	14	2		36
Q1 2021	10	13	8	3		34
Q2 2021	6	24	19	3		52
<b>Total</b>	52	130	123	22		327

TABLE UTIL-ID-AV.5: Number of Antiviral Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	18	58	47	9	132
SFY 2021	28	59	56	9	152
<b>Total</b>	46	117	103	18	284

TABLE UTIL-ID-AV.3: Proportion of Antiviral Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	0.44%	1.93%	2.15%	2.25%	
Q2 2019	2.06%	1.88%	2.35%	1.75%	
Q3 2019	1.72%	4.39%	2.17%	1.79%	
Q4 2019	1.75%	3.65%	2.51%	0.00%	
Q1 2020	2.08%	4.10%	2.93%	2.10%	
Q2 2020	2.02%	3.91%	4.96%	2.68%	
Q3 2020	1.98%	2.69%	4.31%	0.88%	
Q4 2020	2.41%	4.08%	4.14%	1.47%	
Q1 2021	3.32%	4.23%	2.42%	2.33%	
Q2 2021	1.89%	7.52%	5.22%	2.26%	

TABLE UTIL-ID-AV.6: Proportion of Antiviral Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	1.90%	4.01%	3.07%	1.60%	
SFY 2021	2.41%	4.61%	4.06%	1.76%	

TABLE UTIL-ID-AV.4: Total Spend of Antiviral Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)						
Quarter	Pharmacy Program					Total
	FFS	UHC	MAG	MOL		
Q1 2019	\$ 22.03	\$ 127.60	\$ 214.73	\$ 43.78		\$ 408.14
Q2 2019	\$ 93.38	\$ 121.96	\$ 220.39	\$ 42.48		\$ 478.21
Q3 2019	\$ 69.69	\$ 334.83	\$ 191.35	\$ 89.76		\$ 685.63
Q4 2019	\$ 81.63	\$ 315.33	\$ 216.79	\$ -		\$ 613.75
Q1 2020	\$ 117.46	\$ 337.43	\$ 252.57	\$ 75.54		\$ 783.00
Q2 2020	\$ 141.35	\$ 296.85	\$ 428.05	\$ 75.19		\$ 941.44
Q3 2020	\$ 93.95	\$ 203.20	\$ 375.41	\$ 25.25		\$ 697.81
Q4 2020	\$ 140.05	\$ 330.20	\$ 367.75	\$ 58.74		\$ 896.74
Q1 2021	\$ 211.24	\$ 340.71	\$ 228.20	\$ 88.35		\$ 868.50
Q2 2021	\$ 137.31	\$ 630.17	\$ 574.34	\$ 88.78		\$ 1,430.60
<b>Total</b>	\$ 1,108.09	\$ 3,038.28	\$ 3,069.58	\$ 587.87		\$ 7,803.82

TABLE UTIL-ID-AV.7: Total Spend of Antiviral Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 410.13	\$ 1,284.44	\$ 1,088.76	\$ 240.49	\$ 3,023.82
SFY 2021	\$ 582.55	\$ 1,504.28	\$ 1,545.70	\$ 261.12	\$ 3,893.65
<b>Total</b>	\$ 992.68	\$ 2,788.72	\$ 2,634.46	\$ 501.61	\$ 6,917.47

## IMMUNE SUPPRESSION – CORTICOSTEROIDS

TABLE UTIL-IS-COR.1: Beneficiaries' Demographic Characteristics for Corticosteroid Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	7	28	35	4	74
18-25	18	23	26	9	76
26-44	57	198	166	70	491
45-64	172	285	352	51	860
65+	8	0	10	0	18
<b>Total</b>	<b>262</b>	<b>534</b>	<b>589</b>	<b>134</b>	<b>1,519</b>
<b>Gender</b>					
Female	189	355	377	88	1,009
Male	73	179	212	46	510
<b>Total</b>	<b>262</b>	<b>534</b>	<b>589</b>	<b>134</b>	<b>1,519</b>
<b>Race</b>					
Caucasian	72	172	132	42	418
African American	161	287	378	83	909
Other	29	75	79	9	192
<b>Total</b>	<b>262</b>	<b>534</b>	<b>589</b>	<b>134</b>	<b>1,519</b>

TABLE UTIL-IS-COR.2: Number of Corticosteroid Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	22	39	49	4	114
Q2 2019	22	29	47	2	100
Q3 2019	25	42	64	6	137
Q4 2019	29	48	53	11	141
Q1 2020	18	64	66	15	163
Q2 2020	24	70	59	19	172
Q3 2020	31	54	58	19	162
Q4 2020	26	67	61	21	175
Q1 2021	35	52	63	19	169
Q2 2021	30	69	69	18	186
<b>Total</b>	<b>262</b>	<b>534</b>	<b>589</b>	<b>134</b>	<b>1,519</b>

TABLE UTIL-IS-COR.5: Number of Corticosteroid Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	96	224	242	51	613
SFY 2021	122	242	251	77	692
<b>Total</b>	<b>218</b>	<b>466</b>	<b>493</b>	<b>128</b>	<b>1,305</b>

TABLE UTIL-IS-COR.3: Proportion of Corticosteroid Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	1.13%	1.06%	1.05%	0.68%
Q2 2019	1.34%	0.98%	1.23%	0.30%
Q3 2019	1.43%	1.35%	1.71%	0.74%
Q4 2019	1.44%	1.30%	1.21%	1.06%
Q1 2020	0.90%	1.70%	1.57%	1.45%
Q2 2020	2.05%	3.29%	2.62%	3.21%
Q3 2020	1.99%	2.13%	2.10%	2.40%
Q4 2020	1.47%	2.42%	2.03%	2.13%
Q1 2021	2.03%	1.93%	2.27%	1.88%
Q2 2021	1.33%	2.12%	2.04%	1.49%

TABLE UTIL-IS-COR.6: Proportion of Corticosteroid Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	1.38%	1.76%	1.66%	1.47%
SFY 2021	1.67%	2.15%	2.11%	1.93%

TABLE UTIL-IS-COR.4: Total Spend of Corticosteroid Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 363.21	\$ 703.17	\$ 843.53	\$ 81.33	\$ 1,991.24
Q2 2019	\$ 367.92	\$ 500.09	\$ 787.38	\$ 42.68	\$ 1,698.07
Q3 2019	\$ 454.09	\$ 852.41	\$ 1,137.37	\$ 126.67	\$ 2,570.54
Q4 2019	\$ 489.72	\$ 831.00	\$ 929.70	\$ 216.36	\$ 2,466.78
Q1 2020	\$ 318.23	\$ 1,201.27	\$ 1,177.46	\$ 314.70	\$ 3,011.66
Q2 2020	\$ 475.77	\$ 1,161.96	\$ 1,002.51	\$ 345.33	\$ 2,985.57
Q3 2020	\$ 592.03	\$ 905.25	\$ 967.62	\$ 322.55	\$ 2,787.45
Q4 2020	\$ 439.82	\$ 1,096.35	\$ 946.82	\$ 378.30	\$ 2,861.29
Q1 2021	\$ 534.37	\$ 919.31	\$ 973.99	\$ 299.30	\$ 2,726.97
Q2 2021	\$ 565.11	\$ 1,145.02	\$ 1,107.10	\$ 332.47	\$ 3,149.70
<b>Total</b>	<b>\$ 4,600.27</b>	<b>\$ 9,315.83</b>	<b>\$ 9,873.48</b>	<b>\$ 2,459.69</b>	<b>\$ 26,249.27</b>

TABLE UTIL-IS-COR.7: Total Spend of Corticosteroid Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 1,737.81	\$ 4,046.64	\$ 4,247.04	\$ 1,003.06	\$ 11,034.55
SFY 2021	\$ 2,131.33	\$ 4,065.93	\$ 3,995.53	\$ 1,332.62	\$ 11,525.41
<b>Total</b>	<b>\$ 3,869.14</b>	<b>\$ 8,112.57</b>	<b>\$ 8,242.57</b>	<b>\$ 2,335.68</b>	<b>\$ 22,559.96</b>

## IMMUNE SUPPRESSION – TRANSPLANT REJECTION

TABLE UTIL-IS-TR.1: Beneficiaries' Demographic Characteristics for Transplant Rejection Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	14	3	29	3	49
18-25	15	71	75	5	166
26-44	72	156	318	36	582
45-64	52	180	278	44	554
65+					
<b>Total</b>	<b>153</b>	<b>410</b>	<b>700</b>	<b>88</b>	<b>1,351</b>
<b>Gender</b>					
Female	57	237	362	44	700
Male	96	173	338	44	651
<b>Total</b>	<b>153</b>	<b>410</b>	<b>700</b>	<b>88</b>	<b>1,351</b>
<b>Race</b>					
Caucasian	57	163	143	33	396
African American	68	169	490	40	767
Other	28	78	67	15	188
<b>Total</b>	<b>153</b>	<b>410</b>	<b>700</b>	<b>88</b>	<b>1,351</b>

TABLE UTIL-IS-TR.2: Number of Transplant Rejection Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	7	32	59	1	99
Q2 2019	7	32	64	2	105
Q3 2019	10	29	61	2	102
Q4 2019	14	34	66	2	116
Q1 2020	16	44	69	7	136
Q2 2020	12	43	77	13	145
Q3 2020	16	42	68	12	138
Q4 2020	18	49	79	15	161
Q1 2021	24	50	75	17	166
Q2 2021	29	55	82	17	183
<b>Total</b>	<b>153</b>	<b>410</b>	<b>700</b>	<b>88</b>	<b>1,351</b>

TABLE UTIL-IS-TR.5: Number of Transplant Rejection Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	52	150	273	24	499
SFY 2021	87	196	304	61	648
<b>Total</b>	<b>139</b>	<b>346</b>	<b>577</b>	<b>85</b>	<b>1,147</b>

TABLE UTIL-IS-TR.3: Proportion of Transplant Rejection Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	3.17%	12.60%	14.39%	5.56%
Q2 2019	2.95%	12.45%	15.46%	15.39%
Q3 2019	4.15%	10.74%	14.59%	7.69%
Q4 2019	5.79%	11.85%	15.60%	3.85%
Q1 2020	6.67%	14.72%	15.79%	12.28%
Q2 2020	5.43%	14.78%	18.38%	17.11%
Q3 2020	7.14%	15.73%	16.23%	18.46%
Q4 2020	7.20%	18.28%	18.46%	22.39%
Q1 2021	8.39%	18.94%	19.08%	22.97%
Q2 2021	9.45%	17.63%	19.57%	21.52%

TABLE UTIL-IS-TR.6: Proportion of Transplant Rejection Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	5.51%	13.08%	16.09%	11.37%
SFY 2021	8.15%	17.64%	18.32%	21.40%

TABLE UTIL-IS-TR.4: Total Spend of Transplant Rejection Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 865.13	\$ 3,117.15	\$ 10,299.30	\$ 145.10	\$ 14,426.68
Q2 2019	\$ 1,071.57	\$ 3,374.29	\$ 12,320.97	\$ 216.79	\$ 16,983.62
Q3 2019	\$ 940.01	\$ 3,068.52	\$ 11,147.72	\$ 227.56	\$ 15,383.81
Q4 2019	\$ 2,024.24	\$ 4,739.75	\$ 14,757.55	\$ 543.32	\$ 22,064.86
Q1 2020	\$ 3,664.15	\$ 13,270.63	\$ 19,609.56	\$ 1,149.51	\$ 37,693.85
Q2 2020	\$ 2,916.83	\$ 13,265.07	\$ 22,691.22	\$ 3,192.20	\$ 42,065.32
Q3 2020	\$ 5,338.43	\$ 15,970.33	\$ 26,244.05	\$ 4,430.40	\$ 51,983.21
Q4 2020	\$ 3,964.32	\$ 9,924.69	\$ 16,026.29	\$ 2,195.74	\$ 32,111.04
Q1 2021	\$ 5,033.82	\$ 12,629.61	\$ 17,078.02	\$ 2,474.36	\$ 37,215.81
Q2 2021	\$ 5,326.43	\$ 11,208.91	\$ 18,682.99	\$ 2,747.43	\$ 37,965.76
<b>Total</b>	<b>\$ 31,144.93</b>	<b>\$ 90,568.95</b>	<b>\$ 168,857.67</b>	<b>\$ 17,322.41</b>	<b>\$ 307,893.96</b>

TABLE UTIL-IS-TR.7: Total Spend of Transplant Rejection Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 9,545.23	\$ 34,343.97	\$ 68,206.05	\$ 5,112.59	\$ 117,207.84
SFY 2021	\$ 19,663.00	\$ 49,733.54	\$ 78,031.35	\$ 11,847.93	\$ 159,275.82
<b>Total</b>	<b>\$ 29,208.23</b>	<b>\$ 84,077.51</b>	<b>\$ 146,237.40</b>	<b>\$ 16,960.52</b>	<b>\$ 276,483.66</b>

## IMMUNE SUPPRESSION – TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS

TABLE UTIL-IS-RATR.1: Beneficiaries' Demographic Characteristics for RA Transplant Rejection Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	6	13	9	3	31
18-25	6	3	6	2	17
26-44	21	39	27	10	97
45-64	48	64	154	7	273
65+	0	1	4	0	5
<b>Total</b>	<b>81</b>	<b>120</b>	<b>200</b>	<b>22</b>	<b>423</b>
<b>Gender</b>					
Female	62	100	168	18	348
Male	19	20	32	4	75
<b>Total</b>	<b>81</b>	<b>120</b>	<b>200</b>	<b>22</b>	<b>423</b>
<b>Race</b>					
Caucasian	34	38	52	3	127
African American	41	67	111	16	235
Other	6	15	37	3	61
<b>Total</b>	<b>81</b>	<b>120</b>	<b>200</b>	<b>22</b>	<b>423</b>

TABLE UTIL-IS-RATR.2: Number of RA Transplant Rejection Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				Total
	FFS	UHC	MAG	MOL	
Q1 2019	5	8	16	0	29
Q2 2019	4	11	13	1	29
Q3 2019	6	8	21	0	35
Q4 2019	6	12	21	1	40
Q1 2020	4	16	23	2	45
Q2 2020	7	16	26	2	51
Q3 2020	10	12	15	2	39
Q4 2020	15	10	16	2	43
Q1 2021	12	10	22	9	53
Q2 2021	12	17	27	3	59
<b>Total</b>	<b>81</b>	<b>120</b>	<b>200</b>	<b>22</b>	<b>423</b>

TABLE UTIL-IS-RATR.5: Number of RA Transplant Rejection Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				Total
	FFS	UHC	MAG	MOL	
SFY 2020	23	52	91	5	171
SFY 2021	49	49	80	16	194
<b>Total</b>	<b>72</b>	<b>101</b>	<b>171</b>	<b>21</b>	<b>365</b>

TABLE UTIL-IS-RATR.3: Proportion of RA Transplant Rejection Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	2.46%	2.29%	2.64%	0.00%	
Q2 2019	1.86%	2.75%	2.24%	1.85%	
Q3 2019	2.71%	1.79%	3.58%	0.00%	
Q4 2019	2.59%	3.07%	3.94%	1.30%	
Q1 2020	1.65%	3.86%	4.41%	2.47%	
Q2 2020	2.81%	3.88%	5.79%	2.67%	
Q3 2020	4.78%	3.66%	3.36%	2.50%	
Q4 2020	7.01%	3.18%	3.49%	2.70%	
Q1 2021	5.85%	3.23%	5.14%	10.98%	
Q2 2021	5.53%	4.86%	6.08%	3.49%	

TABLE UTIL-IS-RATR.6: Proportion of RA Transplant Rejection Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	2.44%	3.12%	4.35%	1.61%	
SFY 2021	5.80%	3.76%	4.50%	4.97%	

TABLE UTIL-IS-RATR.4: Total Spend of RA Transplant Rejection Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				Total
	FFS	UHC	MAG	MOL	
Q1 2019	\$ 218.52	\$ 444.50	\$ 896.09	\$ -	\$ 1,559.11
Q2 2019	\$ 205.14	\$ 534.84	\$ 762.06	\$ 12.85	\$ 1,514.89
Q3 2019	\$ 354.64	\$ 358.90	\$ 1,345.11	\$ -	\$ 2,058.65
Q4 2019	\$ 280.78	\$ 675.23	\$ 1,212.16	\$ 46.73	\$ 2,214.90
Q1 2020	\$ 211.98	\$ 871.02	\$ 1,243.80	\$ 138.27	\$ 2,465.07
Q2 2020	\$ 471.66	\$ 882.05	\$ 1,468.69	\$ 108.23	\$ 2,930.63
Q3 2020	\$ 513.64	\$ 608.54	\$ 758.22	\$ 162.48	\$ 2,042.88
Q4 2020	\$ 695.29	\$ 499.36	\$ 836.58	\$ 80.92	\$ 2,112.15
Q1 2021	\$ 446.38	\$ 552.11	\$ 1,133.71	\$ 407.41	\$ 2,539.61
Q2 2021	\$ 453.68	\$ 741.90	\$ 1,148.66	\$ 113.16	\$ 2,457.40
<b>Total</b>	<b>\$ 3,851.71</b>	<b>\$ 6,168.45</b>	<b>\$ 10,805.08</b>	<b>\$ 1,070.05</b>	<b>\$ 21,895.29</b>

TABLE UTIL-IS-RATR.7: Total Spend of RA Transplant Rejection Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				Total
	FFS	UHC	MAG	MOL	
SFY 2020	\$ 1,319.06	\$ 2,787.20	\$ 5,269.76	\$ 293.23	\$ 9,669.25
SFY 2021	\$ 2,108.99	\$ 2,401.91	\$ 3,877.17	\$ 763.97	\$ 9,152.04
<b>Total</b>	<b>\$ 3,428.05</b>	<b>\$ 5,189.11</b>	<b>\$ 9,146.93</b>	<b>\$ 1,057.20</b>	<b>\$ 18,821.29</b>

## MISCELLANEOUS – FIBROMYALGIA

TABLE UTIL-MISC-FIB.1: Beneficiaries' Demographic Characteristics for Fibromyalgia Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	0	7	12	1	20
18-25	26	34	19	9	88
26-44	195	431	441	146	1,213
45-64	657	884	982	201	2,724
65+	2	0	7	0	9
<b>Total</b>	<b>880</b>	<b>1,356</b>	<b>1,461</b>	<b>357</b>	<b>4,054</b>
<b>Gender</b>					
Female	669	1,099	1,220	294	3,282
Male	211	257	241	63	772
<b>Total</b>	<b>880</b>	<b>1,356</b>	<b>1,461</b>	<b>357</b>	<b>4,054</b>
<b>Race</b>					
Caucasian	550	773	784	215	2,322
African American	257	435	486	93	1,271
Other	73	148	191	49	461
<b>Total</b>	<b>880</b>	<b>1,356</b>	<b>1,461</b>	<b>357</b>	<b>4,054</b>

TABLE UTIL-MISC-FIB.2: Number of Fibromyalgia Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	1	5	1	0	7
Q2 2019	54	39	47	0	140
Q3 2019	58	105	119	0	282
Q4 2019	76	124	149	0	349
Q1 2020	89	140	156	14	399
Q2 2020	94	166	188	42	490
Q3 2020	114	168	176	64	522
Q4 2020	105	166	201	67	539
Q1 2021	128	202	203	79	612
Q2 2021	161	241	221	91	714
<b>Total</b>	<b>880</b>	<b>1,356</b>	<b>1,461</b>	<b>357</b>	<b>4,054</b>

TABLE UTIL-MISC-FIB.5: Number of Fibromyalgia Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	317	535	612	56	1,520
SFY 2021	508	777	801	301	2,387
<b>Total</b>	<b>825</b>	<b>1,312</b>	<b>1,413</b>	<b>357</b>	<b>3,907</b>

TABLE UTIL-MISC-FIB.3: Proportion of Fibromyalgia Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	0.11%	0.37%	0.06%	0.00%
Q2 2019	5.98%	2.88%	2.83%	0.00%
Q3 2019	6.45%	8.04%	7.77%	0.00%
Q4 2019	7.85%	9.44%	10.49%	0.00%
Q1 2020	8.85%	10.21%	10.77%	3.33%
Q2 2020	9.64%	11.33%	13.15%	10.83%
Q3 2020	10.88%	11.58%	11.97%	15.17%
Q4 2020	9.37%	11.33%	13.33%	13.76%
Q1 2021	10.81%	14.42%	13.82%	15.83%
Q2 2021	12.48%	15.01%	14.20%	16.82%

TABLE UTIL-MISC-FIB.6: Proportion of Fibromyalgia Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	8.24%	9.81%	10.50%	3.85%
SFY 2021	10.94%	13.12%	13.34%	15.44%

TABLE UTIL-MISC-FIB.4: Total Spend of Fibromyalgia Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 23.50	\$ 117.93	\$ 20.95	\$ -	\$ 162.38
Q2 2019	\$ 1,339.96	\$ 937.89	\$ 1,170.37	\$ -	\$ 3,448.22
Q3 2019	\$ 1,539.10	\$ 2,525.49	\$ 3,157.96	\$ -	\$ 7,222.55
Q4 2019	\$ 2,029.25	\$ 2,996.74	\$ 3,682.11	\$ -	\$ 8,708.10
Q1 2020	\$ 2,883.49	\$ 3,423.72	\$ 3,891.42	\$ 373.97	\$ 10,572.60
Q2 2020	\$ 2,638.20	\$ 3,956.13	\$ 4,724.42	\$ 1,361.26	\$ 12,680.01
Q3 2020	\$ 3,313.52	\$ 4,065.52	\$ 4,337.32	\$ 1,874.77	\$ 13,591.13
Q4 2020	\$ 2,771.41	\$ 4,033.80	\$ 5,131.13	\$ 1,842.67	\$ 13,779.01
Q1 2021	\$ 3,443.03	\$ 4,635.36	\$ 4,668.04	\$ 1,971.19	\$ 14,717.62
Q2 2021	\$ 3,763.34	\$ 6,082.90	\$ 5,010.61	\$ 2,733.91	\$ 17,590.76
<b>Total</b>	<b>\$ 23,744.80</b>	<b>\$ 32,775.48</b>	<b>\$ 35,794.33</b>	<b>\$ 10,157.77</b>	<b>\$ 102,472.38</b>

TABLE UTIL-MISC-FIB.7: Total Spend of Fibromyalgia Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 9,090.04	\$ 12,902.08	\$ 15,455.91	\$ 1,735.23	\$ 39,183.26
SFY 2021	\$ 13,291.30	\$ 18,817.58	\$ 19,147.10	\$ 8,422.54	\$ 59,678.52
<b>Total</b>	<b>\$ 22,381.34</b>	<b>\$ 31,719.66</b>	<b>\$ 34,603.01</b>	<b>\$ 10,157.77</b>	<b>\$ 98,861.78</b>

## MISCELLANEOUS – HYPOTHYROIDISM

TABLE UTIL-MISC-HYP.1: Beneficiaries' Demographic Characteristics for Hypothyroidism Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	358	349	249	60	<b>1,016</b>
18-25	239	340	321	81	<b>981</b>
26-44	668	1,591	2,048	444	<b>4,751</b>
45-64	1,808	3,074	4,374	522	<b>9,778</b>
65+	68	30	20	0	<b>118</b>
<b>Total</b>	<b>3,141</b>	<b>5,384</b>	<b>7,012</b>	<b>1,107</b>	<b>16,644</b>
<b>Gender</b>					
Female	2,301	4,237	5,737	941	<b>13,216</b>
Male	840	1,147	1,275	166	<b>3,428</b>
<b>Total</b>	<b>3,141</b>	<b>5,384</b>	<b>7,012</b>	<b>1,107</b>	<b>16,644</b>
<b>Race</b>					
Caucasian	1,703	2,676	3,410	633	<b>8,422</b>
African American	1,118	1,853	2,621	323	<b>5,915</b>
Other	320	855	981	151	<b>2,307</b>
<b>Total</b>	<b>3,141</b>	<b>5,384</b>	<b>7,012</b>	<b>1,107</b>	<b>16,644</b>
Note: 31 claims have missing plan information. As such, there are no demographics data for these claims					

TABLE UTIL-MISC-HYP.2: Number of Hypothyroidism Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	216	452	500	35	<b>1,203</b>
Q2 2019	254	488	627	61	<b>1,430</b>
Q3 2019	286	570	685	65	<b>1,606</b>
Q4 2019	275	547	692	82	<b>1,596</b>
Q1 2020	289	644	740	114	<b>1,787</b>
Q2 2020	310	568	722	111	<b>1,711</b>
Q3 2020	329	490	741	132	<b>1,692</b>
Q4 2020	368	467	748	141	<b>1,724</b>
Q1 2021	396	492	789	186	<b>1,863</b>
Q2 2021	418	666	768	180	<b>2,032</b>
<b>Total</b>	<b>3,141</b>	<b>5,384</b>	<b>7,012</b>	<b>1,107</b>	<b>16,644</b>

TABLE UTIL-MISC-HYP.5: Number of Hypothyroidism Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	1,160	2,329	2,839	372	<b>6,700</b>
SFY 2021	1,511	2,115	3,046	639	<b>7,311</b>
<b>Total</b>	<b>2,671</b>	<b>4,444</b>	<b>5,885</b>	<b>1,011</b>	<b>14,011</b>

TABLE UTIL-MISC-HYP.3: Proportion of Hypothyroidism Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	8.31%	15.97%	12.43%	10.77%
Q2 2019	9.39%	18.06%	15.85%	12.76%
Q3 2019	10.36%	19.94%	17.86%	12.10%
Q4 2019	10.43%	19.97%	19.15%	14.94%
Q1 2020	10.84%	21.82%	20.64%	17.43%
Q2 2020	12.31%	21.59%	22.49%	19.65%
Q3 2020	12.71%	20.44%	22.85%	19.82%
Q4 2020	13.97%	20.08%	23.66%	20.14%
Q1 2021	14.31%	20.52%	26.31%	25.07%
Q2 2021	14.42%	26.24%	26.05%	23.65%

TABLE UTIL-MISC-HYP.6: Proportion of Hypothyroidism Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	10.96%	20.83%	19.93%	16.14%
SFY 2021	13.88%	21.90%	24.66%	22.27%

TABLE UTIL-MISC-HYP.4: Total Spend of Hypothyroidism Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 7,306.42	\$ 15,535.86	\$ 18,979.27	\$ 1,291.87	<b>\$ 43,113.42</b>
Q2 2019	\$ 8,027.32	\$ 15,328.35	\$ 22,506.57	\$ 2,022.62	<b>\$ 47,884.86</b>
Q3 2019	\$ 9,172.81	\$ 18,378.66	\$ 23,406.98	\$ 2,005.41	<b>\$ 52,963.86</b>
Q4 2019	\$ 8,260.60	\$ 16,576.41	\$ 23,859.62	\$ 2,772.10	<b>\$ 51,468.73</b>
Q1 2020	\$ 9,230.31	\$ 19,617.41	\$ 25,585.32	\$ 3,833.35	<b>\$ 58,266.39</b>
Q2 2020	\$ 11,334.16	\$ 17,630.34	\$ 27,156.78	\$ 3,803.88	<b>\$ 59,925.16</b>
Q3 2020	\$ 11,644.21	\$ 15,765.28	\$ 28,862.43	\$ 4,520.10	<b>\$ 60,792.02</b>
Q4 2020	\$ 11,835.69	\$ 15,370.56	\$ 27,286.98	\$ 4,718.71	<b>\$ 59,211.94</b>
Q1 2021	\$ 13,636.43	\$ 15,501.93	\$ 27,869.70	\$ 5,947.61	<b>\$ 62,955.67</b>
Q2 2021	\$ 14,388.67	\$ 20,713.89	\$ 26,962.39	\$ 6,072.30	<b>\$ 68,137.25</b>
<b>Total</b>	<b>\$ 104,836.62</b>	<b>\$ 170,418.69</b>	<b>\$ 252,476.04</b>	<b>\$ 36,987.95</b>	<b>\$ 564,719.30</b>

TABLE UTIL-MISC-HYP.7: Total Spend of Hypothyroidism Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 37,997.88	\$ 72,202.82	\$ 100,008.70	\$ 12,414.74	<b>\$ 222,624.14</b>
SFY 2021	\$ 51,505.00	\$ 67,351.66	\$ 110,981.50	\$ 21,258.72	<b>\$ 251,096.88</b>
<b>Total</b>	<b>\$ 89,502.88</b>	<b>\$ 139,554.48</b>	<b>\$ 210,990.20</b>	<b>\$ 33,673.46</b>	<b>\$ 473,721.02</b>

## MISCELLANEOUS – LEUKOTRIENE MODIFIERS

TABLE UTIL-MISC-LEU.1: Beneficiaries' Demographic Characteristics for Leuketriere Modifiers Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	1,802	3,752	4,355	806	<b>10,715</b>
18-25	352	437	412	98	<b>1,299</b>
26-44	359	740	1,164	279	<b>2,542</b>
45-64	670	1,468	2,277	222	<b>4,637</b>
65+	5	2	17	0	<b>24</b>
<b>Total</b>	<b>3,188</b>	<b>6,399</b>	<b>8,225</b>	<b>1,405</b>	<b>19,217</b>
<b>Gender</b>					
Female	1,746	3,672	4,952	833	<b>11,203</b>
Male	1,442	2,727	3,273	572	<b>8,014</b>
<b>Total</b>	<b>3,188</b>	<b>6,399</b>	<b>8,225</b>	<b>1,405</b>	<b>19,217</b>
<b>Race</b>					
Caucasian	1,398	2,334	2,823	512	<b>7,067</b>
African American	1,491	3,351	4,473	688	<b>10,003</b>
Other	299	714	929	205	<b>2,147</b>
<b>Total</b>	<b>3,188</b>	<b>6,399</b>	<b>8,225</b>	<b>1,405</b>	<b>19,217</b>
Note: 91 claims have missing plan information. As such, there are no demographics data for these claims					

TABLE UTIL-MISC-LEU.2: Number of Leuketriere Modifiers Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	149	231	525	18	<b>923</b>
Q2 2019	191	258	614	30	<b>1,093</b>
Q3 2019	287	579	780	58	<b>1,704</b>
Q4 2019	299	640	842	61	<b>1,842</b>
Q1 2020	356	713	882	124	<b>2,075</b>
Q2 2020	325	705	830	154	<b>2,014</b>
Q3 2020	365	754	933	206	<b>2,258</b>
Q4 2020	375	698	907	225	<b>2,205</b>
Q1 2021	377	811	928	238	<b>2,354</b>
Q2 2021	464	1,010	984	291	<b>2,749</b>
<b>Total</b>	<b>3,188</b>	<b>6,399</b>	<b>8,225</b>	<b>1,405</b>	<b>19,217</b>

TABLE UTIL-MISC-LEU.5: Number of Leuketriere Modifiers Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	1,267	2,637	3,334	397	<b>7,635</b>
SFY 2021	1,581	3,273	3,752	960	<b>9,566</b>
<b>Total</b>	<b>2,848</b>	<b>5,910</b>	<b>7,086</b>	<b>1,357</b>	<b>17,201</b>

TABLE UTIL-MISC-LEU.3: Proportion of Leuketriere Modifiers Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	2.16%	2.06%	3.68%	1.50%
Q2 2019	2.80%	2.36%	4.30%	1.70%
Q3 2019	4.14%	5.33%	5.59%	2.82%
Q4 2019	4.42%	5.85%	6.05%	2.69%
Q1 2020	5.21%	6.35%	6.27%	5.17%
Q2 2020	5.85%	7.85%	7.64%	8.31%
Q3 2020	6.59%	8.75%	8.55%	10.08%
Q4 2020	6.80%	8.18%	8.69%	10.43%
Q1 2021	7.29%	10.26%	9.73%	11.43%
Q2 2021	7.54%	10.21%	9.54%	11.07%

TABLE UTIL-MISC-LEU.6: Proportion of Leuketriere Modifiers Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	4.86%	6.27%	6.32%	4.63%
SFY 2021	7.07%	9.36%	9.10%	10.77%

TABLE UTIL-MISC-LEU.4: Total Spend of Leuketriere Modifiers Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 2,366.90	\$ 3,466.91	\$ 9,076.46	\$ 276.22	<b>\$ 15,186.49</b>
Q2 2019	\$ 3,159.76	\$ 3,870.79	\$ 10,592.82	\$ 443.18	<b>\$ 18,066.55</b>
Q3 2019	\$ 4,955.80	\$ 10,291.88	\$ 13,651.99	\$ 864.16	<b>\$ 29,763.83</b>
Q4 2019	\$ 5,131.21	\$ 11,477.88	\$ 14,813.68	\$ 912.84	<b>\$ 32,335.61</b>
Q1 2020	\$ 6,280.28	\$ 12,617.36	\$ 15,289.55	\$ 2,202.93	<b>\$ 36,390.12</b>
Q2 2020	\$ 5,691.82	\$ 12,159.47	\$ 14,045.41	\$ 2,714.00	<b>\$ 34,610.70</b>
Q3 2020	\$ 6,331.12	\$ 13,334.04	\$ 15,984.85	\$ 3,652.30	<b>\$ 39,302.31</b>
Q4 2020	\$ 6,296.46	\$ 12,286.06	\$ 15,477.72	\$ 3,939.36	<b>\$ 37,999.60</b>
Q1 2021	\$ 6,745.21	\$ 14,792.22	\$ 16,678.41	\$ 4,353.36	<b>\$ 42,569.20</b>
Q2 2021	\$ 8,015.68	\$ 17,900.19	\$ 17,091.71	\$ 5,146.34	<b>\$ 48,153.92</b>
<b>Total</b>	<b>\$ 54,974.24</b>	<b>\$ 112,196.80</b>	<b>\$ 142,702.60</b>	<b>\$ 24,504.69</b>	<b>\$ 334,378.33</b>

TABLE UTIL-MISC-LEU.7: Total Spend of Leuketriere Modifiers Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 22,059.11	\$ 46,546.59	\$ 57,800.63	\$ 6,693.93	<b>\$ 133,100.26</b>
SFY 2021	\$ 27,388.47	\$ 58,312.51	\$ 65,232.69	\$ 17,091.36	<b>\$ 168,025.03</b>
<b>Total</b>	<b>\$ 49,447.58</b>	<b>\$ 104,859.10</b>	<b>\$ 123,033.32</b>	<b>\$ 23,785.29</b>	<b>\$ 301,125.29</b>



## MISCELLANEOUS – MALIGNANCIES

TABLE UTIL-MISC-MAL.1: Beneficiaries' Demographic Characteristics for Malignancies Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	85	191	225	49	550
18-25	5	27	18	2	52
26-44	2	17	44	5	68
45-64	4	6	35	0	45
65+					
<b>Total</b>	96	241	322	56	715
<b>Gender</b>					
Female	61	119	168	24	372
Male	35	122	154	32	343
<b>Total</b>	96	241	322	56	715
<b>Race</b>					
Caucasian	1	1	4	0	6
African American	87	208	243	45	583
Other	8	32	75	11	126
<b>Total</b>	96	241	322	56	715

TABLE UTIL-MISC-MAL.2: Number of Malignancies Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	7	19	29	1	56
Q2 2019	12	21	27	3	63
Q3 2019	9	24	28	5	66
Q4 2019	10	22	31	6	69
Q1 2020	13	27	36	5	81
Q2 2020	9	26	35	6	76
Q3 2020	10	24	36	5	75
Q4 2020	8	21	33	7	69
Q1 2021	13	26	33	10	82
Q2 2021	5	31	34	8	78
<b>Total</b>	96	241	322	56	715

TABLE UTIL-MISC-MAL.5: Number of Malignancies Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	41	99	130	22	292
SFY 2021	36	102	136	30	304
<b>Total</b>	77	201	266	52	596

TABLE UTIL-MISC-MAL.3: Proportion of Malignancies Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	6.86%	11.45%	10.36%	7.14%
Q2 2019	11.22%	11.48%	9.96%	15.00%
Q3 2019	8.18%	13.71%	10.61%	15.15%
Q4 2019	10.64%	13.75%	13.54%	17.65%
Q1 2020	12.62%	15.34%	14.12%	22.73%
Q2 2020	10.00%	16.56%	12.73%	18.75%
Q3 2020	10.31%	16.67%	14.34%	17.24%
Q4 2020	7.84%	16.15%	13.75%	25.00%
Q1 2021	12.75%	15.03%	13.15%	37.04%
Q2 2021	4.85%	16.32%	14.98%	23.53%

TABLE UTIL-MISC-MAL.6: Proportion of Malignancies Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	10.33%	14.82%	12.71%	18.18%
SFY 2021	8.91%	16.01%	14.04%	25.42%

TABLE UTIL-MISC-MAL.4: Total Spend of Malignancies Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 336.75	\$ 846.03	\$ 1,192.07	\$ 32.37	\$ 2,407.22
Q2 2019	\$ 594.64	\$ 918.69	\$ 1,014.33	\$ 102.51	\$ 2,630.17
Q3 2019	\$ 465.21	\$ 976.73	\$ 1,194.47	\$ 209.77	\$ 2,846.18
Q4 2019	\$ 558.55	\$ 933.19	\$ 1,253.29	\$ 239.52	\$ 2,984.55
Q1 2020	\$ 612.29	\$ 1,199.89	\$ 1,359.85	\$ 222.43	\$ 3,394.46
Q2 2020	\$ 429.92	\$ 1,066.54	\$ 1,474.83	\$ 238.57	\$ 3,209.86
Q3 2020	\$ 502.44	\$ 1,081.15	\$ 1,591.50	\$ 216.44	\$ 3,391.53
Q4 2020	\$ 388.24	\$ 1,069.77	\$ 1,336.62	\$ 207.43	\$ 3,002.06
Q1 2021	\$ 667.32	\$ 1,237.85	\$ 1,514.40	\$ 423.07	\$ 3,842.64
Q2 2021	\$ 253.32	\$ 1,726.05	\$ 1,531.16	\$ 252.71	\$ 3,763.24
<b>Total</b>	\$ 4,808.68	\$ 11,055.89	\$ 13,462.52	\$ 2,144.82	\$ 31,471.91

TABLE UTIL-MISC-MAL.7: Total Spend of Malignancies Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 2,065.97	\$ 4,176.35	\$ 5,282.44	\$ 910.29	\$ 12,435.05
SFY 2021	\$ 1,811.32	\$ 5,114.82	\$ 5,973.68	\$ 1,099.65	\$ 13,999.47
<b>Total</b>	\$ 3,877.29	\$ 9,291.17	\$ 11,256.12	\$ 2,009.94	\$ 26,434.52

## PARKINSONS – ANTICHOLINERGICS

TABLE UTIL-PAR-ACH.1: Beneficiaries' Demographic Characteristics for Anticholinergic Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	16	26	12	0	54
18-25	32	49	68	7	156
26-44	118	238	233	32	621
45-64	254	240	344	33	871
65+	6	0	0	0	6
<b>Total</b>	<b>426</b>	<b>553</b>	<b>657</b>	<b>72</b>	<b>1,708</b>
<b>Gender</b>					
Female	183	233	322	27	765
Male	243	320	335	45	943
<b>Total</b>	<b>426</b>	<b>553</b>	<b>657</b>	<b>72</b>	<b>1,708</b>
<b>Race</b>					
Caucasian	145	170	159	21	495
African American	221	324	387	42	974
Other	60	59	111	9	239
<b>Total</b>	<b>426</b>	<b>553</b>	<b>657</b>	<b>72</b>	<b>1,708</b>

TABLE UTIL-PAR-ACH.2: Number of Anticholinergic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	24	24	22	1	71
Q2 2019	33	35	43	3	114
Q3 2019	40	48	56	3	147
Q4 2019	31	57	64	6	158
Q1 2020	49	65	73	4	191
Q2 2020	50	66	70	11	197
Q3 2020	49	58	72	7	186
Q4 2020	43	66	78	13	200
Q1 2021	51	59	79	11	200
Q2 2021	56	75	100	13	244
<b>Total</b>	<b>426</b>	<b>553</b>	<b>657</b>	<b>72</b>	<b>1,708</b>

TABLE UTIL-PAR-ACH.5: Number of Anticholinergic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	170	236	263	24	693
SFY 2021	199	258	329	44	830
<b>Total</b>	<b>369</b>	<b>494</b>	<b>592</b>	<b>68</b>	<b>1,523</b>

TABLE UTIL-PAR-ACH.3: Proportion of Anticholinergic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	1.35%	1.63%	0.98%	0.69%	
Q2 2019	1.82%	2.36%	1.86%	1.49%	
Q3 2019	2.19%	3.02%	2.39%	1.30%	
Q4 2019	1.76%	3.73%	2.70%	2.33%	
Q1 2020	2.74%	4.04%	3.18%	1.35%	
Q2 2020	2.98%	3.82%	3.04%	3.37%	
Q3 2020	2.80%	3.65%	3.22%	2.05%	
Q4 2020	2.42%	4.32%	3.59%	3.33%	
Q1 2021	2.90%	3.75%	3.83%	2.69%	
Q2 2021	2.98%	4.44%	5.04%	2.90%	

TABLE UTIL-PAR-ACH.6: Proportion of Anticholinergic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	2.41%	3.66%	2.82%	2.16%	
SFY 2021	2.78%	4.04%	3.89%	2.77%	

TABLE UTIL-PAR-ACH.4: Total Spend of Anticholinergic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 521.34	\$ 572.71	\$ 454.77	\$ 24.59	\$ 1,573.41
Q2 2019	\$ 895.57	\$ 874.71	\$ 970.51	\$ 74.62	\$ 2,815.41
Q3 2019	\$ 937.05	\$ 1,293.20	\$ 1,356.72	\$ 60.12	\$ 3,647.09
Q4 2019	\$ 771.44	\$ 1,483.71	\$ 1,512.00	\$ 142.31	\$ 3,909.46
Q1 2020	\$ 1,271.09	\$ 1,723.22	\$ 1,742.83	\$ 84.33	\$ 4,821.47
Q2 2020	\$ 1,325.69	\$ 1,605.29	\$ 1,743.37	\$ 258.90	\$ 4,933.25
Q3 2020	\$ 1,261.12	\$ 1,255.28	\$ 1,687.86	\$ 159.51	\$ 4,363.77
Q4 2020	\$ 1,005.07	\$ 1,764.23	\$ 1,820.07	\$ 296.94	\$ 4,886.31
Q1 2021	\$ 1,276.91	\$ 1,475.67	\$ 1,776.56	\$ 240.66	\$ 4,769.80
Q2 2021	\$ 1,299.75	\$ 2,046.55	\$ 2,084.13	\$ 326.94	\$ 5,757.37
<b>Total</b>	<b>\$ 10,565.03</b>	<b>\$ 14,094.57</b>	<b>\$ 15,148.82</b>	<b>\$ 1,668.92</b>	<b>\$ 41,477.34</b>

TABLE UTIL-PAR-ACH.7: Total Spend of Anticholinergic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 4,305.27	\$ 6,105.42	\$ 6,354.92	\$ 545.66	\$ 17,311.27
SFY 2021	\$ 4,842.85	\$ 6,541.73	\$ 7,368.62	\$ 1,024.05	\$ 19,777.25
<b>Total</b>	<b>\$ 9,148.12</b>	<b>\$ 12,647.15</b>	<b>\$ 13,723.54</b>	<b>\$ 1,569.71</b>	<b>\$ 37,088.52</b>

## PARKINSONS – DOPAMINE REPLACEMENTS

TABLE UTIL-PAR-DOP.1: Beneficiaries' Demographic Characteristics for Dopamine Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	5	0	0	0	5
18-25	10	3	3	0	16
26-44	1	1	4	1	7
45-64	36	36	49	8	129
65+	5	1	0	0	6
<b>Total</b>	<b>57</b>	<b>41</b>	<b>56</b>	<b>9</b>	<b>163</b>
<b>Gender</b>					
Female	37	37	44	9	127
Male	20	4	12	0	36
<b>Total</b>	<b>57</b>	<b>41</b>	<b>56</b>	<b>9</b>	<b>163</b>
<b>Race</b>					
Caucasian	27	22	40	3	92
African American	17	10	12	6	45
Other	13	9	4	0	26
<b>Total</b>	<b>57</b>	<b>41</b>	<b>56</b>	<b>9</b>	<b>163</b>

TABLE UTIL-PAR-DOP.2: Number of Dopamine Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	6	4	3	0	13
Q2 2019	3	4	3	0	10
Q3 2019	6	6	8	0	20
Q4 2019	5	4	8	0	17
Q1 2020	6	2	3	1	12
Q2 2020	7	7	5	1	20
Q3 2020	5	4	6	1	16
Q4 2020	7	5	5	1	18
Q1 2021	7	2	7	0	16
Q2 2021	5	3	8	5	21
<b>Total</b>	<b>57</b>	<b>41</b>	<b>56</b>	<b>9</b>	<b>163</b>

TABLE UTIL-PAR-DOP.5: Number of Dopamine Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	24	19	24	2	69
SFY 2021	24	14	26	7	71
<b>Total</b>	<b>48</b>	<b>33</b>	<b>50</b>	<b>9</b>	<b>140</b>

TABLE UTIL-PAR-DOP.3: Proportion of Dopamine Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	4.88%	10.53%	6.98%	0.00%
Q2 2019	2.40%	10.53%	6.00%	0.00%
Q3 2019	4.84%	17.14%	16.33%	0.00%
Q4 2019	5.21%	10.26%	18.61%	0.00%
Q1 2020	5.83%	5.56%	7.90%	25.00%
Q2 2020	6.54%	17.50%	10.20%	50.00%
Q3 2020	4.72%	10.26%	12.77%	33.33%
Q4 2020	6.36%	15.15%	11.91%	25.00%
Q1 2021	6.25%	8.00%	16.67%	0.00%
Q2 2021	4.81%	14.29%	14.82%	83.33%

TABLE UTIL-PAR-DOP.6: Proportion of Dopamine Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	5.58%	12.67%	13.41%	28.57%
SFY 2021	5.56%	11.86%	14.05%	41.18%

TABLE UTIL-PAR-DOP.4: Total Spend of Dopamine Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 163.03	\$ 272.11	\$ 117.21	\$ -	\$ 552.35
Q2 2019	\$ 75.60	\$ 179.70	\$ 187.74	\$ -	\$ 443.04
Q3 2019	\$ 241.73	\$ 246.98	\$ 529.30	\$ -	\$ 1,018.01
Q4 2019	\$ 199.89	\$ 169.73	\$ 471.76	\$ -	\$ 841.38
Q1 2020	\$ 189.93	\$ 79.93	\$ 63.28	\$ 32.77	\$ 365.91
Q2 2020	\$ 360.29	\$ 305.08	\$ 161.47	\$ 33.70	\$ 860.54
Q3 2020	\$ 363.54	\$ 181.95	\$ 213.25	\$ 109.46	\$ 868.20
Q4 2020	\$ 482.23	\$ 172.69	\$ 103.05	\$ 104.17	\$ 862.14
Q1 2021	\$ 551.72	\$ 150.65	\$ 274.55	\$ -	\$ 976.92
Q2 2021	\$ 264.57	\$ 232.92	\$ 210.07	\$ 183.30	\$ 890.86
<b>Total</b>	<b>\$ 2,892.53</b>	<b>\$ 1,991.74</b>	<b>\$ 2,331.68</b>	<b>\$ 463.40</b>	<b>\$ 7,679.35</b>

TABLE UTIL-PAR-DOP.7: Total Spend of Dopamine Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 991.84	\$ 801.72	\$ 1,225.81	\$ 66.47	\$ 3,085.84
SFY 2021	\$ 1,662.06	\$ 738.21	\$ 800.92	\$ 396.93	\$ 3,598.12
<b>Total</b>	<b>\$ 2,653.90</b>	<b>\$ 1,539.93</b>	<b>\$ 2,026.73</b>	<b>\$ 463.40</b>	<b>\$ 6,683.96</b>

## PRENATAL VITAMINS

TABLE UTIL-PRV.1: Beneficiaries' Demographic Characteristics for Prenatal Vitamin Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	4	18	14	0	36
18-25	118	110	63	0	291
26-44	96	163	95	0	354
45-64					
65+					
<b>Total</b>	<b>218</b>	<b>291</b>	<b>172</b>	<b>0</b>	<b>681</b>
<b>Gender</b>					
Female	218	291	172	0	681
Male					
<b>Total</b>	<b>218</b>	<b>291</b>	<b>172</b>	<b>0</b>	<b>681</b>
<b>Race</b>					
Caucasian	50	70	31	0	151
African American	163	205	135	0	503
Other	5	16	6	0	27
<b>Total</b>	<b>218</b>	<b>291</b>	<b>172</b>	<b>0</b>	<b>681</b>

TABLE UTIL-PRV.2: Number of Prenatal Vitamin Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	22	24	0	0	46
Q2 2019	17	31	0	0	48
Q3 2019	37	20	1	0	58
Q4 2019	30	26	0	0	56
Q1 2020	15	31	28	0	74
Q2 2020	15	36	37	0	88
Q3 2020	19	31	35	0	85
Q4 2020	18	23	19	0	60
Q1 2021	26	25	14	0	65
Q2 2021	19	44	38	0	101
<b>Total</b>	<b>218</b>	<b>291</b>	<b>172</b>	<b>0</b>	<b>681</b>

TABLE UTIL-PRV.5: Number of Prenatal Vitamin Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	97	113	66	0	276
SFY 2021	82	123	106	0	311
<b>Total</b>	<b>179</b>	<b>236</b>	<b>172</b>	<b>0</b>	<b>587</b>

TABLE UTIL-PRV.3: Proportion of Prenatal Vitamin Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	
Q1 2019	4.34%	3.69%	0.00%	0.00%	
Q2 2019	3.39%	4.88%	0.00%	0.00%	
Q3 2019	7.21%	2.84%	0.10%	0.00%	
Q4 2019	6.68%	3.03%	0.00%	0.00%	
Q1 2020	2.76%	3.23%	3.23%	0.00%	
Q2 2020	3.01%	3.85%	4.41%	0.00%	
Q3 2020	3.62%	3.68%	4.29%	0.00%	
Q4 2020	4.16%	4.26%	3.62%	0.00%	
Q1 2021	3.72%	3.33%	1.87%	0.00%	
Q2 2021	2.24%	4.32%	4.50%	0.00%	

TABLE UTIL-PRV.6: Proportion of Prenatal Vitamin Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	
SFY 2020	4.84%	3.27%	1.78%	0.00%	
SFY 2021	3.27%	3.90%	3.61%	0.00%	

TABLE UTIL-PRV.4: Total Spend of Prenatal Vitamin Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 784.62	\$ 1,171.36	\$ -	\$ -	\$ 1,955.98
Q2 2019	\$ 354.43	\$ 1,268.24	\$ -	\$ -	\$ 1,622.67
Q3 2019	\$ 1,123.96	\$ 622.78	\$ 99.85	\$ -	\$ 1,846.59
Q4 2019	\$ 1,167.83	\$ 1,312.40	\$ -	\$ -	\$ 2,480.23
Q1 2020	\$ 372.02	\$ 1,388.89	\$ 1,018.49	\$ -	\$ 2,779.40
Q2 2020	\$ 325.60	\$ 1,814.13	\$ 2,051.22	\$ -	\$ 4,190.95
Q3 2020	\$ 416.34	\$ 1,489.50	\$ 1,770.19	\$ -	\$ 3,676.03
Q4 2020	\$ 382.36	\$ 1,081.47	\$ 697.05	\$ -	\$ 2,160.88
Q1 2021	\$ 518.76	\$ 1,155.48	\$ 361.82	\$ -	\$ 2,036.06
Q2 2021	\$ 380.88	\$ 2,112.76	\$ 1,329.52	\$ -	\$ 3,823.16
<b>Total</b>	<b>\$ 5,826.80</b>	<b>\$ 13,417.01</b>	<b>\$ 7,328.14</b>	<b>\$ -</b>	<b>\$ 26,571.95</b>

TABLE UTIL-PRV.7: Total Spend of Prenatal Vitamin Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 2,989.41	\$ 5,138.20	\$ 3,169.56	\$ -	\$ 11,297.17
SFY 2021	\$ 1,698.34	\$ 5,839.21	\$ 4,158.58	\$ -	\$ 11,696.13
<b>Total</b>	<b>\$ 4,687.75</b>	<b>\$ 10,977.41</b>	<b>\$ 7,328.14</b>	<b>\$ -</b>	<b>\$ 22,993.30</b>

## PSYCH – ANTIDEPRESSANTS – SELECTIVE SEROTONIN REUPTAKE INHIBITORS

TABLE UTIL-PSY-SSRI.1: Beneficiaries' Demographic Characteristics for SSRI Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	489	877	710	228	<b>2,304</b>
18-25	707	938	776	386	<b>2,807</b>
26-44	1,620	4,121	4,366	1,614	<b>11,721</b>
45-64	3,140	6,162	7,282	1,229	<b>17,813</b>
65+	41	25	14	0	<b>80</b>
<b>Total</b>	<b>5,997</b>	<b>12,123</b>	<b>13,148</b>	<b>3,457</b>	<b>34,725</b>
<b>Gender</b>					
Female	4,331	9,019	10,119	2,797	<b>26,266</b>
Male	1,666	3,104	3,029	660	<b>8,459</b>
<b>Total</b>	<b>5,997</b>	<b>12,123</b>	<b>13,148</b>	<b>3,457</b>	<b>34,725</b>
<b>Race</b>					
Caucasian	3,663	7,141	7,381	2,185	<b>20,370</b>
African American	1,818	3,365	4,217	830	<b>10,230</b>
Other	516	1,617	1,550	442	<b>4,125</b>
<b>Total</b>	<b>5,997</b>	<b>12,123</b>	<b>13,148</b>	<b>3,457</b>	<b>34,725</b>
Note: 64 claims have missing plan information. As such, there are no demographics data for these claims					

TABLE UTIL-PSY-SSRI.2: Number of SSRI Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	181	379	770	42	<b>1,372</b>
Q2 2019	334	578	1,007	73	<b>1,992</b>
Q3 2019	413	944	1,178	108	<b>2,643</b>
Q4 2019	486	1,097	1,274	117	<b>2,974</b>
Q1 2020	545	1,361	1,357	300	<b>3,563</b>
Q2 2020	640	1,553	1,425	418	<b>4,036</b>
Q3 2020	703	1,422	1,537	500	<b>4,162</b>
Q4 2020	779	1,469	1,486	547	<b>4,281</b>
Q1 2021	888	1,508	1,528	636	<b>4,560</b>
Q2 2021	1,028	1,812	1,586	716	<b>5,142</b>
<b>Total</b>	<b>5,997</b>	<b>12,123</b>	<b>13,148</b>	<b>3,457</b>	<b>34,725</b>

TABLE UTIL-PSY-SSRI.3: Proportion of SSRI Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	1.95%	2.64%	4.10%	1.97%
Q2 2019	3.61%	4.14%	5.49%	2.48%
Q3 2019	4.40%	6.62%	6.55%	2.84%
Q4 2019	5.10%	7.81%	7.19%	2.97%
Q1 2020	5.63%	9.04%	7.68%	7.11%
Q2 2020	6.52%	9.99%	8.41%	10.28%
Q3 2020	6.68%	9.60%	8.88%	10.51%
Q4 2020	6.67%	9.87%	8.67%	10.40%
Q1 2021	7.24%	10.06%	9.11%	10.99%
Q2 2021	7.54%	10.92%	9.45%	11.45%

TABLE UTIL-PSY-SSRI.4: Total Spend of SSRI Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 2,302.55	\$ 5,222.99	\$ 12,916.66	\$ 494.99	<b>\$ 20,937.19</b>
Q2 2019	\$ 5,288.91	\$ 8,519.34	\$ 17,463.19	\$ 950.44	<b>\$ 32,221.88</b>
Q3 2019	\$ 6,468.00	\$ 17,033.44	\$ 21,202.68	\$ 1,419.30	<b>\$ 46,123.42</b>
Q4 2019	\$ 7,735.40	\$ 19,751.91	\$ 21,730.99	\$ 1,570.03	<b>\$ 50,788.33</b>
Q1 2020	\$ 9,118.86	\$ 25,088.88	\$ 23,163.17	\$ 5,131.49	<b>\$ 62,502.40</b>
Q2 2020	\$ 11,489.95	\$ 27,555.41	\$ 24,385.65	\$ 7,172.05	<b>\$ 70,603.06</b>
Q3 2020	\$ 12,822.11	\$ 26,998.39	\$ 26,374.88	\$ 8,878.52	<b>\$ 75,073.90</b>
Q4 2020	\$ 12,863.47	\$ 26,654.51	\$ 25,761.05	\$ 9,536.80	<b>\$ 74,815.83</b>
Q1 2021	\$ 14,384.23	\$ 27,646.42	\$ 25,914.43	\$ 11,078.78	<b>\$ 79,023.86</b>
Q2 2021	\$ 16,572.78	\$ 33,658.72	\$ 26,410.82	\$ 12,404.43	<b>\$ 89,046.75</b>
<b>Total</b>	<b>\$ 99,046.26</b>	<b>\$ 218,130.01</b>	<b>\$ 225,323.52</b>	<b>\$ 58,636.83</b>	<b>\$ 601,136.62</b>

TABLE UTIL-PSY-SSRI.5: Number of SSRI Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	2,084	4,955	5,234	943	<b>13,216</b>
SFY 2021	3,398	6,211	6,137	2,399	<b>18,145</b>
<b>Total</b>	<b>5,482</b>	<b>11,166</b>	<b>11,371</b>	<b>3,342</b>	<b>31,361</b>

TABLE UTIL-PSY-SSRI.6: Proportion of SSRI Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	5.43%	8.41%	7.44%	5.88%
SFY 2021	7.07%	10.13%	9.02%	10.87%

TABLE UTIL-PSY-SSRI.7: Total Spend of SSRI Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 34,812.21	\$ 89,429.64	\$ 90,482.49	\$ 15,292.87	<b>\$ 230,017.21</b>
SFY 2021	\$ 56,642.59	\$ 114,958.04	\$ 104,461.18	\$ 41,898.53	<b>\$ 317,960.34</b>
<b>Total</b>	<b>\$ 91,454.80</b>	<b>\$ 204,387.68</b>	<b>\$ 194,943.67</b>	<b>\$ 57,191.40</b>	<b>\$ 547,977.55</b>

## PSYCH – ANTISPYCHOTICS – ATYPICAL

TABLE UTIL-PSY-ATYP.1: Beneficiaries' Demographic Characteristics for Atypical Antipsychotic Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	247	378	315	110	<b>1,050</b>
18-25	232	312	225	71	<b>840</b>
26-44	512	1,045	1,102	296	<b>2,955</b>
45-64	751	1,489	1,763	246	<b>4,249</b>
65+	42	15	16	0	<b>73</b>
<b>Total</b>	<b>1,784</b>	<b>3,239</b>	<b>3,421</b>	<b>723</b>	<b>9,167</b>
<b>Gender</b>					
Female	845	1,886	2,170	446	<b>5,347</b>
Male	939	1,353	1,251	277	<b>3,820</b>
<b>Total</b>	<b>1,784</b>	<b>3,239</b>	<b>3,421</b>	<b>723</b>	<b>9,167</b>
<b>Race</b>					
Caucasian	819	1,501	1,553	399	<b>4,272</b>
African American	684	1,228	1,352	223	<b>3,487</b>
Other	281	510	516	101	<b>1,408</b>
<b>Total</b>	<b>1,784</b>	<b>3,239</b>	<b>3,421</b>	<b>723</b>	<b>9,167</b>
Note: 1 claim has missing plan information. As such, there are no demographics data for this claim					

TABLE UTIL-PSY-ATYP.2: Number of Atypical Antipsychotic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	35	60	178	1	<b>274</b>
Q2 2019	103	94	247	3	<b>447</b>
Q3 2019	140	251	285	9	<b>685</b>
Q4 2019	160	282	309	7	<b>758</b>
Q1 2020	196	371	345	52	<b>964</b>
Q2 2020	208	430	383	102	<b>1,123</b>
Q3 2020	212	383	380	114	<b>1,089</b>
Q4 2020	221	414	427	122	<b>1,184</b>
Q1 2021	239	428	411	151	<b>1,229</b>
Q2 2021	270	526	456	162	<b>1,414</b>
<b>Total</b>	<b>1,784</b>	<b>3,239</b>	<b>3,421</b>	<b>723</b>	<b>9,167</b>

TABLE UTIL-PSY-ATYP.5: Number of Atypical Antipsychotic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	704	1,334	1,322	170	<b>3,530</b>
SFY 2021	942	1,751	1,674	549	<b>4,916</b>
<b>Total</b>	<b>1,646</b>	<b>3,085</b>	<b>2,996</b>	<b>719</b>	<b>8,446</b>

TABLE UTIL-PSY-ATYP.3: Proportion of Atypical Antipsychotic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	0.40%	0.61%	1.33%	0.08%
Q2 2019	1.19%	0.96%	1.87%	0.19%
Q3 2019	1.62%	2.58%	2.18%	0.46%
Q4 2019	1.84%	2.92%	2.42%	0.33%
Q1 2020	2.24%	3.61%	2.66%	2.37%
Q2 2020	2.52%	4.26%	3.05%	4.60%
Q3 2020	2.46%	3.92%	3.05%	4.68%
Q4 2020	2.52%	4.11%	3.40%	4.43%
Q1 2021	2.66%	4.23%	3.36%	5.25%
Q2 2021	2.90%	4.74%	3.81%	5.11%

TABLE UTIL-PSY-ATYP.6: Proportion of Atypical Antipsychotic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	2.05%	3.36%	2.57%	2.00%
SFY 2021	2.64%	4.27%	3.40%	4.88%

TABLE UTIL-PSY-ATYP.4: Total Spend of Atypical Antipsychotic Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 832.51	\$ 1,614.66	\$ 5,072.33	\$ 7.00	<b>\$ 7,526.50</b>
Q2 2019	\$ 2,404.16	\$ 2,549.10	\$ 6,732.30	\$ 49.89	<b>\$ 11,735.45</b>
Q3 2019	\$ 3,517.56	\$ 6,954.67	\$ 7,893.21	\$ 123.37	<b>\$ 18,488.81</b>
Q4 2019	\$ 3,734.55	\$ 7,527.36	\$ 9,149.22	\$ 168.82	<b>\$ 20,579.95</b>
Q1 2020	\$ 5,195.59	\$ 11,896.64	\$ 10,127.60	\$ 1,842.30	<b>\$ 29,062.13</b>
Q2 2020	\$ 6,037.89	\$ 12,068.63	\$ 12,393.44	\$ 3,059.56	<b>\$ 33,559.52</b>
Q3 2020	\$ 5,609.83	\$ 10,050.52	\$ 11,063.00	\$ 2,931.57	<b>\$ 29,654.92</b>
Q4 2020	\$ 5,364.39	\$ 10,187.93	\$ 12,468.69	\$ 2,936.67	<b>\$ 30,957.68</b>
Q1 2021	\$ 5,771.04	\$ 10,420.31	\$ 11,777.99	\$ 3,225.57	<b>\$ 31,194.91</b>
Q2 2021	\$ 7,497.07	\$ 12,372.25	\$ 13,057.65	\$ 3,708.81	<b>\$ 36,635.78</b>
<b>Total</b>	<b>\$ 45,964.59</b>	<b>\$ 85,642.07</b>	<b>\$ 99,735.43</b>	<b>\$ 18,053.56</b>	<b>\$ 249,395.65</b>

TABLE UTIL-PSY-ATYP.7: Total Spend of Atypical Antipsychotic Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 18,485.59	\$ 38,447.30	\$ 39,563.47	\$ 5,194.05	<b>\$ 101,690.41</b>
SFY 2021	\$ 24,242.33	\$ 43,031.01	\$ 48,367.33	\$ 12,802.62	<b>\$ 128,443.29</b>
<b>Total</b>	<b>\$ 42,727.92</b>	<b>\$ 81,478.31</b>	<b>\$ 87,930.80</b>	<b>\$ 17,996.67</b>	<b>\$ 230,133.70</b>

## SEIZURES – ANTICONVULSANTS

TABLE UTIL-SEI.1: Beneficiaries' Demographic Characteristics for Anticonvulsants Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	398	514	489	122	<b>1,523</b>
18-25	447	731	494	185	<b>1,857</b>
26-44	1,124	2,283	2,323	583	<b>6,313</b>
45-64	1,524	2,446	2,713	434	<b>7,117</b>
65+	48	15	12	0	<b>75</b>
<b>Total</b>	<b>3,541</b>	<b>5,989</b>	<b>6,031</b>	<b>1,324</b>	<b>16,885</b>
<b>Gender</b>					
Female	2,084	3,748	3,892	843	<b>10,567</b>
Male	1,457	2,241	2,139	481	<b>6,318</b>
<b>Total</b>	<b>3,541</b>	<b>5,989</b>	<b>6,031</b>	<b>1,324</b>	<b>16,885</b>
<b>Race</b>					
Caucasian	1,578	2,555	2,437	572	<b>7,142</b>
African American	1,488	2,400	2,755	591	<b>7,234</b>
Other	475	1,034	839	161	<b>2,509</b>
<b>Total</b>	<b>3,541</b>	<b>5,989</b>	<b>6,031</b>	<b>1,324</b>	<b>16,885</b>
Note: 12 claims have missing plan information. As such, there are no demographics data for these claims					

TABLE UTIL-SEI.2: Number of Anticonvulsants Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	164	276	285	19	<b>744</b>
Q2 2019	235	316	426	34	<b>1,011</b>
Q3 2019	306	483	529	72	<b>1,390</b>
Q4 2019	319	488	563	74	<b>1,444</b>
Q1 2020	373	644	634	111	<b>1,762</b>
Q2 2020	338	712	678	145	<b>1,873</b>
Q3 2020	396	673	757	180	<b>2,006</b>
Q4 2020	424	706	671	209	<b>2,010</b>
Q1 2021	464	759	715	238	<b>2,176</b>
Q2 2021	522	932	773	242	<b>2,469</b>
<b>Total</b>	<b>3,541</b>	<b>5,989</b>	<b>6,031</b>	<b>1,324</b>	<b>16,885</b>

TABLE UTIL-SEI.5: Number of Anticonvulsants Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	1,336	2,327	2,404	402	<b>6,469</b>
SFY 2021	1,806	3,070	2,916	869	<b>8,661</b>
<b>Total</b>	<b>3,142</b>	<b>5,397</b>	<b>5,320</b>	<b>1,271</b>	<b>15,130</b>

TABLE UTIL-SEI.3: Proportion of Anticonvulsants Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	1.64%	2.93%	2.38%	1.90%
Q2 2019	2.35%	3.37%	3.64%	2.51%
Q3 2019	3.10%	5.11%	4.59%	4.39%
Q4 2019	3.25%	5.40%	5.03%	4.03%
Q1 2020	3.79%	6.82%	5.55%	5.56%
Q2 2020	3.57%	7.54%	6.21%	6.87%
Q3 2020	4.10%	7.51%	6.92%	7.85%
Q4 2020	4.26%	7.96%	6.42%	8.13%
Q1 2021	4.68%	8.47%	7.01%	8.51%
Q2 2021	4.99%	9.36%	7.72%	8.26%

TABLE UTIL-SEI.6: Proportion of Anticonvulsants Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	3.43%	6.22%	5.34%	5.30%
SFY 2021	4.52%	8.36%	7.01%	8.21%

TABLE UTIL-SEI.4: Total Spend of Anticonvulsants Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 6,972.17	\$ 13,365.29	\$ 12,054.82	\$ 526.55	<b>\$ 32,918.83</b>
Q2 2019	\$ 10,486.68	\$ 15,106.57	\$ 16,812.95	\$ 1,613.49	<b>\$ 44,019.69</b>
Q3 2019	\$ 15,510.97	\$ 25,351.31	\$ 23,109.06	\$ 3,148.52	<b>\$ 67,119.86</b>
Q4 2019	\$ 15,063.99	\$ 25,793.69	\$ 24,581.26	\$ 4,113.62	<b>\$ 69,552.56</b>
Q1 2020	\$ 19,663.89	\$ 34,104.16	\$ 30,686.76	\$ 5,302.40	<b>\$ 89,757.21</b>
Q2 2020	\$ 18,214.29	\$ 38,185.30	\$ 29,988.51	\$ 6,740.29	<b>\$ 93,128.39</b>
Q3 2020	\$ 20,451.58	\$ 37,475.96	\$ 39,279.69	\$ 8,413.12	<b>\$ 105,620.35</b>
Q4 2020	\$ 22,569.73	\$ 35,889.33	\$ 30,761.57	\$ 9,118.72	<b>\$ 98,339.35</b>
Q1 2021	\$ 22,508.28	\$ 36,753.49	\$ 31,316.67	\$ 9,664.54	<b>\$ 100,242.98</b>
Q2 2021	\$ 25,251.82	\$ 45,413.55	\$ 32,894.62	\$ 10,457.00	<b>\$ 114,016.99</b>
<b>Total</b>	<b>\$ 176,693.40</b>	<b>\$ 307,438.65</b>	<b>\$ 271,485.91</b>	<b>\$ 59,098.25</b>	<b>\$ 814,716.21</b>

TABLE UTIL-SEI.7: Total Spend of Anticonvulsants Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 68,453.14	\$ 123,434.46	\$ 108,365.59	\$ 19,304.83	<b>\$ 319,558.02</b>
SFY 2021	\$ 90,781.41	\$ 155,532.33	\$ 134,252.55	\$ 37,653.38	<b>\$ 418,219.67</b>
<b>Total</b>	<b>\$ 159,234.55</b>	<b>\$ 278,966.79</b>	<b>\$ 242,618.14</b>	<b>\$ 56,958.21</b>	<b>\$ 737,777.69</b>

## SELECT CONTRACEPTIVES – ORAL CONTRACEPTIVES

TABLE UTIL-OC.1: Beneficiaries' Demographic Characteristics for Oral Contraceptives Claims with 90 days of supply (Jan 2019- Jun 2021)					
Variable	FFS	UHC	MAG	MOL	Total
<b>Age Category (yrs)</b>					
0-17	960	1,182	1,697	322	4,161
18-25	4,187	901	1,235	366	6,689
26-44	2,935	714	1,409	383	5,441
45-64	21	46	46	10	123
65+					
<b>Total</b>	<b>8,103</b>	<b>2,843</b>	<b>4,387</b>	<b>1,081</b>	<b>16,414</b>
<b>Gender</b>					
Female	8,100	2,842	4,386	1,081	16,409
Male	3	1	1	0	5
<b>Total</b>	<b>8,103</b>	<b>2,843</b>	<b>4,387</b>	<b>1,081</b>	<b>16,414</b>
<b>Race</b>					
Caucasian	3,730	1,365	1,937	520	7,552
African American	4,029	1,325	2,215	513	8,082
Other	344	153	235	48	780
<b>Total</b>	<b>8,103</b>	<b>2,843</b>	<b>4,387</b>	<b>1,081</b>	<b>16,414</b>
Note: 152 claims have missing plan information. As such, there are no demographics data for these claims					

TABLE UTIL-OC.2: Number of Oral Contraceptives Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	615	207	303	0	1,125
Q2 2019	594	205	342	7	1,148
Q3 2019	755	269	414	18	1,456
Q4 2019	748	271	422	28	1,469
Q1 2020	781	268	421	27	1,497
Q2 2020	806	268	453	33	1,560
Q3 2020	898	322	512	176	1,908
Q4 2020	961	321	497	238	2,017
Q1 2021	874	328	507	261	1,970
Q2 2021	1,071	384	516	293	2,264
<b>Total</b>	<b>8,103</b>	<b>2,843</b>	<b>4,387</b>	<b>1,081</b>	<b>16,414</b>

TABLE UTIL-OC.5: Number of Oral Contraceptives Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	3,090	1,076	1,710	106	5,982
SFY 2021	3,804	1,355	2,032	968	8,159
<b>Total</b>	<b>6,894</b>	<b>2,431</b>	<b>3,742</b>	<b>1,074</b>	<b>14,141</b>

TABLE UTIL-OC.3: Proportion of Oral Contraceptives Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)				
Quarter	Pharmacy Program			
	FFS	UHC	MAG	MOL
Q1 2019	7.36%	3.03%	4.10%	0.00%
Q2 2019	7.22%	3.20%	4.89%	0.39%
Q3 2019	9.22%	4.31%	6.07%	0.79%
Q4 2019	9.53%	4.57%	6.57%	1.19%
Q1 2020	10.08%	4.39%	6.83%	1.25%
Q2 2020	10.18%	4.60%	7.85%	1.54%
Q3 2020	10.01%	5.07%	8.55%	7.23%
Q4 2020	9.87%	5.09%	8.18%	9.29%
Q1 2021	9.11%	5.15%	8.57%	10.47%
Q2 2021	10.05%	5.37%	8.45%	11.39%

TABLE UTIL-OC.6: Proportion of Oral Contraceptives Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)				
Year	Pharmacy Program			
	FFS	UHC	MAG	MOL
SFY 2020	9.75%	4.46%	6.79%	1.19%
SFY 2021	9.76%	5.18%	8.44%	9.62%

TABLE UTIL-OC.4: Total Spend of Oral Contraceptives Claims with 90 days of supply by Quarter and Pharmacy Program (Jan 2019- Jun 2021)					
Quarter	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
Q1 2019	\$ 26,026.86	\$ 23,656.77	\$ 19,677.51	\$ -	\$ 69,361.14
Q2 2019	\$ 33,942.06	\$ 22,034.99	\$ 25,207.09	\$ 122.21	\$ 81,306.35
Q3 2019	\$ 48,840.03	\$ 30,730.00	\$ 35,400.87	\$ 463.26	\$ 115,434.16
Q4 2019	\$ 46,808.28	\$ 42,729.78	\$ 39,235.46	\$ 557.02	\$ 129,330.54
Q1 2020	\$ 55,361.09	\$ 36,614.76	\$ 37,763.15	\$ 645.97	\$ 130,384.97
Q2 2020	\$ 60,473.33	\$ 35,320.33	\$ 40,588.73	\$ 924.60	\$ 137,306.99
Q3 2020	\$ 73,270.84	\$ 38,624.50	\$ 42,174.94	\$ 15,622.48	\$ 169,692.76
Q4 2020	\$ 64,068.24	\$ 44,083.19	\$ 38,166.17	\$ 19,010.98	\$ 165,328.58
Q1 2021	\$ 57,919.50	\$ 40,703.93	\$ 36,700.53	\$ 21,406.14	\$ 156,730.10
Q2 2021	\$ 73,744.75	\$ 49,431.07	\$ 35,739.67	\$ 25,252.36	\$ 184,167.85
<b>Total</b>	<b>\$ 540,454.98</b>	<b>\$ 363,929.32</b>	<b>\$ 350,654.12</b>	<b>\$ 84,005.02</b>	<b>\$ 1,339,043.44</b>

TABLE UTIL-OC.7: Total Spend of Oral Contraceptives Claims with 90 days of supply by State Fiscal Year and Pharmacy Program (SFY 2020 - SFY 2021)					
Year	Pharmacy Program				
	FFS	UHC	MAG	MOL	Total
SFY 2020	\$ 211,482.73	\$ 145,394.87	\$ 152,988.21	\$ 2,590.85	\$ 512,456.66
SFY 2021	\$ 269,003.33	\$ 172,842.69	\$ 152,781.31	\$ 81,291.96	\$ 675,919.29
<b>Total</b>	<b>\$ 480,486.06</b>	<b>\$ 318,237.56</b>	<b>\$ 305,769.52</b>	<b>\$ 83,882.81</b>	<b>\$ 1,188,375.95</b>



## Summaries of Categories with Minimal Utilization:

### Cystic Fibrosis

A total of 3,967 prescription claims for medications of cystic fibrosis are identified. Of these, seven claims (0.2%) are found with days of supply over 80 days. All these seven claims are covered by Magnolia. They are prescribed for three patients with two beneficiaries received a 90-day supply and one received an 84-day supply.

### Alpha-Glucosidase Inhibitors

A total of 12 prescription claims for alpha-glucosidase inhibitors for diabetes treatment with a 90-day supply are identified. Of these 12 claims, 2 are FFS, 2 are in UHC, and the remainder are in Magnolia. They are prescribed for 12 patients, and represent 36.67% of all alpha-glucosidase inhibitor claims in 2020 and 47.54% of these claims in 2021.

### Incretin Mimetics

A total of 109 prescription claims for incretin mimetics for diabetes treatment with a 90-day supply are identified. Of these claims, 13 are in FFS, 66 are in UHC, 11 are in Magnolia, and 19 are in Molina. They are prescribed for 109 patients, and represent 2.20% of total incretin mimetic prescription claims in 2020 and 3.20% of these in 2021.

### Meglitinides

A total of 6 prescription claims for meglitinides for diabetes treatment with a 90-day supply are identified. Of these 6 claims, 1 is FFS, 2 are in UHC, 2 are in Magnolia, and 1 is in Molina. They are prescribed for 6 patients, and represent 15.79% of all meglitinide claims in 2020 and 52.94% of these claims in 2021.

### Antiretrovirals - Hep C

A total of 22 prescription claims of antiretrovirals for Hep C (generic ribavirin, 200mg) are identified. Of these 22 claims, no claims are found with days of supply other than 28 days.

### Azole Antifungals

A total of 81,472 prescription claims of fluconazole are identified. Of these, 81 claims (0.10%) have 90 days' supply. The distribution of claims by plan are as follows: 21 are in FFS, 22 are in UHC, 29 are in MAG, and 9 are in MOL. The 81 claims account for 55 patients and are associated with a total cost of \$3,349.39 between January 2019 and June 2021.

### Sulfonamide antibiotics

A total of 71,169 prescription claims of sulfamethoxazole/TMP are identified across the four plans. Of these, 316 claims (0.44%) have 90 days' supply. The distribution of claims by plan are as follows: 78 are in FFS, 116 are in UHC, 84 are in MAG, and 38 are in MOL. The 316 claims account for 139 patients and are associated with a total cost of \$4,808.01 between January 2019 and June 2021.

### MAO Inhibitors

A total of 19 prescription claims of MAO inhibitors for Parkinson's (generic selegiline, 5mg) are identified; however, all claims have a days' supply of 30 days.

## **FDA DRUG SAFETY COMMUNICATIONS**

**September 2021 – November 2021**

- 11/02/2021 FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury.

## **APPENDIX**



MISSISSIPPI DIVISION OF  
**MEDICAID**

**Division of Medicaid  
Drug Utilization Review Board  
By-Laws**

**Article I. Purpose**

The Drug Utilization Review Board (DUR) is a requirement of the Social Security Act, Section 1927. The purpose of the DUR Board is to provide clinical guidance to the Division of Medicaid (DOM) regarding the utilization of pharmaceutical products within the Mississippi Medicaid program. The DUR Board makes recommendations to DOM to promote patient safety and cost effective care in the Mississippi Medicaid program. The DUR Board shall advise DOM with respect to the content of medical criteria and standards for utilization management strategies including prospective drug prior authorization (PA), concurrent patient management, retrospective drug utilization review, and educational intervention programs. DOM retains the authority to accept or reject the recommendations by the DUR Board.

**Article II. Membership**

**Section 1 – Board Composition**

- A. The DUR Board will consist of not less than twelve (12) voting members.
- B. The DUR Board voting members will be comprised of at least one-third (1/3), but no more than fifty-one percent (51%), licensed and actively practicing physicians and at least one-third (1/3) licensed and actively practicing pharmacists. Voting members may consist of health care professionals with knowledge/expertise in one or more of the following:
  - 1) Prescribing of drugs,
  - 2) Dispensing and monitoring of drugs,
  - 3) Drug use review, evaluation, and intervention,
  - 4) Medical quality assurance.
- C. Non-voting board members consist of the Division of Medicaid (DOM) Executive Director, Office of Pharmacy pharmacists, DUR Coordinator, the DUR contractor and Medical Director.

DUR Bylaws V2= updated 12/06/2018

## **Section 2 – Appointment selection methodology**

- A. DOM's Office of Pharmacy in consultation with officially recognized state professional healthcare associations recommends potential, qualified new candidates for appointment or reappointment of existing board members to DOM's Executive Director.
- B. Nominations are considered internally and appointments are given final approval by the DOM Executive Director.
- C. Board members are appointed by the Governor of the State of Mississippi, or Governor's designee, pursuant to state law.

## **Section 3 - Term of Office**

- A. All members are appointed for three year terms following a staggered appointment fulfillment as follows: one-third of DUR Board members shall be appointed each term. All subsequent appointments shall be for terms of three years from the expiration date of the previous term.
- B. Members may serve up to three consecutive three-year terms (for a total of nine consecutive years).
- C. Members may serve for either an extended term or a fourth consecutive term at the discretion of the Executive Director and by recommendation of both the DUR Coordinator and Division of Medicaid Office of Pharmacy in the event that no qualified, willing candidate is found in sufficient time. Members, including those filling vacated positions, may be re-appointed by the Executive Director for a subsequent term.
- D. In the event of an unexpected or expected vacancy, the DUR Coordinator and Office of Pharmacy may recommend a qualified replacement candidate to DOM's Executive Director for emergency approval.
- E. The Executive Director shall fill any vacancy before the end of the term, and the person appointed to fill the vacancy shall serve for the remainder of the unexpired term. Members, including those filling vacated positions, may be re-appointed by the Executive Director for a subsequent term.

## **Section 4 - Attendance**

- A. Members are required to attend at least fifty percent of the meetings per year. Failure to attend meetings without an explanation of extenuating circumstances will result in the termination of the member's appointment.
- B. Members are asked to give advance notice regarding any planned absences so that a quorum may be determined prior to meetings.

## **Section 5 - Resignation**

A member of the DUR Board may resign by giving a 30 day written advance notice to the DUR Board Chair and DUR Coordinator.

## **Section 6 - Removal**

A member of the DUR Board may be removed by either the DUR Board Chair or majority vote of the DUR Board for good cause. Good cause may be defined as one or more of the following conditions:

- A. Lack of attendance –failure to attend at least 50% of the scheduled DUR meetings shall constitute a resignation by said DUR Board member,
- B. Identified misconduct or wrongdoing during any DUR Board term, or

DUR Bylaws V2= updated 12/06/2018

- C. Not disclosing a conflict of interest either upon initial disclosure or throughout the rest of the term.

### **Section 7 - Board Officers**

At the first meeting of the state fiscal year, which constitutes July 1 through June 30, board members shall select two members to serve as Chair and Chair-Elect of the board, respectively. The Chair and Chair-Elect shall both serve one year terms. At the end of the serving year, the Chair-Elect assumes the role of Chair, and a new Chair-Elect will be chosen.

If the persons serving as Chair and Chair-Elect have either previously served as Chair or Chair-Elect, that person may be reelected to either posting.

The Chair-Elect will serve as Chair in absentia of the Chair or by the Chair's request.

### **Section 8 – Reimbursement**

The Division of Medicaid will reimburse DUR Board members for travel related expenses.

## **Article III. Meetings**

### **Section 1 – Frequency**

The DUR Board shall meet at least quarterly, and may meet at other times as necessary for the purpose of conducting business that may be required. The DUR Board Chair, a majority of the members of the board, or the Division of Medicaid Office of Pharmacy and DUR Coordinator, shall maintain the authority of calling DUR meetings.

### **Section 2 – Regular Meetings**

The DUR Board will hold regular quarterly meetings in the city of Jackson, Mississippi. Meetings will occur at the predesignated time and place. Dates for the upcoming year's quarterly meetings will be posted before the first quarterly meeting of the upcoming year.

### **Section 3 – Special Meetings**

The DUR Board may meet at other times other than regular quarterly meetings as deemed necessary and appropriate. The DUR Coordinator and Office of Pharmacy must notify DUR Board members of any special meeting at least two weeks, i.e., ten (10) days, prior to the requested meeting date. Special meetings may be requested by the following officials:

- A. Division of Medicaid Executive Director,
- B. DUR Coordinator and Office of Pharmacy,
- C. DUR Board Chair, or
- D. Majority of DUR Board members via communication to DUR Coordinator and/or DUR Board Chair.

### **Section 4 – Meeting Notice**

DUR Board members will be notified of the location for the meeting a minimum of ten (10) days in advance. Notification may include one or a combination of the following methods: e-mail, fax, or other written communication. DUR Board members are required to keep on file with

DOM Office of Pharmacy his or her address, primary phone number, alternate phone number (i.e., cell), fax number, and email address to which notices and DUR related communications may be submitted.

DUR Bylaws V2= updated 12/06/2018

Meetings may be cancelled due to lack of quorum, severe inclement weather, or other reasons as determined by the DUR Coordinator and Office of Pharmacy. In the event of a cancellation, the DUR Coordinator and DOM Pharmacy staff will communicate with DUR Board members regarding the meeting cancellation as soon as circumstances permit. Notifications shall also be posted with DFA and on DOM's website to ensure that the public is notified of any meeting cancellation.

DUR Board Meetings shall be open to the public and conducted in accordance with state law, specifically the Open Meetings Act. Notice of any meetings held shall be provided at least five (5) days in advance of the date scheduled for the meeting. The notice shall include the date, time, place and purpose for the meeting and shall identify the location of the meeting to the general public.

### **Section 5 – Meeting Sign-In**

All meeting attendees will be required to sign-in at the meeting entrance for DUR meetings. Sign-in sheets will be logged, scanned and transferred to electronic medium for official records. All attendees shall include participant's name and entity represented (as applicable).

### **Section 6 – Quorum**

A simple majority of voting board members shall constitute a quorum and must be present for the transaction of any business of the board. For a fully-appointed 12-person DUR Board as required by state law, seven voting board members constitutes a quorum. If a quorum is not present, the Chair, Chair-Elect or DUR Coordinator maintains the responsibility to conclude meeting proceedings. Meeting minutes shall reflect that a quorum was not present.

### **Section 7 – Voting**

The voting process shall be conducted by the Chair or the Chair-Elect in absentia of the Chair.

All board recommendations shall begin with a motion by a voting board member. The motion may then be seconded by a voting board member. If a recommendation does not receive a second motion, the motion shall not pass. If a recommendation receives a second motion, then the board shall vote on the motion. A motion shall be considered as passed if the motion carries a majority of votes if a quorum of the board is present.

In the event that a motion receives a tie vote in the presence of a quorum, the motion shall not pass. The motion can be brought up for further discussion after which a subsequent motion may be made to vote on the issue again during the same meeting, or a motion can be made to table the issue and discussion until the next quarterly DUR Board meeting.

A vote abstention occurs when a voting member is present for the meeting and the action but has chosen not to vote on the current motion. An abstention is a vote with the majority on the measure. A recusal, on the other hand, is necessitated when a voting member has a conflict of interest or potential pecuniary benefit resulting from a particular measure. In order to properly and completely recuse oneself from a matter, the DUR Board member must leave the room or area where discussions, considerations, or other actions take place.



*before* the matter comes up for discussion. The member must remain absent from the meeting until the vote is concluded. The minutes will state the recusing member left the room before the matter came before the DUR Board and did not return until after the vote.

### **Section 8 – Minutes**

A public body speaks only through its minutes. State law, specifically the Open Meetings Act, requires minutes be kept of all meetings of a public body, whether in open or executive session, showing the following:

- A. Members present or absent,
- B. Date, time and place of meeting,
- C. Accurate recording of any final actions taken,
- D. Record, by individual member, of how s/he voted on any final action, and
- E. Any other information that the public body requests is reflected in the minutes.

The minutes shall be finalized no later than thirty (30) days after the adjournment of the DUR Board meeting and shall be made available for public inspection. DOM Office of Pharmacy posts all DUR Board Minutes on the DUR webpage.

### **Section 9 – Speakers & Special Topics**

DUR Board members may request various healthcare, industry, or specialized professionals to present at DUR meetings regarding a posted topic on an upcoming DUR agenda.

- A. The DUR Board may allow up to 20 minutes for topic presentation by an invited speaker.
- B. DUR Board Members may ask a member of the audience to provide information on a topic being discussed by the Board. Invited participants may be asked to disclose any potential conflicts of interests if applicable. (See Article IV, Section 1).
- C. Members of the audience may not speak unless so designated at the appropriate time by a DUR Board member.
- D. DUR Board Members, both voting and non-voting, maintain speaking privileges at DUR meetings.
- E. Contracted employees of DOM and employees of other DOM vendors are considered members of the audience.

### **Section 10 – Executive Session**

During special circumstances, the DUR Board may go into executive session at the conclusion of normal meeting proceedings; however, all DUR Board meetings must commence as an open meeting. In order for executive session to be called, the following procedure must be followed in accordance with the Open Meetings Act:

- A. A member may move to close the meeting to determine whether board needs to go into executive session; vote in open meeting with vote recorded in minutes, majority rules.
- B. Closed meeting: vote taken on whether to declare executive session, requires 3/5 of all members present.
- C. Board comes back into open session and states statutory reason for executive session. The reason for the executive session shall be recorded in the meeting minutes.
- D. Board members then will go into executive session where action may be taken on stated subject matter only.

- E. Minutes must be kept in accordance with the Open Meetings Act.

### **Section 11 – Conduct of Participants**

Pursuant to state law, specifically the Open Meetings Act, the DUR Board may make and enforce reasonable rules and regulations for the conduct of persons attending the DUR meetings. The following is a non-exhaustive list of rules for DUR Board meetings:

- A. Attendees should please remain silent and allow for the efficient transaction of business.
- B. Cell phones should be placed on silent or vibrate.
- C. Laptop computers are discouraged from being utilized during meetings as frequent typing may distract board members.
- D. Food and drink are not allowed in the meeting room.
- E. Security is provided by the state. Guests not following proper decorum may be asked to leave by security.

## **Article IV. Public Participation**

### **Section 1 - Disclosure of Persons Appearing Before DUR Board**

The DUR Board may ask individuals appearing before the board to disclose either in writing or verbally their relationship, as applicable, including but not limited to pharmaceutical companies or special interest groups. Any such disclosures should be recorded as a matter of public record in the documented meeting minutes.

## **Article V. Conflicts of Interest**

DUR Board members are expected to maintain the highest professional, ethical standards. A conflict of interest may exist when a DUR Board member maintains a financial/pecuniary, personal, or professional interest that may compete or interfere with the DUR Board member's ability to act in a fair, impartial manner while acting in the best interests of the Division of Medicaid and the beneficiaries that it serves.

As such, DUR Board members are required to complete and submit annually a Conflict of Interest disclosure statement with the DOM Office of Pharmacy and DUR Coordinator. Statements shall be maintained by the Office of Pharmacy. Members have an ongoing responsibility to update and revise said statements, disclosing any new conflicts of interest to the DUR Coordinator and DOM Office of Pharmacy.

It is the sole responsibility and requirement of each board member to review the agenda of each forthcoming board meeting to determine any if any potential conflicts of interest exist. If so, an aforementioned Disclosure statement must be updated indicating the conflict of interest. The board member should notify the Chair or Chair-Elect of the conflict of interest prior to the meeting.

A DUR Board member shall recuse himself/herself from any vote, action, or discussion pertaining to any product or product class if there is documentation stating an actual or perceived conflict of interest. Please refer to the procedure outlined in Article III, Section 7.

## **Article VI. Confidentiality**

DUR Board members are required to safeguard all confidential and proprietary information, including but not limited to pricing information, which is disclosed by the Mississippi Division of Medicaid for purposes of conducting DUR Board activities. Any provider or patient specific information discussed by the DUR Board shall also be kept strictly confidential in accordance with state and federal law.

## **Article VII. Amendments**

### **Proposed Amendments of By-Laws**

- A. Proposed amendments must be submitted to the DUR Coordinator at least thirty (30) days prior to the next scheduled DUR meeting and the proposed amendments will be disseminated to the DUR Board en masse for consideration at said DUR Board meeting.
- B. Proposed amendments will be distributed to board members no less than five (5) business days prior to next DUR Board meeting.
- C. Proposed amendments will be initiated by the Chair, or the Chair-Elect in absentia of the Chair, prior to Next Meeting Information announcements.
- D. Proposed amendments will be voted upon at the next scheduled DUR Board meeting. If majority of DUR Board votes to ratify amendment, the amendment will take effect immediately at the conclusion of the meeting.

## MS-DUR BOARD COMMON ABBREVIATIONS

AWP	Any Willing Provider, Average Wholesale Price
BENE	Beneficiary
CAH	Critical Access Hospital
CCO	Coordinated Care Organization
CDC	Centers for Disease Control
CHIP	Children's Health Insurance Program
CMS	Center for Medicare and Medicaid Services
COB	Coordination of Benefits
CPC	Complex Pharmaceutical Care
DME	Durable Medical Equipment
DOC	Department of Corrections
DOM	Division of Medicaid
DUR	Drug Utilization Review
EOB	Explanation of Benefits
EPSDT	Early and Periodic Screening, Diagnosis and Treatment
FA	Fiscal Agent
FFS	Fee For Service
FPW	Family Planning Waiver
FQHC	Federally Qualified Health Clinic
FY	Fiscal Year
HB	House Bill
HCPCS/ HEIDIS	Health Plan Employer Data and Information Set
HHS	Department of Health and Human Services
HIPAA	Health Insurance Portability and Accountability
IDD	Intellectual and Developmental Disabilities
LTC	Long Term Care
MAG	Magnolia Health
MEDD	Morphine Equivalent Daily Dose
MOL	Molina Healthcare
MPR	Medication Possession Ratio
MSCAN	Mississippi Coordinated Access Network
MSDH	Mississippi State Department of Health
NADAC	National Average Drug Acquisition Cost

NDC	National Drug Code
P&T	Pharmacy and Therapeutics
PA	Prior Authorization
PBM	Pharmacy Benefit Manager
PDC	Proportion of Days Covered
PDL	Preferred Drug List
PI	Program Integrity
PIP	Performance Improvement Program
POS	Point of Sale, Place of Service, Point of Service
Pro-DUR	Prospective Drug Use Review
OTC	Over the Counter
QI	Quality Indicator
QIO	Quality Improvement Organization
QM	Quality Management
RA	Remittance Advise
REOMB	Recipient's Explanation of Medicaid Benefits
Retro-DUR	Retrospective Drug Utilization Review
RFI	Request for Information
RFP	Request for Proposal
RHC	Rural Health Clinic
SB	Senate Bill
SCHIP	State Child Health Insurance Program
SMART PA	Conduent's Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims
SPA	State Plan Amendment
UHC	United Healthcare
UM/QIO	Utilization Management and Quality Improvement Organization
UPDL	Universal Preferred Drug List
UR	Utilization Review
VFC	Vaccines for Children
WAC	Wholesale Acquisition Cost
WIC	Women, Infants, Children
340B	Federal Drug Discount Program

